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Introduction 
1. General Introduction 
Tricuspid valve regurgitation (TR) occurs in a variety of clinical settings. Historically, 
research was mainly focussed on left-sided heart disease. Therefore, TR and right 
heart disease have not been studied as extensively. However, in recent years, 
pathology of the right heart and tricuspid valve disease has gained more interest. 
Increasing TR severity and right heart dysfunction has been shown to impair 
prognosis in different heart disease.
1
 Moreover, TR is often encountered in different 
heart disease, and has been shown to independently influence prognosis in patients 
with heart failure, congenital heart disease or pulmonary hypertension, and in patients 
undergoing resynchronisation therapy or implantation of a left ventricular assist 
device.
2-9
 Furthermore, the impaired outcome after isolated tricuspid valve surgery 
remains incompletely understood.  
Evaluation of the effect of TR is difficult because of its heterogenous presentation, 
and both its severity and prognosis is dependent on loading conditions. Therefore, in 
this thesis project, we evaluated the epidemiology, determinants and management of 
TR in selected patient populations. 
 
2. Embryology and anatomy of the right heart 
2.1 Embryology 
The heart valves, supporting apparatus and cytoskeleton develop from the 5
th
 to 12
th
 
week of embryogenesis, although the definitive trilaminar morphology of the leaflets 
further develops postnatally.  
After formation and folding of the heart tube, endocardial cushions are formed at the 
level of the atrioventricular canal, located between the developing (left) atrium and 
the embryonic ventricle. (Figure 1 a-d) Four cushions are formed during embryonic 
development, namely the superior and inferior cushions, and the right and left lateral 
cushions. (Figure 1d) Extracellular matrix, called the cardiac jelly, is accumulated 
between the endocardium and the myocardium. This results in localized swellings. 
(Figure 2a) Next, a subset of endocardial cells delaminates from the myocardium and 
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transdifferentiates into mesenchymal cells by a process called epithelial-to-
mesenchymal transformation (EMT). (Figure 2a) These cells proliferate and 
cellularize the endocardial cushions. In this rudimentary form, the cushions already 
prevent retrograde blood flow.
9
 The atrioventricular canal expands, migrates 
rightwards and becomes funnel shaped, underlying the right and the left atrium.
10
 
(Figure 1 c-f) Furthermore, during atrial siltation by growth of the septum primum, 
the superior and inferior endocardial cushions fuse together. (Figure 1 e-f) The 
migration of the atrioventricular canal, the growth of the endocardial cushions and the 
atrial septation all lead to the separation of the atrioventricular canal into the mitral 
(left) and tricuspid (right) orifices and forms the inlet of the left and right ventricle 
respectively. (Figure 1f) 
From the fused superior and inferior atrioventricular cushions arise the anterior mitral 
leaflet and the septal tricuspid leaflet. The left lateral atrioventricular cushion 
becomes the posterior mitral leaflet, whereas the right lateral cushion produces the 
anterior and posterior tricuspid leaflets.
11
 The endocardial cushions elongate towards 
the ventricular cavity wall first along the atrioventricular canal myocardium and 
further down towards the ventricular myocardium. (Figure 2 a-c) As embryogenesis 
continues, the part overlying the atrioventricular canal myocardium gradually thins 
and elongates by a combination of apoptosis and cell proliferation, which results in 
further morphological changes towards the eventual valve leaflets.
12
 Further down 
towards the ventricular cavity, the underlying ventricular myocardium separates and 
forms the papillary muscles, connected via the chordae tendinae and the developing 
leaflet.
11, 13
 (Figure 2c)  Although most of the formation of the valve leaflets is 
completed at 8 weeks of gestation, the adult trilaminar arrangement of the leaflets is 
only obtained after birth. The “fibrosa” at the ventricular side of the leaflet consists of 
densely packed collagen and the “atrialis” is located on the atrial side and consists 
mainly of elastic fibers. In between the fibrosa and the atrialis is a thin layer, rich in 
glycosaminoglycan and versican located, called the “spongiosa”.14 
Around 7 weeks of gestation, formation of the fibrous annulus starts. The septal part 
of the annulus consists of the central fibrous body, the fused inferior and superior 
endocardial cushions and is continuous with the membranous ventricular septum.
15
 
On the other hand, from the free wall at the level of the atrioventricular groove, 
fibroadipose tissue grows towards the forming leaflets and further along the 
INTRODUCTION 
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atrioventricular sulcus towards the septal part of the annulus. The septal tricuspid 
leaflet and the anterior mitral leaflet are connected to each other through the septal 
part of the annulus and the central fibrous body.  The annulus functions as a stable 
platform for the valvular complex and electrically isolates the atrium from the 
ventricle. 
 
Figure 1 Schematic representation of the embryogenesis of the heart: Looping and 
septation of the heart.  
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Figure 2 Formation of the heart valves: a. Migration of cells after epithelial-to-
mesenchymal transdifferentiation to form the endocardial cushions; b. formation of 
rudimentary valve leaflets and septation of the ventricular myocardium to form the 
papillary muscles; c. Completion of the valvular complex consisting of valve leaflets, 
chordae tendinae and papillary muscles. 
 
 
2.2 Anatomy 
2.2.1 Valve structure 
The tricuspid valve is located anteriorly in the chest, at the level of the right 
atrioventricular junction. It consists of 3 leaflets, a septal, posterior and anterior 
leaflet. (Figure 3) The anterior and posterior papillary muscles, and a less well-
defined septal group of papillary muscles complete the valvular apparatus. However, 
this septal group of papillary muscles is an important part of the right ventricle as it 
separates the inflow part of the right ventricle from the infundibulum/outflow tract. 
(Figure 4) Furthermore, the septal chordal insertions play an important role in the 
development of tricuspid regurgitation in right ventricular dilatation. Multiple chordae 
originate from the papillary muscles and provide support for the 3 leaflets. Especially 
primary or edge chordae are important to preserve valvular competence whereas 
secondary chordae, which insert on the ventricular surface of the leaflet, are less 
essential for valvular function. It is easily possible to discriminate between the mitral 
valve and the tricuspid valve as the tricuspid valve has 3 leaflets, a lower insertion of 
the septal leaflet compared to the anterior mitral leaflet and chordal insertions are 
present on the ventricular septum. (Figure 1f and Figure 3)
16, 17
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Figure 3 Transthoracic echocardiographic image of the tricuspid valve in (A) end-
diastole and (B) end-systole. 
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Figure 4 Right ventricular morphology and its relation with 2D transthoracic 
echocardiography (A-C) and 3D volume rendering in systole (green) and diastole 
(mesh) (C). 
 
 
 
INTRODUCTION 
17 
2.2.2 Cardiac cytoskeleton 
The valve leaflets anchor on the cardiac cytoskeleton. The tricuspid annulus has a 
complex ellipsoid structure with 2 distinct high points (posteroseptal and 
anterolateral) and 2 low points, (anteroseptal and posterolateral). During a cardiac 
cycle, the tricuspid annulus is flatter at end-diastole and reaches its maximum height 
at end-systole. Furthermore, during cardiac contraction, the annular area shows a 
biphasic pattern with the area of the tricuspid annulus decreasing from late-diastole to 
mid-systole and during mid-diastole.
18, 19
 Overall, the tricuspid annular area decreases 
29.6 ± 5.5% during the cardiac cycle, which contributes to valvular competence.
20, 21
  
2.2.3 The right ventricle 
The right ventricle lies directly behind the sternum and has a complex 3-dimensional 
crescent shape, wrapped around the left ventricle. It consists of an inlet part, a 
trabeculated apical part, which contains the tension apparatus of the tricuspid valve, 
and a smooth but muscular outlet part. (Figure 3) The discriminator of the 
trabeculated apical part is the moderator band.
17
 Compared to the left ventricle, which 
consists from 3 layers, the right ventricular wall is only composed of a superficial and 
deep muscle layer and lacks the middle, circumferential layer, responsible for the 
radial contraction of the left ventricle. The fibers of the superficial layer are arranged 
obliquely and continue into the superficial fibres of the left ventricle. This results in a 
close interrelation in contraction of both ventricles, known as ventricular 
interdependence. On the other hand, the deep muscle fibres are arranged 
longitudinally form base to apex. This myofibre orientation thus explains the 
contraction pattern of the normal right ventricle with a predominant longitudinal 
contraction, ejecting ±85% of the right ventricular volume.
22, 23
  
2.2.4  Coronary circulation 
The coronary blood supply of the heart consists of a left coronary artery, arising from 
the left sinus of valsalva, and a right coronary artery, arising from the right sinus of 
valsalva. The left coronary artery splits into the left anterior descending artery, 
following a course in the anterior interventricular groove providing blood to the 
anterior wall, the septal wall and the anterolateral wall of the ventricle. The 
circumflex artery runs around the heart in the left atrioventricular groove providing 
blood to the lateral wall. The right coronary artery runs along the right atrioventricular 
INTRODUCTION 
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groove and delivers blood to the right ventricular infundibulum (the conus branch), 
the sinus node and the atrioventricular node, and the right ventricular free wall. In 
85% of individuals, the posterior descending artery arises from the right coronary 
artery, which travels along the posterior interventricular groove and provides blood to 
the inferior and posterior wall. 
Noteworthy is that anomalous right ventricular blood supply occurs in fewer than 1 % 
of the normal population.
24, 25
 In these patients it is important to identify if a coronary 
artery runs between the aortic valve/aorta and the pulmonary valve/pulmonary artery. 
This “malignant” course of the coronary arteries can impair coronary blood supply 
during exercise, which can lead to arrhythmias or sudden cardiac death.  
 
3. Imaging the right ventricle and the tricuspid valve. 
3.1 Evaluation of the right ventricle 
The right ventricle consists of the inflow compartment, an apical part and the 
infundibulum. Moreover, the 3 compartments relate to each other in a complex 3-
dimensional configuration. (Figure 4) This makes 2-dimensional imaging 
cumbersome as it is not possible to image all 3 compartments simultaneously. Two-
dimensional echocardiography should therefore include different imaging planes to 
accurately visualize all parts of the right ventricle. Furthermore, the crescent shape in 
the frontal plane and the triangular shape of the ventricle in the sagittal plane explain 
why the geometric assumptions used to calculate left ventricular volume cannot be 
applied for volumetry of the right ventricle. Finally, endocardial border delineation is 
difficult because of the anterior position of the right ventricular free wall and because 
of the coarse trabeculations in the ventricle. (Figure 4)  
The gold standard in evaluation of right ventricular morphology and function is 
cardiac magnetic resonance (CMR). It allows visualizing the right ventricle in the 
sagittal plane. The obtained slices can than be traced and combined to obtain a 
volume. The advent of 3D echocardiography offers an alternative to this. However, 
the volumes obtained by 3D echocardiography underestimate those obtained by CMR 
by 20-34%.
26
 The most used echocardiographic measurement of right ventricular 
function is the tricuspid annular plane systolic excursion (TAPSE), obtained by M-
mode imaging of the tricuspid annulus along the right ventricular free wall. 
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Calculation of right ventricular fractional area change from the apical 4-chamber view 
is more useful in patients with right ventricular dilatation. Myocardial performance 
index (MPI) represents a combination of isovolumic periods and ejection-time. 
However, isovolumic contraction and relaxation time are dependent on right 
ventricular systolic and diastolic function respectively, and of the loading conditions. 
Therefore, changes of the MPI don’t necessarily point towards changes in ventricular 
function. Tissue Doppler velocity imaging can be used to evaluate the velocity of the 
tricuspid annulus during systole, as an alternative evaluation of longitudinal function 
of the right ventricle. Furthermore, strain and strain rate can be obtained by Tissue 
Doppler or by Speckle tracking imaging. This offers information of the myocardial 
deformation and velocities and offers an alternative approach in the assessment of 
right ventricular contractility. However, accurate tracking of the right ventricular free 
wall is challenging and the inter-vendor variability of the strain imaging packages 
makes that reference values are currently unavailable.  
Lastly, one should take into account that all measurements are load-dependent. 
Because the right ventricle is prone to changes in loading conditions, indices of right 
ventricular function should always be interpreted with regards to right ventricular 
pressure- and/or volume-load.
27
 
3.2 Evaluation of tricuspid regurgitation severity 
In the assessment of tricuspid regurgitation, the cause, severity and impact on the 
right ventricular morphology and function should be evaluated. Quantification 
methods of TR are largely similar to those performed in mitral regurgitation. 
However, reference values are based on small studies and quantification methods are 
less robust.  
First, leaflet abnormalities should be evaluated. Lower insertion of the septal leaflet in 
Ebstein’s anomaly, or multiple TR jets in case of dysplastic valve leaflets point 
towards primary tricuspid valve disease. Likewise, thickening and calcification of 
valve leaflets should be reported. Three-dimensional echocardiography might be of 
use in the evaluation of tricuspid valve leaflets.
28
 Secondary TR, with normal leaflets, 
most often presents with a single regurgitant jet, annular dilation and increased an 
tricuspid regurgitant velocity.
29
  
Initial evaluation of the severity of TR is performed by Colour Doppler flow. 
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Dependent on the area of the regurgitant jet, patients can be classified as having mild 
(1/4) to severe TR (4/4). Although associated with several caveats, this measurement 
is still readily used in clinical practice as it presents an easy and quick way to grade 
TR. However, when more than moderate TR is suspected, these measurements should 
be supplemented with more semi-quantitative and quantitative measurements. A vena 
contracta width > 7 mm (at Nyquist limit of 50-60 cm/sec), a proximal isovelocity  
surface area (PISA) radius of >9 mm (at baseline Nyquist limit shifted down to 28 
cm/sec), a calculated EROA of ≥ 40 mm2 and a regurgitant volume of ≥ 45 mL are 
indicative for severe TR. Furthermore, indirect signs of severe TR are systolic flow 
reversal in the hepatic veins, significant dilatation of the inferior vena cava or signs of 
volume-loading of the right ventricle are additive to the grading of TR severity.
30
  
Lastly, the effect of TR on RV morphology and function should be assessed. 
Significant volume-loading results in right ventricular dilation, right atrial dilatation, 
RV eccentricity index > 2 at end-systole and signs of right ventricular dysfunction can 
help identify patients eligible for surgery.
31-33
  
 
4. Origin of tricuspid valve regurgitation 
In reference to the complex anatomy of the right ventricle and the tricuspid valvular 
complex, valvular incompetence originates from (1) changes in morphology of the 
tricuspid leaflets, both congenital and acquired; (2) tricuspid annular dilatation; (3) 
changes in right ventricular geometry and (4) right ventricular function, the latter 
closely related to left ventricular function.  
Tricuspid valve regurgitation is divided into 2 types: (a) primary and (b) secondary or 
functional tricuspid valve regurgitation. 
4.1 Primary tricuspid valve regurgitation 
In only 10-20% of patients, tricuspid regurgitation is due to primary disease of the 
tricuspid leaflets.
34-36
 Common causes of primary tricuspid valve regurgitation are 
rheumatic heart disease, myxomatous heart disease, Ebstein's anomaly, 
endomyocardial fibrosis, endocarditis, carcinoid disease or traumatic (blunt chest 
injury, laceration).  
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4.2 Secondary tricuspid valve regurgitation 
Tricuspid valve regurgitation is secondary in 80-90% of cases. In these patients, 
tricuspid valve leaflets morphology is normal and TR originates from left heart 
disease (LV dysfunction or valve disease) resulting in pulmonary hypertension, any 
cause of increased right ventricular pressure (chronic lung disease, pulmonary 
thromboembolism, left to right shunt) or any cause of right ventricular dysfunction 
(myocardial disease, RV ischemia or infarction).
34, 35
 
The pathogenesis is mainly attributable to changes in morphology of the right heart 
(tricuspid annular dilatation, right ventricular dilatation due to left heart failure 
(myocardial or valvular causes), right ventricular volume-overload (e.g. atrial septal 
defect)) or right ventricular pressure-load. Furthermore, the presence of atrial 
fibrillation has shown to be associated with increased tricuspid regurgitation. Lastly, 
tricuspid valve regurgitation itself causes a volume-overload of the right ventricle, 
causing further dilatation of the right ventricle and tricuspid annulus, resulting in 
more severe tricuspid valve regurgitation.
20, 31, 37-40
 (Figure 5) 
However, each geometric or hemodynamic change in right heart morphology is not 
necessarily associated with severe tricuspid regurgitation. In tricuspid regurgitation, 
the tricuspid annulus looses its 3-dimensional shape and becomes more planar.
19
 In 
vitro studies have shown that an increase of the annular circumference by 40% leads 
to severe TR.
38
 Conversely, patient data show that annular dilatation does not 
invariably lead to severe TR. Sadeghi et al studied patients with chronic 
thromboembolic pulmonary hypertension after pulmonary endarterectomise. 
Although the circumference of the tricuspid annulus remained equal, great differences 
in persistence of TR could be seen after surgery, mainly attributed to the success of  
lowering the right ventricular pressure load.
41
  
Inducing acute increases in pressure-load by infusing Methoxamine in a pig-model 
causes an increase in tricuspid regurgitation severity.
42
 However, in patients with 
pulmonary hypertension, all degrees of severity of tricuspid regurgitation are 
encountered.
39
  
Furthermore, the geometry of the right ventricle is of the utmost importance in the 
pathogenesis of tricuspid regurgitation. The insertion of the chordae and the 
placement of the papillary muscles make the valvular complex very prone to 
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geometric changes of the right ventricle. Dilatation occurs mainly along the right 
ventricular free wall, which results into a displacement of all papillary muscles from 
the centre of the ventricle and annular dilatation.
38
 Fukuda et al. confirmed that 
tenting area and tenting height were predictive of the result of tricuspid annuloplasty, 
confirming the importance of right ventricular geometry and papillary muscle 
placement in these patients.
43
  
The above indicates the complex interplay of the different determinants of tricuspid 
regurgitation and indicates the difficulty in assessing the tricuspid valve pre-
operatively and predicting outcome after surgery.   
4.3 Iatrogenic tricuspid valve regurgitation 
TR can also occur after repetitive RV biopsies for instance in patients after heart 
transplantation or after placement of a pacemaker or defibrillator lead.  
 
Figure 5 Pathogenesis of functional tricuspid regurgitation. (Adapted from Shoran et 
al. J Am Coll Cardiol 2009;53(5):401-8)   
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5. Epidemiology 
Any severity of TR is present in 79.5-85.9% of people in the general population. Low 
severity TR is frequent and has long been regarded as a chance finding.
44
 Some 
authors even suggested mild TR to be an artefact of the movement of the tricuspid 
valve leaflets.
45
 On the other hand the prevalence of significant TR, defined as TR > 
2/4, was found to be 1.2 to 5.6% in the general population. Furthermore, the 
prevalence of TR is age-dependent and ranges from 0.9% in people younger than 50 
years to 5.6% in people over 70 years of age.
44, 46
 
Functional TR has long been regarded as a consequence of the underlying, often left-
sided heart disease. More specifically, in mitral valve disease it was thought TR 
would resolve after surgery of the mitral valve, as this would remove the cause of 
right ventricular hypertension.
47, 48
 In recent years, it has become clear that TR is not 
simply a bystander phenomenon. In the general population, increasing severity of TR 
has been shown to have an impact on prognosis.
1
 Moreover, TR is often encountered 
in different heart disease, and has been shown to independently influence prognosis in 
patients with heart failure, congenital heart disease or pulmonary hypertension, and in 
patients undergoing resynchronisation therapy or implantation of a left ventricular 
assist device.
2-8
 
This indicates that the development of TR should alert the clinician for possible 
disease progression and indicates patients at higher risk for mortality.  However, 
although TR is associated with worse prognosis, the reason for this remains unclear.   
 
6. Studied populations 
In this thesis, we first evaluated the prevalence and determinants of TR in the 
population referred for echocardiography. Next, we selected 4 patient populations, in 
whom excessive pressure or volume load of the right ventricle was present for further 
study.   
6.1 Pulmonary valve stenosis 
The incidence of patients with pulmonary valve stenosis is 1 in 2000 live births and it 
accounts for 8% of all congenital heart defects. Stenosis occurs due to absent 
separation of the valve leaflets, resulting in a dome-shaped valve with a pinpoint 
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orifice. In 10-20% of patients, the stenosis occurs due to thickening of the valve 
leaflets with commissural fusion or is caused by pulmonary valve dysplasia. The latter 
valvular abnormalities are often part of a collection of clinical signs associated with a 
specific syndrome.
49-51
 
In the clinical work-up, Doppler echocardiography is the evaluation tool of choice. A 
transvalvular gradient of <36 mmHg, between 36-64 mmHg and >64 mmHg is 
considered as mild, moderate and severe pulmonary valve stenosis respectively.
52
 
Severe pulmonary valve stenosis impairs functional capacity, and valvular dilatation, 
valve repair or valve replacement is often indicated. On the other hand, mild 
pulmonary valve stenosis seldomly progresses after adolescence and is considered 
benign.
51, 53
 
6.2 Tetralogy of Fallot 
The incidence of patients with “Tetralogy of Fallot” is estimated around 1/3000 to 
1/1500 life births. It is the most common cyanotic congenital heart disease and 
accounts for approximately 10% of all congenital heart defects. It consists of a 
combination of 4 defects: (1) a non-restrictive ventricular septal defect; (2) an 
overriding aorta; (3) right ventricular outflow tract obstruction at the level of the 
infundibulum, the pulmonary valve, postvalvular, at the level of the pulmonary 
arteries or a combination and (4) right ventricular hypertrophy. In approximately 15 
% of patients, tetralogy of Fallot occurs as part of a deletion of chromosome 22q11, 
which results into the “DiGeorge Syndrome” (CATCH22).54, 55 
Patients with tetralogy of Fallot are often recognized early, as significant outflow tract 
obstruction results in right-to-left shunting through the ventricle septum defect, which 
results in cyanosis. Rarely, outflow tract stenosis is mild, with hemodynamics 
comparable to patients with an isolated ventricle septum defect, the so-called “pink 
Fallot”.  
Patients undergo surgery at young age, sometimes as a staged approach to increase 
blood flow to the pulmonary circulation allowing the pulmonary vasculature to 
mature. Eventually, and nowadays in infancy, a complete correction with closure of 
the ventricle septum defect and relieve of the outflow tract obstruction, sometimes 
with a pulmonary homograft. 
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From a morphological point of view, 2 elements especially warrant close follow-up: 
(1) outflow tract function (stenosis and regurgitation) and (2) right ventricular 
function. Furthermore, left ventricular dysfunction, aortic regurgitation and root 
dilatation, endocarditis, arrhythmias (supraventricular and ventricular) and sudden 
cardiac death are late complications after complete repair.
56, 57
  
6.3 Pulmonary hypertension 
Pulmonary hypertension can be seen in multiple clinical conditions. It is diagnosed by 
right heart catheterisation and is defined as a mean pulmonary artery pressure ≥ 25 
mmHg and a pulmonary capillary wedge ≤ 15 mmHg (pre-capillary pulmonary 
hypertension) or pulmonary capillary wedge ≥ 15 mmHg (post-capillary pulmonary 
hypertension). At the moment of the study, patients with PH were classified according 
to the Dana Point classification into 5 groups according to the cause of the elevated 
pulmonary pressures: Group 1: pulmonary arterial hypertension (PAH); Group 2: 
pulmonary hypertension due to left heart disease; Group 3: pulmonary hypertension 
due to lung disease; Group 4: chronic thromboembolic pulmonary hypertension and 
Group 5 consists of patients with an unclear or multifactorial mechanism resulting in 
elevated pulmonary pressures.
58, 59
 Recently, a new classification has been proposed.
60
 
Although the availability of pulmonary-specific therapy has significantly improved 
outcome in patients with PAH, mortality and functional impairment remains high.
61, 62
 
Furthermore, pulmonary endarterectomy (PEA) effectively reduces right ventricular 
afterload. Although the right ventricle can successfully adapt to the progressive and 
chronic pressure-load by hypertrophy of the right ventricular myocardium, eventually 
right ventricular failure occurs. Although therapy successfully reduces pulmonary 
vascular resistance, lowering the load on the right ventricle, progressive right 
ventricular dysfunction may occur. This decrease in right ventricular function is 
closely associated with worse outcome.
63
 
6.4 Atrial septum defect type secundum 
Atrium septum defect type secundum occurs in approximately 1/1000 live births, 
consists of 70% of all atrium septum defects. As an isolated lesion, it accounts for 6-
10% of all congenital heart lesions. It originates from excessive reabsorption of the 
septum primum.
54, 64, 65
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After birth, as pulmonary vascular resistance is diminished, a predominantly left-to-
right shunt occurs which exposes the right ventricle to an increased volume-load. This 
results in right ventricular dilatation, tricuspid valve regurgitation and increased 
pulmonary pressures due to high pulmonary flow. If the atrial septal defect is closed 
early in life, patients have a survival equal to the general population.
66, 67
 Although the 
closure of an atrial septum defect at older age has been subject of debate, several 
studies have indicated closure results in decreased mortality and morbidity, and 
remodelling of the right heart chambers occurs.
68, 69
 However, if closed later in life, a 
lesser decline in pulmonary vascular resistance during exercise is observed. This 
results in higher pulmonary pressures relative to the cardiac output developed by the 
patients during exercise.
70
  
 
7. Right ventricular function and hemodynamic 
consequences of volume- and/or pressure-load.  
Right ventricular contraction is dependent on loading conditions.
23
 The right ventricle 
arrives at developing similar cardiac output, only at one fifth of the energy cost 
needed for left ventricular contraction.  The pressure-volume curve of the normal 
right ventricle differs from the left ventricle in different aspects. In the right ventricle, 
a time difference between the pulmonary arterial dicrotic notch and peak right 
ventricular pressure can be noted, the so-called hangout period.
71, 72
 The pulmonary 
valve closes only when a significant decrease in right ventricular pressure has already 
occurred. Hence, when plotting the pressure-volume loop of the right ventricle, there 
is no clearly defined isovolumic relaxation time and the curve has a more triangular 
shape as compared to the square curve of the left ventricular P-V loop.
73
 
This contraction pattern is mainly related to the low impedance of pulmonary vascular 
bed more then an intrinsic myocardial property, as a sub-pulmonary left ventricle 
assumes a comparable pattern. Vice versa, a systemic right ventricle assumes a 
contraction pattern comparable to that of the normal left ventricle. 
Acute changes in afterload of the right ventricle, even small, have already an 
important impact on right ventricular contractile performance and stroke volume. 
Small (acute) increases in afterload can be seen during respiration.
74
 At the other end 
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of the spectrum, acute pulmonary emboli cause a large and acute increase of right 
ventricular afterload severely impairing right ventricular function.   
Changes in loading conditions of the right ventricle, result in different changes of the 
pressure-volume load.(Figure 6) 
 
Figure 6 Impact of pressure and/or volume-load on the right ventricular pressure-
volume relationship. 
 
 
The right ventricle tolerates an increased volume-load fairly well. The major changes 
in the pressure-volume plot are an increase in end-diastolic and, to a lesser extent of 
the end-systolic volume. This results in an increased stroke work. The right ventricle, 
with its thin wall and longitudinally oriented myocardial fibers, is well suited to 
support this additional volume-load.
75, 76
 
When a pressure-load is imposed on the right ventricle, the pressure-volume loop 
changes and closely resembles the loop of the left ventricle. This means end systolic 
pressures are more elevated, when well tolerated, with similar end-diastolic and end-
systolic volumes. Importantly, distinct isovolumic periods can be identified. 
Furthermore, the stroke work is increased. Studies have shown that this pressure-load 
is initially well tolerated, but fast deterioration of right ventricular function occurs. 
The right ventricle dilates, becomes more spherical and hypertrophies, which also 
results in impaired blood supply to the myocardial wall.
77
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The combination of pressure and volume-load results in increase in right ventricular 
end-diastolic and end-systolic volumes, in combination with increased end-systolic 
pressure and a further increase of stroke work, delivered by the ventricle. At least 
from theoretical point-of-view, this represents considerable strain on the right 
ventricle and could lead to quick deterioration of right ventricular function. 
The blood supply to the right ventricular free wall is dependent on a single coronary 
vessel, which makes it more vulnerable to coronary artery disease, especially in 
patients with a systemic right ventricle. Furthermore, in case of increased wall stress 
due to either volume- or pressure-load on the right ventricle, blood flow through the 
right coronary artery is limited or absent throughout systole. This impairs blood 
supply and can cause ischemia of the right ventricular wall. This results in 
endomyocardial fibrosis, and can lead towards impaired right ventricular contractile 
function.
78, 79
 
 
8. Prediction of pulmonary hypertension 
Pulmonary hypertension is associated with different heart disease and is associated 
with morbidity and mortality.
61, 80
 More specifically in pulmonary arterial 
hypertension, current evidence points towards improved prognosis if diagnosis is 
made early.
81-83
 In patients susceptible for development of pulmonary hypertension, 
echocardiographic determination of the tricuspid regurgitant velocity is advised as 
initial screening.
58
 
In an attempt to develop screening algorithms and prediction methods for pulmonary 
hypertension, symptoms, echocardiography, lung function tests and biomarkers are 
often used. With these data, a risk score is developed by regression analysis.
84
 It is 
important to emphasize that these algorithms and scores are only applicable to the 
studied population and the prevalence of the disease in the studied cohort has to be 
comparable to that of the population that will be screened. Many of the prediction 
algorithms and scores are focused on the early detection of PH in specific patient 
populations, such as in systemic sclerosis.
85, 86
 The prediction scores can therefore 
only be used in these patient populations. Furthermore, referring to Bayes theorem, 
predictive values will vary greatly if prevalence in the screened population is different 
from the studied population. 
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Doppler derived tricuspid regurgitant velocities in the individual patients are 
sometimes difficult to obtain. The measurement can only be acquired in 75-90% of 
patients in experienced hands and even then suboptimal CW traces are often 
obtained.
87, 88
 Therefore, a simple echocardiographic technique to exclude pulmonary 
hypertension might be interesting. 
 
9. Management of tricuspid valve regurgitation 
Medical treatment of severe tricuspid regurgitation is limited to the use of loop 
diuretics and aldosterone blockers. However, decreasing afterload by specific 
pulmonary vasodilators has shown to improve right ventricular function and decrease 
tricuspid regurgitation in the post-operative setting and might be an alternative, 
although experience is very limited.
58, 89, 90
  
Often, the only successful treatment for tricuspid regurgitation is surgery. In the 
evaluation of patients for surgery, 2 distinct scenarios can be identified: (1) tricuspid 
valve repair at the time of left-sided valvular surgery and (2) Isolated tricuspid valve 
repair. The current recommendations of the European society of cardiology are listed 
in Table 1.
33
 These largely agree with the more recently published guidelines of the 
American Heart Association and the American College of Cardiology.
32
 
9.1 Tricuspid valve regurgitation in mitral valve disease 
Mitral regurgitation is often associated with tricuspid regurgitation. Furthermore, TR 
progression towards moderate and severe TR occurs in up to 30% of patients 
undergoing isolated mitral valve surgery and can even occur 10 years after the initial 
surgery. Late occurrence of tricuspid regurgitation is known to be associated with 
worse prognosis.
91-95
 Left-sided valvular surgery offers a unique opportunity to 
prevent further deterioration of tricuspid valve function. Key factors, associated with 
an increased prevalence of tricuspid regurgitation progression after surgery are 
annulus dilatation, right ventricular dysfunction, tricuspid leaflet tethering, pulmonary 
hypertension, atrial fibrillation, non-myxomateous aetiology of mitral regurgitation 
and the presence of a transvalvular pacemaker.
95-97
 However, even then, the natural 
history is unpredictable. Although reduction of tricuspid regurgitation severity has 
been observed after pulmonary endarterectomy and mitral valve surgery, progression 
of TR is observed after mitral valve repair in ischemic cardiomyopathy, dilated 
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cardiomyopathy and in rheumatic heart disease.
41, 47, 98-101
 Therefore, some authors 
even argue in favour of “prophylactic” tricuspid annuloplasty at the time of left-sided 
heart surgery.
102
 
 
Table 1 Indication for surgery in patients with tricuspid valve regurgitation. 
(Vahanian et al. Eur Heart J 2012;33(20):2569-619) 
 Class Level 
At the time of left-sided valve surgery:   
Surgery is indicated in patients with severe 
primary or secondary TR undergoing left-sided 
valve surgery 
I C 
Surgery should be considered in patients with 
moderate primary TR undergoing left-sided valve 
surgery. 
IIa C 
Surgery should be considered inpatients with mild 
or moderate secondary TR with dilated annulus 
(≥40 mm or >21 mm/m2) undergoing left-sided 
valve surgery 
IIa C 
In isolated tricuspid regurgitation   
Surgery is indicated in symptomatic patients with 
severe isolated primary TR without severe right 
ventricular dysfunction. 
I C 
Surgery should be considered in asymptomatic or 
mildly symptomatic patients with severe isolated 
primary TR and progressive right ventricular 
dilatation or deterioration of right ventricular 
function 
IIa C 
After left-sided valve surgery, surgery should be 
considered in patients with severe TR who are 
symptomatic or have progressive right ventricular 
dilatation/dysfunction, in the absence of left-sided 
valve dysfunction, severe right or left ventricular 
dysfunction, and severe pulmonary vascular 
disease. 
IIa C 
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However, it is important to emphasize that the true clinical benefit of tricuspid 
annuloplasty in the setting of mitral valve disease has not been proven. On the other 
hand, several studies have shown favourable remodelling after concomitant tricuspid 
surgery as well as improved functional capacity.
103-105
 
9.2 Isolated tricuspid valve regurgitation 
The surgical indication in patients with isolated tricuspid regurgitation is not well 
established. Furthermore, clinicians are reluctant towards isolated tricuspid valve 
surgery, as this historically is associated with a high post-operative mortality. At 
present, only symptomatic patients with severe tricuspid regurgitation have a strong 
indication for surgery. Furthermore, progressive right ventricular dysfunction and 
right ventricular dilatation in follow-up echocardiography is seen as an indication to 
refer patients towards surgery. However, this advice is mainly based on small studies 
performed in patients with carcinoid disease and in patients with flail leaflets or are 
based on studies in patients with mitral valve regurgitation.
106, 107
 The heterogeneity of 
patients presenting with isolated tricuspid regurgitation makes generalisation of these 
guidelines difficult.  
9.3 Tricuspid valve surgery after left-sided valve surgery 
Lastly, a specific patient population are those patients referred for severe tricuspid 
regurgitation after mitral valve surgery. Especially in this patient population, high 
post-operative mortality is observed after isolated tricuspid valve surgery.
108-111
 
Referral for patients with severe tricuspid regurgitation after mitral valve regurgitation 
is most often late, after significant right ventricular dilatation and dysfunction is 
already present.
111-113
 
 
10. Choice of surgical intervention 
Controversy still exists concerning which procedure should be performed when 
performing tricuspid valve surgery. Surgery of the tricuspid valve should focus on the 
annulus, the commissures, the leaflets morphology and the tethering of the leaflets. In 
many patients, the morphology of the valve leaflets is normal, and tricuspid 
regurgitation is mainly a result of increased annular dimensions. In these patients 
tricuspid annuloplasty can be performed, with or without insertion of a ring. If 
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leaflets are slightly damaged, the surgeon can choose to repair the valve. Leaflet 
tethering is sometimes relieved by leaflet augmentation, increasing the amount of 
valve tissue resulting in better coaptation of the valve leaflets.
114
  
On the other hand, when the tricuspid leaflets or the right ventricle is importantly 
damaged, tricuspid valve replacement has to be performed. Current guidelines favour 
tricuspid valve repair because of the better post-operative outcome compared to 
patients undergoing valve replacement.
32, 33
 However, it is clear that patients 
undergoing tricuspid valve replacement present in a worse clinical state and often 
have a more severely damaged tricuspid valve. 
115
 Even more so, if corrected for co-
morbidities, outcome of tricuspid valve replacement is similar compared to patients 
undergoing tricuspid valve repair and is associated with lower degrees of tricuspid 
valve regurgitation post-operatively and in in long-term follow-up.
116, 117
 Likewise, 
the choice to implant a mechanical or biological tricuspid valve is subject of 
discussion. No difference in post-operative outcome and overall survival rates is 
observed in patients either receiving a mechanical or a biological tricuspid valve 
replacement, even in younger patients.
118-121
 More thrombosis, embolism and bleeding 
occurred in the group receiving a mechanical tricuspid valve replacement compared to 
patients who received a biological tricuspid valve, even though both patient groups 
received oral anticoagulation therapy. On the other hand, a higher rate of bioprosthetic 
degeneration can be observed.
121
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Aims of the study 
1) Epidemiology and prevalence tricuspid regurgitation in patients referred for 
echocardiographic evaluation and in different heart disease. 
2) Evaluation of the determinants of tricuspid regurgitation severity and 
applicability in clinical practice. 
3) Changes in tricuspid regurgitation and right ventricular function in the setting 
of acute afterload increase by exercise. 
a. After closure of atrial septum type secundum. 
b. In patients with mild to moderate pulmonary valve stenosis. 
c. In patients with repaired tetralogy of Fallot. 
4) Evaluation of surgical management of tricuspid regurgitation. 
a. In patients with isolated tricuspid regurgitation 
b. In the setting of mitral valve surgery.  
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CHAPTER 1 
TRICUSPID VALVE REGURGITATION: PREVALENCE AND RELATIONSHIP WITH DIFFERENT 
TYPES OF HEART DISEASE. 
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Abstract 
Objectives 
The clinical impact of tricuspid valve regurgitation (TR) is in most cases 
undetermined. This study aimed at evaluating: (1) the prevalence of tricuspid valve 
regurgitation, (2) the degree of its relationship with several types of heart disease and 
(3) the association of the routine echocardiographic variables with TR in each cardiac 
pathology. 
Methods and results   
The database of the University Hospitals of Leuven was searched for all transthoracic 
echocardiographic studies, performed between November 2010 and January 2011, to 
reach a target of at least 2000 patients. The study population was divided into 
predefined categories of heart disease: cardiac hypertrophy, heart transplantation, 
ischaemic cardiomyopathy, non-ischaemic cardiomyopathy, valvular heart disease 
and pulmonary hypertension. Furthermore a subgroup with a structurally normal heart 
was identified. Significant TR was defined as graded > 2/4 on colour Doppler. In total 
2054 consecutive echocardiographic studies were retrieved. The prevalence of 
significant TR was 10.2% in the total population, ranging from 1.1% to 34.4%. 
Compared to patients with a structurally normal heart, TR was strongly associated 
with pulmonary arterial hypertension (PAH)[OR 35.8 (11.7-110.3; P < 0.001)], 
valvular heart disease [OR 6.7 (2.3-19.2; P < 0.001)], heart transplantation [OR 10.4 
(3.4-31.8; P < 0.001)], non-ischaemic cardiomyopathy [OR 6.2 (1.8-21.3; P = 0.004)], 
and ischaemic cardiomyopathy [OR 5.6 (1.5-21.8; P = 0.012)]. TR was significantly 
related to the degree of mitral valve regurgitation (MR) in all categories (P < 0.001). 
Conclusion  
TR occurs frequently and is in a different degree related to the underlying heart 
disease. TR was also associated to MR. This might suggest valvular interdependence 
between the tricuspid and mitral valves. 
 
Introduction 
Tricuspid valve regurgitation (TR) is a common finding on routine echocardiography. 
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TR of any severity is detected in up to 85.7% of echocardiographic examinations.
1
 
The prevalence of moderate to severe TR varies in patients between 1.5% and 15% 
and is age-related.
1,2
  
The anatomy of the tricuspid valve and its subvalvular apparatus is complex. It 
consists of a fibrous tricuspid annulus, three leaflets (anterior, posterior and septal), 
two well-defined papillary muscles (anterior and medial) and one septal group of 
papillary muscles. The papillary muscles provide chordae to the tricuspid leaflets. 
Accessory chordal attachments to the right ventricular free wall and to the moderator 
band are present as well.
3,4
  
TR is most often functional, caused by tricuspid annular dilation that changes its 
three-dimensional geometry, and is frequently a consequence of left-sided heart 
failure.
5,6
 Primary (structural) TR accounts for 8-10% of all TR.
2,7
 Finally, iatrogenic 
causes such as a transvenous right ventricular pacing or shock lead, and repetitive 
right ventricular myocardial biopsies may induce significant TR.
8,9
  
TR has also an impact on the physical capacity. Patients who underwent successful 
mitral valve surgery, however, without simultaneous tricuspid valve annuloplasty, had 
a lower NYHA functional class and exercise capacity when compared to patients who 
underwent tricuspid valve annuloplasty.
10,11
 Increasing severity of TR is also 
associated with progression of symptoms, heart failure, and even death.
10,12,13
 Despite 
these findings, guidelines do not advise early intervention on the tricuspid valve, 
probably because isolated tricuspid valve surgery is considered a high-risk procedure 
with a perioperative mortality as high as 50% in some older series, but actually 
estimated between 8.8 and 25%.
14-21
  
To avoid ignoring TR, this study aimed at evaluating: (1) the prevalence of tricuspid 
valve regurgitation, (2) the degree of its relationship with several types of heart 
disease and (3) the association of the routine echocardiographic variables with TR in 
each cardiac pathology  
 
Methods 
Patient selection and data collection 
Patients were identified throughout the database of cardiac imaging at our institution, 
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a tertiary care centre. The database consists of hospitalized patients, referrals from the 
outpatient clinics as well as externally referred patients. The data of all consecutive 
routine transthoracic echocardiographic examinations, performed between November 
2010 and January 2011, were exported to a separate database for statistical analysis. 
The target was to achieve a total of at least 2000 echocardiographic examinations of 
different patients. When patients underwent more than one examination in this time 
period, the first available examination was used for inclusion in the study. Patients 
under age 16, patients with complex congenital defects, and patients with a 
structurally normal heart but a transvenous lead were excluded (figure 1). The local 
ethics committee approved the selection and the review process. 
 
Figure 1 Number of patients excluded from analysis 
 
 
 
Echocardiographic studies 
Experienced staff, supervised by a senior cardiologist, performed all 
echocardiographic studies. Measurements where done according to the criteria of the 
American Society of Echocardiography.
22
  
Left ventricular function was evaluated by means of a combination of visual 
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assessment and echocardiographic measurements and is represented by the left 
ventricular ejection fraction (LVEF, %). A LVEF ≤ 50% was considered as 
ventricular systolic dysfunction. Left ventricular dilation was defined as an end-
diastolic diameter larger than 53 mm. Left ventricular cardiac output was determined 
based on the continuity equation. The right ventricle was termed dilated when the 
maximal end-diastolic diameter exceeded 33 mm. The right and left atrial dimensions 
were determined at end systole. Valvular regurgitation severity was graded on a scale 
of 0 (no regurgitation) to a maximum score of 4, based on semi-quantitative colour 
Doppler flow mapping in all possible incidences with a jet-to-atrial-area ratio below 
10% (grade 1), from 10 to 20% (grade 2), from 20 to 40% (grade 3) and above 40% 
(grade 4). Aortic valvular stenosis was evaluated by determining the pressure gradient 
across the valve using continuous wave (CW) Doppler echocardiography and the end-
systolic aortic valve area (AVA) using the continuity equation. The severity of the 
valve lesion was defined as follows: no stenosis, elevated pressure gradient (CW 
Doppler derived peak pressure gradient > 12 mmHg), mild (CW Doppler derived 
peak pressure gradient > 20 mmHg), moderate (AVA ≥ 1 cm2 and CW Doppler 
derived peak pressure gradient > 80 mmHg or mean pressure gradient < 50 mmHg) 
and severe aortic stenosis (AVA < 1 cm2). Pulmonary artery systolic pressure (PASP) 
was estimated by CW Doppler echocardiographic measurement of peak regurgitant 
systolic velocity, using the simplified Bernoulli equation (4*TR velocity
2
). Right 
atrial pressure was not taken into account. A specific cut-off value for elevated PASP 
has not been defined in the literature. A value of ≥ 40 mmHg (TR velocity ≥ 3.2 
m/sec) was used as the cut-off for elevated PASP to avoid overestimating the 
prevalence of pulmonary hypertension. Dilation of the inferior vena cava was noted if 
the diameter was larger than 20 mm at inspiration and in absence of normal 
respiratory variation. 
Predefined categories of heart disease 
Patients were divided into 9 groups: (1) structurally normal heart, (2) cardiac 
hypertrophy, (3) coronary artery disease (CAD), (4) ischaemic cardiomyopathy 
(CMP), (5) non-ischaemic CMP, (6) valvular heart disease, (7) pulmonary arterial 
hypertension (PAH), (8) heart transplant, and (9) oncologic pathology. When a patient 
could be allocated to more than one group, the main reason of follow-up or the reason 
for referral was the first criterion for assignment to one specific category. Next, 
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echocardiographic structural abnormalities were considered more important than non-
structural abnormalities in the allocation process.  
The “structurally normal heart” refers to patients who were referred for a variety of 
non-specific complaints or as part of a standard workup in known non-cardiac 
pathologies (e.g. auto-immune disease) but in whom no structural abnormalities of the 
heart were noted. The presence of TR was not considered pathological if no other 
structural abnormalities were noted. “Cardiac hypertrophy” refers to patients with 
concentric remodelling, left chamber hypertrophy, isolated septal hypertrophy and 
hypertrophic cardiomyopathy (with preserved left ventricular systolic function). 
Patients with myocardial hypertrophy of the basal septum only were not included in 
this group. When left ventricular systolic function was compromised, patients were 
classified as “non-ischaemic CMP”. “CAD” was defined by the presence of 
atherosclerosis of the coronary arteries with preserved left ventricular systolic 
function and in the absence of regional myocardial wall contractility abnormalities. 
“Ischaemic CMP” consisted of patients with known coronary artery disease and 
prior myocardial infarction with a diminished left ventricular systolic function (LVEF 
≤ 50%) and/or regional myocardial wall contractility abnormalities. “Non-ischemic 
CMP” refers to patients with a decreased left ventricular systolic function (LVEF ≤ 
50%) without evidence of CAD. Patients who had a transient episode of decreased 
LVEF were still categorized as non-ischaemic cardiomyopathy. “Valvular heart 
disease” was defined as patients with worse than grade 2 mitral regurgitation (MR > 
2), worse than or equal to grade 2 aortic valve regurgitation (AR ≥ 2), any sign of 
elevated transvalvular aortic pressure 
gradient or any sign of degenerative or structural valvular lesions. Importantly, 
patients with isolated right-sided valvular regurgitation were not included in this 
group. “Heart transplant” were patients who underwent heart transplantation. 
“Oncologic pathology” consisted of patients who underwent treatment with 
chemotherapeutic agents. “PH” consisted of patients with type 1, 3, 4 or 5 PH 
according to the Dana point classification, in use at the time of study design and 
conduct.
23
 
Statistical analysis 
First, demographics were explored in the entire population and the predefined groups. 
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Continuous variables are presented as mean ± SD. Categorical data are presented as 
frequencies (percentage). Secondly, echocardiographic data of each subgroup were 
compared with those of patients with a structurally normal heart. To facilitate 
interpretation, TR severity was dichotomized in non-significant (TR ≤ 2) versus 
significant TR (TR > 2). For continuous data an unpaired t-test was used, whereas for 
categorical data a chi square test or a Fisher’s exact test was performed. Thirdly, 
univariate and multivariate (controlling for age, gender, body mass index (BMI) and 
mean blood pressure) logistic regression was performed to assess the degree of 
association between significant TR (defined as TR > 2/4) and the different categories 
of heart disease. Fourthly, correlations (Pearson’s correlation coefficient and 
Spearman’s rho where appropriate) were calculated for the severity of TR (0-4/4) and 
other standard echocardiographic variables. Partial correlations were calculated 
controlling for known determinants of TR (pulmonary artery pressure, right 
ventricular dilation, and atrial fibrillation).
24 
P < 0.05 was considered significant. All 
tests were two-tailed. Statistical analyses were performed using SPSS® (version 19, 
SPSS, Chicago). 
 
Results 
Patient selection 
A total of 2116 unique consecutive transthoracic echocardiographic studies were 
retrieved for analysis. Sixty-two patients were excluded: five because they were under 
16 years of age, eight because of a right ventricular pacing or shock-lead was present, 
and 49 because of the presence of complex defects (figure 1). Demographic data of 
the total study population (n=2054) and those of the different subgroups are 
summarized in table 1. Clinical parameters are listed in table 1 as well. More than 
99% of the patients were Caucasian. 
Prevalence of tricuspid valve regurgitation and association with type of heart disease 
The prevalence of significant TR was 10.2% in the total population. Significant TR 
was significantly more prevalent in cardiac hypertrophy (6.5%; P = 0.003), after heart 
transplantation (10.8%; P < 0.001), ischaemic CMP (12.8%; P < 0.001), non-
ischaemic CMP (13.7%; P < 0.001), valvular heart disease (15.7%; P < 0.001), and 
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PAH (34.4%; P < 0.001) when compared to patients with a structurally normal heart. 
The distribution of TR across the different subcategories is presented in figure 2.  
The univariate logistic regression showed an association with significant TR for all 
groups, except for CAD and oncologic pathology. In multivariate logistic regression, 
controlling for differences in demographics, significant TR was significantly 
associated with (in descending order) PAH [OR 35.8 (95% CI 11.7-110.3; P <0.001)], 
heart transplant [(OR 10.4 (95% CI 3.4-31.8; P < 0.001)], valvular heart disease [OR 
6.7 (95% CI 2.3-19.2; P < 0.001)], non-ischaemic CMP [OR 6.2 (95% CI 1.8-21.3; P 
= 0.004)] and ischaemic CMP (OR 5.6 (95% CI 1.5-21.8; P = 0.012)]. In multivariate 
logistic regression, significant TR was not significantly associated with CAD, 
oncologic pathology and cardiac hypertrophy. ORs are summarized in figure 3. 
 
Figure 2 Distribution of TR across different subcategories. 
 
 
Association of routine echocardiographic variables and TR 
Correlations and partial correlations between the degree of severity of TR and all 
echocardiographic parameters were calculated. In the total population, the highest 
correlation coefficient was found for PASP (R = 0.512; P < 0.001) followed by the 
degree of MR (R = 0.455; P < 0.001). When controlling for known determinants of 
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TR (PASP, RV dilation, atrial fibrillation), TR persisted to correlate with the degree 
of MR. Correlations are summarized in table 2. 
Figure 3 (A) Univariate logistic regression: effect of the dichotomized TR severity (≤ 
2/4 vs. > 2/4) on the prevalence of pathology compared to the structurally normal 
heart. (B) Multivariate logistic regression controlled for demographics: age, gender, 
BMI, mean blood pressure and degree of TR were forced in the model. Categories of 
pathology were compared with the structurally normal heart. *p < 0.05 
A. 
 
B. 
 
  
 
Table 1 Demographic and clinical characteristics of the study population, subdivided in categories of cardiac pathology. Syst BP = systolic 
blood pressure, diast BP = diastolic blood pressure, mean BP = mean blood pressure, BMI = body mass index, BSA = body surface area, aFib = 
atrial fibrillation, RV = right ventricle. 
 
 
 
total population 
structurally 
normal heart 
cardiac 
hypertrophy 
CAD 
 
ischemic CMP 
 
non-ischemic 
CMP 
PAH 
 
valvular heart 
disease 
oncologic 
pathology 
heart 
transplant 
Total  
n (%) 
2054 (100) 378 (18.40) 108 (5.3) 106 (5.2) 242 (11.8) 117 (5.7) 93 (4.5) 543 (26.4) 226 (11) 241 (11.7) 
Age 
Mean (±SD; range) 
61.9 
(± 15.8; 16-98) 
49.8 
(± 16.3; 16-94) 
61.7 
(± 14.7; 22-82) 
68.3 
(± 11.2; 31-88) 
71.2 
(± 10.6; 36-98) 
63.3 
(± 15.2; 21-89) 
61.3 
(± 14.8; 18-86) 
69.5 
(± 12.7; 22-93) 
54.3 
(± 11.5; 18-85) 
58.3 
(± 15; 17-84) 
male gender  
n (%) 
1123 (54.7) 179 (47.4) 64 (59.3) 81 (76.4) 200 (82.6) 79 (67.5) 35 (37.6) 261 (48.1) 38 (16.8) 186 (77.2) 
mean BP (mmHg) 99.3 (± 14) 99.7 (± 12.8) 102.2 (± 14.6) 98 (± 13.3) 95.5 (± 14.3) 94.1 (± 14.0) 94.2 (± 13.1) 100.9 (± 14.7) 97.9 (± 12,9) 103.6 (± 12.9) 
BMI (kg/m2) 
mean (±SD) 
26.3 (± 4.9) 25.5 (± 4.8) 28.3 (± 5.2) 27.6 (± 4.2) 27.2 (± 4.5) 26.8 (± 5.2) 26.7 (± 5.7) 26.5 (± 4.9) 25.6 (± 5) 25 (± 4,4) 
Rhythm 
 
          
- no aFib  
  n (%) 
1898 (92.4) 374 (98.9) 99(91.7) 100 (94.4) 210 (86.8) 91 (77.8) 91 (97.8) 470 (86.6) 225 (99.6) 238 (98.8) 
- aFib 
  n (%) 
156 (7.6) 4 (1.1) 9 (8.3) 6 (5.7) 32 (13.2) 26 (22.2) 2 (2.2) 73 (13.4) 1 (0.4) 3 (1.2) 
RV pacemaker lead 
n (%) 
134 (6.5) 0 (0) 10 (9.3) 3 (2.8) 40 (16.5) 28 (23.9) 1 (1.1) 29 (5.34) 0 (0) 23 (9.5) 
Mean BP = mean blood pressure; BMI = body mass index; aFib = atrial fibrillation; RV = right ventricular. 
  
Table 2 Correlations and partial correlations between TR and MR. TR = tricuspid regurgitation, MR = mitral regurgitation, aFib = atrial 
fibrillation, RV = right ventricular, PASP = pulmonary artery systolic pressure. 
 
 
  
 
total  
population 
structurally normal 
heart 
cardiac 
hypertrophy 
CAD ischemic 
CMP 
non-ischemic 
CMP 
PAH valvular heart 
disease 
oncologic 
pathology 
heart 
transplant 
MR (0-1-2-3-4/4) Correlation coefficient  .455* .327* .319* .608* .469* .427* .400* .397* .399* .413* 
   p<0.001 p<0.001 p=0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 
 Corrected for PASP, 
rythm, RV dilation 
 .392 .273 .272 .557 .343 .343 .426 .335 N/A .400 
   p<0.001 p<0.001 p=0.024 p<0.001 p<0.001 p=0.001 p<0.001 p<0.001 N/A p<0.001 
no aFib/ aFib Correlation coefficient  .220$ .087$ .241$ .197$ .235$ .255$ .195$ .276$ .053$ -.127$ 
   p<0.001 p=0.092 p=0.012 p=0.043 p<0.001 p=0.006 p=0.06 p<0.001 p=0.429 0.049 
 Corrected for PASP, 
MR, RV dilation 
 .121 .076 .034 .108 .105 .188 .117 .183 N/A -.184 
   p<0.001 p=0.203 p=0.779 p=0.342 p=0.164 p=0.076 p=0.28 p<0.001 N/A p=0.008 
RV dilation Correlation coefficient  .349$ .026$ .337$ .027$ .327$ .265$ .549$ .327$ -.056$ .143$ 
   p<0.001 p=0.614 p<0.001 p=0.787 p<0.001 p=0.004 p<0.001 p<0.001 p=0.399 p=0.026 
 Corrected for PASP, 
MR, rythm 
 .131 -.113 .125 .045 .216 .237 .29 .195 N/A .19 
   p<0.001 p=0.06 p=0.307 p=0.693 p=0.004 p=0.025 p=0.007 p<0.001 N/A p=0.006 
PASP Correlation coefficient  .512* .374* .395* .484* .555* .337* .626* .484* ,394* ,403* 
   p<0.001 p<0.001 p=0,001 p<0.001 p<0.001 p=0,001 p<0.001 p<0.001 p<0.001 p<0.001 
 Corrected for RV 
dilation, MR, rythm 
 0.369 0.328 0.297 0.429 0.437 0.272 0.499 0.341 N/A 0.379 
   p<0.001 p<0.001 p=0.013 p<0.001 p<0.001 p=0.009 p<0.001 p<0.001 N/A p<0.001 
* Pearson’s correlation coefficient; $ Spearman correlation coefficient;  MR = mitral regurgitation; aFib = atrial fibrillation; RV = right ventricular; PASP = pulmonary artery systolic pressure. 
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Discussion 
This study showed that the prevalence of significant TR is 10.2% in the entire study 
population. It is even more prevalent in PAH, heart transplantation, valvular heart 
disease, non-ischaemic CMP, and ischaemic CMP. We could confirm that significant 
TR is associated with the known determinants: elevated pulmonary artery pressure, 
right ventricular dilatation, and atrial fibrillation. Interestingly, we found a significant 
correlation between TR and the degree of MR, independently of previously identified 
determinants. 
TR occurs frequently in an echocardiographic protocol, but data are scarce on when 
and how it should be treated. Although low severity TR is generally well tolerated, 
significant TR may cause symptoms, biventricular failure and death.
10,12,13
 Studies 
have confirmed that increasing TR severity is associated with worse survival 
regardless of LVEF or pulmonary artery pressure.
2
 Therefore, in recent years, the 
evaluation of TR has regained interest of the clinician and researcher.  
Given the proposed scheme of pathogenesis as described in the introduction, TR 
should be more abundant in those pathologies that present with high pulmonary artery 
pressure, RV dilation, primary tricuspid valve disease, as well as atrial fibrillation. 
Indeed, also in this study, independently of demographic differences between the 
groups, the finding of TR is significantly more often linked with PAH, valvular heart 
disease, non-ischaemic and ischaemic CMP and heart transplantation. The first four 
categories typically present with elevated atrial pressures, higher pulmonary artery 
pressure, increased pre- and afterload, decreased myocardial function or dilation of 
the cardiac chambers. The occurrence of TR reflects these underlying haemodynamic 
changes. However, in transplants, the presence of TR is generally attributed to 
repetitive RV myocardial biopsies which causes injuries and scarring of both the 
tricuspid valve and the subvalvular apparatus.
9
 Adversely, in patients with CAD, 
oncologic pathology and cardiac hypertrophy (with preserved left ventricular 
function), haemodynamic changes are not expected to occur, thus the prevalence of 
TR was not statistically different from the control group. 
Interestingly, after controlling for the known determinants of TR, a significant and 
independent relation persisted with the degree of MR. This highly significant 
correlation between TR and MR was even present across all predefined groups, 
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inclusively the structurally normal heart subgroup. It is possible that apart from the 
thoroughly described ventricular interdependence, a kind of “valvular 
interdependence” might exist.14,25  
Several explanations for this apparent relation are possible, although they remain 
hypothetical. First, given the close relation of the fibrous tricuspid and mitral annulus, 
geometric disturbance of the cytoskeleton of the heart may occur if one of the two 
valves fails. The fibrous skeleton of the heart consists of a stable but deformable 
platform with two pairs of collagenous prongs spreading from the central fibrous body 
toward the left and the right, forming the mitral and tricuspid annulus, respectively.
26
  
The tricuspid annulus in particular is very dynamic and its size and geometry changes 
with loading conditions.
6,27
 In the paediatric population, the interaction between the 
two annuli of the tricuspid and mitral valve and its importance to maintain normal 
valve function has been illustrated by 3D echocardiography.
28
 In the adult population, 
the presence of aortic-mitral valve coupling has been evaluated using 3D-
transoesophageal echocardiography. The fibrous aortic curtain as part of the cardiac 
cytoskeleton was indicated as an important contributor to this coupling.
29
 These 
epidemiologic and experimental findings suggest that changes in the mitral valve 
annulus could thus provoke changes in the geometry of the tricuspid annulus, 
independently from haemodynamics, and cause TR. Secondly, valvular heart disease 
could be caused by degeneration of the fibrous skeleton, challenging both the mitral 
and tricuspid valve. Mitral valve disease may precede tricuspid valve disease, as the 
mitral valve is subject to higher pressure gradients than the tricuspid valve. This might 
be the reason why TR continues to evolve although mitral valve disease is stabilized 
by surgical intervention.
30-32
 In this process of simultaneous degeneration, humoral 
factors may play an important role. The role of matrix metalloproteinase and the 
renin-angiotensin system in structural remodelling of the volume-loaded heart has 
been studied both in rats and in a canine model for MR.
33-35
 In humans, it has been 
established that volume overload leads to a loss of interstitial collagen of the 
myocardium, producing a more compliant ventricle.
36,37
 Humoral factors, produced as 
a consequence of the volume loading caused by a regurgitant valve may alter the 
entire geometry and structure of the heart as the right and left ventricles share a 
common biochemical milieu. Thirdly, TR may originate from the haemodynamic 
changes caused by left-sided heart disease, thus causing functional changes in the 
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pulmonary circulation and the right ventricle. However, although pulmonary 
hypertension is a known determinant of TR, elevated PASP does not lead invariably 
to TR.
38
 Vice versa, the resolution of the elevated pulmonary artery pressure after 
mitral valve surgery does not always eliminate TR and TR often develops years after 
surgery.
30-32
 Fourthly, it is likely that the development of TR is best described by 
several mechanisms acting simultaneously on the valvular system, with a different 
contribution of each mechanism in a specific cardiac pathology. As several clinical 
observations remain unexplained, further research to unveil the contributing factors of 
TR development is warranted. Further, this may help us to obviate the reluctance to 
intervene early on the tricuspid valve and to identify patients eligible for correction of 
tricuspid valve pathology, isolated or in conjunction with mitral valve repair.  
Finally, our study has some limitations. Being based on the data from the echo-lab at 
a tertiary care centre, a selection bias is possible. However, rare pathology was 
excluded from the analysis. Next, echocardiography is a highly operator-dependent 
examination. However, due to the large sample size, over- and underestimation of 
echocardiographic parameters should be evened out. Thirdly, categorizing patients in 
groups of cardiac pathology remains an artificial process, but it might help to better 
understand the dataset. Finally, these findings are based on descriptive statistics. A 
causative relationship between observed factors can thus only be hypothesized. 
 
Conclusions 
Our findings show that TR is a common and important finding on routine 
echocardiography and is present in many different types of heart disease. We could 
confirm the current concept that significant TR is mainly associated with heart disease 
that presents with changes in cardiac haemodynamics and related geometry. However, 
the proposed pathogenesis seems to be incomplete. Independently of known 
determinants of TR, the degree of MR correlated significantly with TR. We 
hypothesize a kind of ‘valvular interdependence’. The key to this relation may lie in 
the cardiac cytoskeleton. More studies are needed to understand the impact of the 
tricuspid valve on cardiac geometry, haemodynamics, functional capacity, and 
outcome. 
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1. Pulmonary Arterial Pressure and Right Ventricular 
Dilatation Independently Determine Tricuspid Valve 
Insufficiency Severity in Pre- Capillary Pulmonary 
Hypertension. 
Abstract 
Background and aim of the study 
Elevated pulmonary artery systolic pressure (PASP) causes functional tricuspid valve 
insufficiency (TI). However, the differential contribution of pressure load and right 
ventricular (RV) dilatation is not well established. The study aim was to evaluate both 
variables in relation to TI. 
Methods 
A cross-sectional study was performed of consecutive transthoracic 
echocardiographic studies of patients with pre-capillary pulmonary hypertension 
(PH). Both, demographic data and echocardiographic RV parameters were reviewed. 
TI was graded semi-quantitatively with colour Doppler Flow imaging. Trend analyses 
for TI severity (TI grade 0/4, 1/4, 2/4, 3/4, or 4/4) were performed. A proportional 
odds logistic regression analysis was carried out to identify independent predictors of 
TI severity. 
Results 
Eighty-one patients (56 females, 25 males; mean age 60 ± 15 years) with pre-capillary 
PH were evaluated. Patients with more severe TI had a significantly lower body mass 
index, a lower mean systemic blood pressure, a shorter pulmonary acceleration time, a 
higher tricuspid regurgitant gradient, and a more dilated right ventricle. From the 
echocardiographic parameters, RV dilatation (p = 0.0143) and the tricuspid 
regurgitant gradient (p = 0.0026) were independently related to the degree of TI. 
Conclusion 
In patients with pre-capillary PH, PASP and RV dilatation were both related to the 
increasing severity of TI. When focusing on TI to improve the prognosis of patients 
with pre-capillary PH, both PASP and RV dimensions should be taken into
consideration. 
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Introduction 
Pre-capillary pulmonary hypertension (PH) is a serious and progressive disease with 
an important impact on right ventricular (RV) function. Patients with pre-capillary PH 
have a severely impaired prognosis, and the median survival of patients with 
pulmonary arterial hypertension (PAH) without treatment is 2.8 years.
1
 When  therapy 
is initiated survival is substantially improved, with a one-year survival of 88.4% 
compared to 71.8% if the patients are left untreated.
1,2 
Although specific vasodilator 
treatment effectively lowers the pulmonary vascular resistance (PVR), the patients 
will eventually develop RV dysfunction.
3 Most importantly, the patient’s 
characteristics appear to have a substantial impact on their individual prognosis.
4
 
Tricuspid valve insufficiency (TI) is a frequent echocardiographic finding, and is most 
often functional.
5,6
 Although functional TI is a frequent occurrence in patients with 
PAH, and its severity has an impact on functional capacity and prognosis, it is often 
disregarded in the routine clinical follow up.
7-9
 However, significant TI can cause an 
important additional volume-loading of the right ventricle and, when focusing on TI 
to reduce the volume overload of the right ventricle, a good understanding of the 
genesis of TI is necessary.  
The determinants of functional TI mostly have been studied in patients with mitral 
valve disease.
10-13
 However, in one retrospective study the determinants of functional 
TI were identified in patients with an increased pulmonary arterial systolic pressure 
(PASP), though unfortunately in this case the aetiology of the elevated PASP was not 
defined.
14 
In pre-capillary PH, TI is thought to occur mainly as a consequence of the 
elevated pulmonary artery pressure (PAP). However, a reduction in PAP after 
pulmonary endarterectomy (PEA) in patients with chronic thromboembolic 
pulmonary hypertension does not invariably reduce TI, indicating that other factors 
are involved.
15
 
Hence, the aim of the present study was to examine the determinants of functional TI 
in patients with precapillary PH. 
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Clinical material and methods 
Patient selection and data acquisition 
Patients with pre-capillary PH undergoing transthoracic echocardiography in routine 
clinical follow-up were retrospectively included from the database of 
echocardiography between November 2010 and May 2011. 
The patients were identified throughout the database of cardiac imaging at the 
authors’ institution, a tertiary care center. The demographic data and 
echocardiographic parameters were exported to a separate database for statistical 
analysis. An experienced staff, supervised by a senior cardiologist, performed all 
echocardiographic studies. The selection process and reviewing of the data were 
approved by the local ethics committee. No patients were excluded from the analysis. 
Echocardiographic parameters 
All RV two-dimensional (2D) echocardiographic and Doppler measurements were 
included for analysis.  
The tricuspid regurgitant gradient (TRG) was calculated by the continuous-wave 
Doppler echocardiographic measurement of peak regurgitant systolic velocity, using 
the simplified Bernouilli equation (4*TR velocity
2
). The inferior vena cava (IVC) 
diameter as a surrogate for right atrial pressure was considered as a separate 
parameter.  
Valvular regurgitation severity was graded on a scale of 0 (no regurgitation) to a 
maximum score of 4, based on semi-quantitative color Doppler flow mapping in all 
possible incidences with a jet-to-atrial area ratio of <10% termed grade 1, 10-20% 
grade 2, 20-40% grade 3, and >40% grade 4. The RV diameter was measured at end-
diastole at the level of the chordae; dilatation of the right ventricle was defined as 
none if the diameter was <3.3 cm, mild if between 3.4 and 3.7 cm, moderate if 
between 3.8 and 4.1 cm, and severe if ≥4.2 cm, or if the RV diameter was larger than 
the diameter of the left ventricle. Right atrial dimensions were determined at end-
systole. The diameter of the IVC was measured at inspiration. Measurements were 
made according to the criteria of the American Society of Echocardiography.
16
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Statistical analysis 
Continuous variables were presented as mean ± SD, or as median and interquartile 
range (IQR) when appropriate. Categorical data were presented as frequencies and 
percentages. Initially, all patients were allocated to groups according to the TI severity 
(0/4, 1/4, 2/4, 3/4, 4/4). Trend analyses for TI severity and demographic and RV 
parameters were performed using Spearman’s rank test and a chi-square analysis 
when applicable. A univariable proportional odds logistic regression analysis was 
then performed to determine the degree of association of the studied parameters with 
the degree of TI severity. Finally, in order to assess independence between the 
determinants of TI, a multivariable proportional odds logistic regression was applied 
to patients in whom values for all studied parameters were present. 
A p-value <0.05 was considered to be statistically significant, and all tests were two-
tailed. All statistical analyses were performed using SAS for Windows. 
 
Results 
The data acquired from 81 echocardiographic studies of unique patients with an 
established diagnosis of pre-capillary PH were reviewed and analyzed. Diagnosis of 
PH was made according to current guidelines and patients were classified according 
to the Dana point classification. (Figure 1) Thirty-nine patients (48%) had pulmonary 
arterial hypertension, 4 (4,9%) had pulmonary hypertension due to lung disease, 37 
had chronic thrombo-embolice pulmonary hypertension and in 1 patient (1%), 
pulmonary hypertension was caused by unclear/multifactorial reasons. Among those 
patients with pre-capillary PH, 15 had TI 1/4, 29 had TI 2/4, 20 had TI 3/4, and nine 
had TI 4/4, whereas in eight patients either none or only trace TI was detected. The 
demographic data (with respective p-values) are listed in Table I. Patients with more 
severe TI had a significantly lower body mass index (BMI) and a lower mean 
systemic blood pressure. Patients with a more severe TI presented with a significantly 
higher TRG, a more dilated right ventricle, a more enlarged IVC, and a shorter 
pulmonary valve acceleration time (PAT). Echocardiographic 2D and Doppler 
findings (with respective p-values) are listed in Table II. The distribution of the TRG 
and of RV dilatation in the different groups of TI severity are shown in Figures 2 and 
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3, respectively. 
When performing the multivariable analysis, patients were excluded when values of 
one or more of the studied parameters were missing (n = 67). From the 
echocardiographic parameters, RV dilatation (p = 0.0143) and TRG (p = 0.0026) were 
independently related to the degree of TI. Results from the univariable and 
multivariable proportional odds logistic regression analysis are listed in Table III. 
 
Figure 1 Type of pre-capillary PH according to the Dana point classification. 
 
 
 
Figure 2 Relationship between TI severity (grade 0 to 4/4) and tricuspid regurgitant 
gradient (Reg grad). Values are mean ± SD; p-value assessed using Pearson’s Rank 
Correlation test. 
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Figure 3 Relationship between TI severity and RV dilatation; p-value assessed using 
chi-square test for trend. 
 
  
Table 1 Demographics.  
 total TI 0/4 TI 1/4 TI 2/4 TI 3/4 TI 4/4 p-value 
Total N 81 8 15 29 20 9  
Age (y) (mean ± SD) 60 (± 15) 61 (± 13) 63 (± 11) 55 (± 17) 62 (± 13) 67 (± 20) 0.4759† 
Male gender N(%) 25 (30.9) 5 (62.5) 2 (13.3) 10 (34.5) 4 (20.0) 4 (44.4) 0.6439‡ 
Mean BP (mmHg)  
(mean ± SD) 
95.1 (± 13.2) 102.8 (± 14.1) 98.8 (± 13.5) 94.9 (± 11.5) 92.5 (± 14.3) 89 (± 12.3) 0.0095*,† 
BMI (kg/m2) (mean ± SD) 26.9 (± 6.0) 29.4 (± 5.4) 29.1 (± 5.4) 26.9 (± 6.1) 26.5 (± 6.3) 22.2 (± 3.5) 0.0024*,† 
Rhythm N(%)        
- Sinus 77 (95.1) 8 (100) 14 (93.3) 29 (100) 19 (95) 7 (77.8) 0.188‡ 
- AFib 3 (3.7)  1 (6.7)  1 (5) 1 (11.1)  
- Pacemaker 1 (1.2)     1 (11.1)  
TI=Tricuspid valve insufficiency; BP=Blood Pressure; BMI=Body Mass Index; AFib=Atrial Fibrillation. *=significant at p<0.05; † Spearman’s Rank 
for trend; ‡ Chi square for trend 
  
Table 2 Right Ventricle Echocardiographic parameters.  
 total TI 0/4 TI 1/4 TI 2/4 TI 3/4 TI 4/4 p-value 
Total N 81 (100) 8 15 29 20 9  
TV Reg Grad (mmHg)  
mean (± SD) 
63.8 (± 26.9) 33.8 (± 13) 36.1 (± 13.3) 67.6 (± 22.7) 76.4 (± 23.0) 86.9 (± 20.8) <0.0001
*,†
 
RV dilation n(%)       <0.0001
*,‡
 
  - No dilation 28 (34.6) 7 (87.5) 11 (73.3) 8 (27.6) 2 (10.0) 0 (0)  
  - Mild dilation 19 (23.5) 1 (12.5) 1 (6.7) 11 (37.9) 5 (25.0) 1 (11.1)  
  - Moderate dilation 19 (23.5) 0 (0) 3 (20.0) 6 (20.7) 7 (35.0) 3 (33.3)  
  - Severe dilation 15 (18.5) 0 (0) 0 (0) 4 (13.8) 6 (30.0) 5 (55.6)  
PAT (sec)  
mean (± SD) 
83.7 (± 18.7) 95.6 (± 19.9) 95.3 (± 20.6) 79.1 (± 16.1) 80.4 (± 17.9) 73.5 (± 10.4) 0.0026
*,†
 
IVC diameter (mm)  
median (Q1;Q3) 
9.0 (4.0;12.0) 5.0 (0.0;8.0) 7.0 (3.0; 9.0) 9.0 (5.0;11.0) 8.0 (3.5;13.0) 16.0 (13.0;22.0) 0.0022
*,†
 
TI=Tricuspid valve insufficiency; RV=Right Ventricular; TV Reg Grad=Tricuspid Valve Regurgitant Gradient; PAT=Pulmonary Acceleration Time; 
IVC=Inferior Vena Cava. *=significant at p<0.05; † Spearman’s Rank for trend; ‡ Chi square for trend 
  
Table 3 Univariate and multivariate proportional odds logistic regression for TI severity.  
  n univariable Odds Ratio (95% CI) 
univariable 
p- value 
univariable 
Odds Ratio (95% CI) 
multivariable (n=67) 
p-value 
multivariable (n=67) 
TV Reg Grad 
(mmHg)  
 78 1.059 (1.038-1.080) <0.0001 1.040 (1.014-1.066) 0.0026* 
RV dilatation Severe vs.  
no dilation 
81 52.803 (12.505-222.968) <0.0001 9.043 (1.322-61.855) 0.0143* 
 Moderate vs.  
no dilation 
 17.187 (4.804-61.486)  8.136 (1.651-40.100)  
 Mild vs. 
no dilation 
 9.052 (2.683-30.539)  4.026 (0.928-17.473)  
Gender Female vs. male 81 1.171 (0.502-2.732) 0.7148 1.463 (0.529-4.043) 0.4631 
age  81 1.009 (0.983-1.035) 0.5001 1.013 (0.982-1.045) 0.4131 
BMI  81 0.909 (0.848-0.975) 0.0072 0.907 (0.838-0.982) 0.0157* 
Mean BP  81 0.959 (0.930-0.990) 0.0089 0.987 (0.948-1.028) 
 
0.5180 
PAT  77 0.965 (0.943-0.987) 0.0021 0.991 (0.963-1.021) 
 
0.5627 
RV=Right Ventricular; TV Reg Grad=Tricuspid Valve Regurgitant Gradient; PAT=Pulmonary Acceleration Time. [n (%)]; *=significant at p<0.05 
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Discussion 
The study results showed that, in patients with precapillary PH, RV dilatation and 
elevated PASP, a combination of TVRG and IVC diameter, were both independent 
and strong determinants of TI severity. 
In the past, research focusing on the pathogenesis of TI has been mostly confined to 
functional TI secondary to mitral valve disease.
13
 Studies focusing on isolated TI, 
which is not caused by left-sided heart disease, have been scarce, although in one 
study the determinants of moderate and severe TI in patients with elevated PASP due 
to various reasons were investigated.
14
 In this heterogeneous population, RV 
dilatation, right atrial dilatation, and also PASP all contributed independently to the 
genesis of TI.
14
 Furthermore, the function of the right and left ventricle were 
interdependent, as dilatation of the right ventricle restricted filling of the left ventricle 
during late diastole, thus causing a further increase in the PAP.
17,18
 Taken together, 
these findings indicate that not only hemodynamic changes but also changes in the 
geometry of the right ventricle contribute to the genesis of TI.  
In patients with pre-capillary PH, these determinants have not yet been studied. In the 
present population, it was shown that TI severity was related independently with an 
increasing RV pressure-load and with increasing RV dilatation. This has been 
demonstrated in vitro as well as in patients with TI due to left-sided heart 
disease.
14,15,19-21 
The geometric remodeling of the right ventricle most likely originates 
secondary to the chronic pressure overload of the right ventricle, but may evolve 
autonomously after structural remodeling has been initiated.  
Tricuspid valve insufficiency is a frequent occurrence in the general population and 
also in patients with PAH.
5 
An increasing TI severity has an impact on both prognosis 
and on functional capacity.
7,8
 Although the prognosis of patients with PAH has 
improved since the introduction of PAH-specific therapies, it is strongly influenced by 
individual factors.
4
 Current therapeutic strategies are focused on lowering the PVR, 
either pharmacologically or surgically. However, although significant reductions in 
PVR can be obtained, its normalization is seldom achieved and consequently, over a 
period of time, progressive RV failure will occur and the patient’s functional status 
will further decline.
3
 This indicates that, in order to improve prognosis, attention 
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should be focused more on the entire hemodynamic status of the patient, rather than 
on the PVR and PAP alone.  
With this goal in mind, and as TI is a known cause of volume overload of the right 
ventricle, TI should be taken into account when performing diagnostic testing in 
patients with PAH. Furthermore, the results of the present study confirm that 
geometric remodeling plays an important role in maintenance of the TI induced 
volume-overload of the right ventricle. Consequently, the follow up examination 
should also focus on geometric remodeling of the right ventricle.  
Indeed, a supplemental and prolonged volume-overload in a pressure-loaded right 
ventricle leads to RV failure.
22
 Attempts to lower the PVR and PAP might be less 
effective when dilatation of the right ventricle is present, as right-sided volume-
overload might persist. Hence, the presence of TI might warrant a more aggressive 
therapy to improve the prognosis of patients with PAH. 
 
Study limitations 
The primary limitation was that the study findings were based on descriptive statistics 
in an ad hoc analysis of patients at routine follow up. Second, echocardiography is an 
operator-dependent examination. Third, right atrial enlargement was not taken into 
account because no effective data on right atrial dimensions were available. However, 
as the RV and right atrial dimensions were closely correlated, it was considered that 
the introduction of right atrial dimensions into the model would not have altered the 
findings.  
 
Conclusion: 
In conclusion, in patients with PAH, hemodynamic changes due to the elevation of 
PASP, as well as geometric changes of the right ventricle, are independently related to 
TI severity. Hence, a more aggressive therapy in patients with PAH might be 
warranted if significant TI were to be noted at echocardiographic follow up 
examination. 
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2. Geometry of the heart and tricuspid regurgitation to 
exclude elevated pulmonary artery pressure: new insights. 
 
Abstract 
Objectives 
The value of the right heart morphology is not well established for the evaluation of 
elevated pulmonary artery pressure (PAP). We aimed (1) to assess the relationship 
between right heart morphology and PAP and (2) to evaluate whether morphology can 
help to exclude elevated PAP. 
Methods 
 From 11-2010 until 01-2011, 1640 consecutive patients were included from  the 
database of echocardiography. Tricuspid regurgitation (TR) severity, right ventricular 
(RV) dilatation and right atrial (RA) dilatation were evaluated for (1) tricuspid 
regurgitant gradient (TRG) ≤ 30 mm Hg; (2) TRG = 30–40 mm Hg, and (3) TRG > 
40 mm Hg. A weighted score model was developed to diagnose TRG > 30 mm Hg. 
The model was validated with data from right heart catheterization in 100 patients. 
Results 
TR severity and RA diameter increased significantly from group 1 to group 2 and to 
group 3 whereas RV diameter differed only significantly from group 2 to group 3. To 
integrate TR severity, RA dilatation and RV dilatation, a point-based model was 
constructed. A total score ≥ 3 was associated with a sensitivity and specificity of 95% 
and 31% and with a positive and negative likelihood ratios of 1.37 and 0.17, 
respectively to diagnose TRG > 30 mm Hg. Negative predictive value for TRG > 30 
mmHg was 92%. Prediction numbers could be reproduced when right heart 
catheterization was used as a reference standard. 
Conclusions 
Increasing TRG is characterized by a steady increase in TR severity and RA 
dilatation. However, the RV dilates only significantly when TRG is markedly 
elevated. Integrating morphological parameters could reliably exclude the presence of 
elevated TRG and thus can be useful in screening for elevated PAP. 
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Introduction 
Elevated pulmonary artery pressures (PAP) can be present in a variety of diseases and 
can severely impair prognosis, however, the diagnosis remains difficult.
1, 2
 An exact 
measurement of PAP can only be obtained by right heart catheterization (RHC).
3, 4
 
However, RHC is an invasive procedure that is associated with a risk for serious 
adverse events and mortality.
5 
Therefore, non-invasive imaging modalities are used to 
provide estimates of PAP.
6
 Currently, the best echocardiographic estimate of systolic 
PAP is calculated by adding an estimated right atrial pressure (RAP) to the tricuspid 
regurgitant gradient (TRG) obtained by continuous wave (CW) Doppler 
echocardiography.
7, 8
 However, the measurement can only be acquired in 75-90% of 
patients in experienced hands and even then suboptimal CW traces are often 
obtained.
8, 9
 
If a good CW Doppler signal cannot be obtained, other measurements are proposed, 
including amongst others right ventricle ejection time, isovolumic relaxation time or 
right ventricular anterior wall thickness, and pulmonary acceleration time but none 
have been implemented in routine clinical practice often because of difficulties 
obtaining reproducible measurements.
10-16
 Pulmonary hypertension guidelines 
indicate that changes in right heart morphology should be taken into account when 
evaluating a patient suspect for elevated PAP.
3
 Unfortunately, the value of these 
measurements is not established yet and instructions on what should be measured are 
not given. Therefore, we aimed (1) to assess the relationship between right heart 
morphology and elevated PAP and (2) to evaluate if morphology can help to exclude 
patients with elevated PAP. 
 
Methods 
Population and echocardiographic analysis 
The digitalized echocardiographic database at the University Hospitals of Leuven was 
searched for all adult patients in whom a transthoracic echocardiographic study was 
done between November 2010 and January 2011. A total of 2054 unique patients 
were retrieved from the database. Patients with intracardiac shunts were excluded. 
TRG was calculated by means of the simplified Bernouilli equation (4 times velocity 
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squared). Only those patients in whom tricuspid regurgitant velocities could be 
obtained were included for analysis (n=1640). Based on TRG, patients were divided 
into 3 groups: (1) TRG ≤ 30 mmHg; (2) TRG = 30-40 mmHg and (3) TRG > 40 
mmHg.
3, 17
 
Indications for echocardiography included: “arterial hypertension”, known or suspect 
“ischemic heart disease”, known or suspect “valvular heart disease”, known or 
suspect “cardiomyopathy”, known or suspect “non-cardiac pulmonary hypertension”, 
“oncology” treated with cardiotoxic drugs and work-up pre- or post-“transplant” 
(kidney, lung, liver and heart). Lastly a group “miscellaneous” included patient 
referred for a variety of reasons being, pre-operatively, because of palpitations, 
syncope, neuro-muscular disorders, atypical chest pain, suspect for endocarditis and 
systemic disease screening. 
Right heart parameters studied included the severity of tricuspid regurgitation (TR), 
right ventricular (RV) and right atrial (RA) dilatation. TR severity was graded semi-
quantitatively based on colour Doppler echocardiography. The RV diameter was 
measured at end-diastole at the mid-ventricular level and was considered normal if 
RV diameter was smaller than 33 mm, mild dilatation if diameter was between 34 and 
37 mm, moderate dilatation if diameter was between 38 and 41 mm and severe 
dilation if diameter was larger than or equal to 42 mm.
18
 Categories were considered 
as ordinal variables and were numbered 0 (no dilatation) to 3 (severe dilatation). The 
RA long-axis dimensions were measured at end-systole and was considered normal if 
RA measured smaller than 53 mm, mild dilation if long-axis diameter was between 
53-57 mm, moderate between 58 to 60 mm and severe dilation >60mm.
19
 Categories 
were again considered as ordinal variables and were numbered accordingly 0 to 3. 
Acceleration time of pulmonary artery systolic flow (PAT) was measured from the 
PW Doppler tracings at the right ventricular outflow tract.
18, 19
 
Statistical analysis 
Continuous variables are presented by means and standard deviations. Categorical 
variables are presented using observed frequencies and percentages. 
First, comparative statistics were calculated with an analysis of variance (one-way 
ANOVA). Post-hoc test with Bonferroni-adjusted p-values were calculated 
subsequently. Second, multivariable logistic regression for TRG > 30 mmHg was 
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performed to obtain the regression coefficients for RA dilatation, RV dilatation and 
TR severity. Regression coefficients were determined by bootstrapping with 
resampling from 1,000 simulations thus obtaining a representable value for each 
parameter and improving prediction accuracy in the total population. Based on the 
regression coefficients, points were determined for each category of the right heart 
parameters to construct a weighted score model for diagnosing TRG > 30 mmHg. 
Next, probabilities associated with point totals were calculated.
20
 
Third, the score model was compared with PAT to predict TRG > 30 mmHg by 
means of a ROC analysis on the study sample. Sensitivity, specificity, positive 
likelihood ratio (LHR+), negative likelihood ratio (LHR-) were calculated 
appropriately. For the studied sample, positive predictive value (PPV) and negative 
predictive value (NPV) were calculated as well. Based on the calculated likelihood 
ratio, the post-test probability for a negative and a positive test was plotted for 
increasing prevalence of elevated pulmonary artery pressure in the studied population. 
Finally, a subset of patients that underwent right heart catheterisation was used as a 
validation cohort for the score model. Patients with an invasively measured mean 
PAP ≥ 25 mmHg were diagnosed with pulmonary hypertension.3 Corresponding 
echocardiographic data of transthoracic echocardiography were used to calculate the 
corresponding score and to assess the post-test probability of having elevated 
pulmonary artery pressure. For these patients in whom right heart catheterisation was 
performed, the predicted post-test probability to exclude pulmonary hypertension was 
compared with the definite diagnosis of pulmonary hypertension as obtained from 
invasive measurements of the mean PAP. 
Data were analyzed using SPSS
®
 (version 20, SPSS, Chicago). The local ethics 
committee approved the selection process and the review of the data. 
 
  
Table 1 Demographic and clinical characteristics of the study population 
 Total TRG obtainable TRG not obtainable 
  Total Group 1 
TRG ≤ 30 mmHg 
Group 2 
TRG 30-40 mmHg 
Group 3 
TRG > 40 mmHg 
 
n (%) 2014 (100%) 1640 (79.8%) 1146 (69.9%) 289 (17.6%) 205 (12.5%) 414 (20.2%) 
Demographics       
Male gender, n (%) 1123 (54.7%) 871 (53.1%) 614 (53.6%) 161 (55.7%) 96 (46.8%) 252(60.9%) 
Age, y (mean±SD) 62±16 63±16 59±16 70±12 71±14 59±15 
Atrial Fibrillation, n (%) 156 (7.6) 136 (8.3%) 54 (4.7%) 47 (16.3%) 35 (17.1%) 20 (4.8%) 
Mean BP, mmHg (mean±SD) 99±14 99±14 99±13 102±15.4 96±14 100±15 
Weight, kg (mean±SD) 75 ± 15 74±16 74±15 75±16 72±16 77±15 
BMI, kg/m
2
 (mean±SD) 26,3 ± 4.9 26.1±4.9 25.8±4.5 27.2±5.4 26.5±5.6 26.9±4.9 
Echocardiography       
TR severity x/4 (mean±SD) 1.12±1.020 0.98 ± 0.024 1.05 ± 0.85 1.80 ± 0.87 2.35 ± 0.89 0.23±0.61 
RA dilatation x (mean±SD) 0.51±0.84 0.57 ± 0.88 0.35 ± 0.67 0.88 ± 0.98 1.40 ± 1.11 0.28 ±0.60 
RV dilatation x (mean±SD) 0.12±0.47 0.14 ± 0.50 0.05 ± 0.28 0.10 ± 0.40 0.71 ± 0.99 0.04± 0.28 
Indication       
Arterial hypertension 55 (2.7%) 39 (2.4%) 29 (2.5%) 7 (2.4%) 3 (1.5%) 16 (3.9%) 
Ischemic heart disease 352 (17.1%) 265 (16.2%) 173 (15.1%) 58 (20.1%) 34 (16.6%) 87 (21.0%) 
Valvular heart disease 536 (26.1%) 461 (28.1%) 273 (23.8%) 118 (40.8%) 70 (34.1%) 75 (18.1%) 
Cardiomyopathy 142 (6.9%) 113 (6.9%) 74 (6.5%) 25 (8.7%) 14 (6.8%) 29 (7.0%) 
Non-cardiac PH 90 (4.4%) 88 (5.4%) 8 (0.7) 13 (4.5%) 67 (32.7%) 2 (0.5%) 
Oncology 257 (12.5%) 185 (11.3%) 165 (14.4%) 15 (5.2%) 5 (2.4%) 72 (17.4%) 
Transplant 297 (14.5%) 251(15.3%) 206 (18.0%) 37 (12.8%) 8 (3.9%) 46 (11.1%) 
Miscellaneous 325 (15.8%) 238 (14.5%) 218 (19.0%) 16 (5.5%) 4 (2.0%) 87 (21.0%) 
TRG: tricuspid regurgitant gradient; BP: blood pressure; BMI: body mass index; PH: pulmonary hypertension 
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Table 2 Differences in right heart parameters between groups 
 Total Group 1 
TRG ≤ 30 mmHg 
Group 2 
TRG 30-40 mmHg 
Group 3 
TRG > 40 mmHg 
p-value 
ANOVA 
p-value 
1 vs. 2 
p-value 
2 vs. 3 
n (%) 1640 (100%) 1146 (69.9%) 289 (17.6%) 205 (12.5%)    
TR severity x/4 (mean±SD) 0.98 ± 0.024 1.05 ± 0.85 1.80 ± 0.87 2.35 ± 0.89 <0.001 <0.001 <0.001 
RA dilatation x (mean±SD) 0.57 ± 0.88  0.35 ± 0.67 0.88 ± 0.98  1.40 ± 1.11  <0.001 <0.001 <0.001 
RV dilatation x (mean±SD) 0.14 ± 0.50  0.05 ± 0.28  0.10 ± 0.40  0.71 ± 0.99  <0.001 0.271 <0.001 
PAT, ms (mean±SD) 110±29 116±27 101±26 90±26 <0.001 <0.001 <0.001 
TRG: tricuspid regurgitant gradient; TR: tricuspid regurgitation; RA: right atrium; RV: right ventricle; PAT: pulmonary acceleration time; RA dilation graded 0 (no 
dilatation) to 3 (severe dilatation); RV dilatation graded 0 (no dilatation) to 3 (severe dilatation). 
 
 
 
 
 
  
Figure 1 Comparison of (A) RA dilatation between groups, (B) TR severity between groups and (C) RV dilatation between groups; mean ± SD. 
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Results 
Population and morphological changes 
A total of 2054 patients were retrieved from the database. Tricuspid regurgitant 
velocities could be obtained in 78.8% of patients (n=1640). Demographics and 
echocardiographic parameters are listed in Table 1 and 2.  
The indication to perform echocardiography and the prevalence of the echo alterations 
in each subgroup is described in Table 1 and 3. 
TR severity and RA dilation increased significantly from group 1 to group 2 and to 
group 3 (One-way ANOVA with Bonferroni post-hoc p<0.001) (Fig. 1A and 1B). 
RV dilatation differed only significantly from group 2 to group 3 (one-way ANOVA 
with Bonferroni post-hoc test p=0.271 and p<0.001 respectively) (Fig 1C). 
 
Table 3 Differences in right heart parameters for each indication for 
echocardiography.  
 TR severity RA dilatation RV dilatation 
 x/4 (mean ± SD) x (mean ± SD) x (mean ± SD) 
Arterial hypertension 0.76 ± 0.860 0.45 ± 0.662 0.02 ± 0.135 
Ischemic heart disease 1.13 ± 1.025 0.72 ± 0.866 0.09 ± 0.371 
Valvular heart disease 1.42 ± 1.045 0.75 ± 0.934 0.09 ± 0.381 
Cardiomyopathy 1.37 ± 1.082 0.97 ± 1.098 0.19 ± 0.595 
Non-cardiac PH 2,1 ± 1,086 1,32 ± 1,084 1,22 ± 1,124 
Oncologic 0.61 ± 0.721 0.14 ± 0.443 0.01 ± 0.108 
Transplant 1.24 ± 0.944 0.05 ± 0.242 0.07 ± 0.316 
Miscellaneous 0.61 ± 0.724 0.21 ± 0.509 0.02 ± 0.135 
PH: pulmonary hypertension; TR: tricuspid regurgitation; RA: right atrium; RV: right ventricle; RA 
dilation graded 0 (no dilatation) to 3 (severe dilatation); RV dilatation graded 0 (no dilatation) to 3 
(severe dilatation). 
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Score model to exclude elevated TRG 
Multivariate regression analysis showed that TR severity, RA and RV dilatation were 
independently related to TRG > 30 mmHg (Table 4). A scoring model was 
constructed based on TR severity, RA and RV dilatation. The score of each parameter 
is listed in Table 4. ROC-analysis to differentiate between TRG ≤ 30 mmHg and 
TRG > 30 mmHg was performed for the scoring model (AUC=0.808; CI 0.781-0.834; 
p<0.0001) and for PAT (AUC=0.716; CI 0.685-0.748; p<0.0001) (Fig 2). Sensitivity, 
specificity, LHR+ and LHR- are listed in Table 5. Post-test probability for a positive 
and a negative test is plotted for different prevalence (Fig 3). The prevalence of 
patients with a TRG ≥ 30 mmHg was 36%. A score ≥ 3 corresponded with a positive 
predictive value of 43% and a negative predictive value of 92 %. When compared to 
PAT < 100 msec, positive and negative predictive value was 56% and 77%, 
respectively and for PAT < 120 msec was this 45% and 83%, respectively.  
Table 4 Logistic regression to predict TRG > 30 mmHg 
 log regression bèta log regression p-value  points 
RA 0,457 <0,0001 no dilatation 0 
   mild dilatation 1 
   moderate dilatation 2 
   severe dilatation 3 
RV 0,377 0,016 no dilatation 0 
   mild dilatation 1 
   moderate dilatation 2 
   severe dilatation 2 
TR severity 1,071 <0,0001 0/4 0 
   1/4 2 
   2/4 4 
   3/4 6 
   4/4 8 
RA: right atrium; RV: right ventricle; TR: tricuspid regurgitation 
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Figure 2 Receiver operator characteristics curve for PAT and Score. PAT = 
pulmonary artery systolic flow acceleration time. 
 
Table 5 Performance of diagnostic test to predict TRG > 30 mmHg 
 SCORE ≥ 3 PAT < 100 ms PAT < 120 ms 
 "= TRG>30 mmHg" "= TRG>30 mmHg" "= TRG>30 mmHg" 
Sensitivity; % (95% CI) 94.9% (93.7-96.0) 61.5% (58.7-64.4) 83.9% (81.8-86.1) 
Specificity; % (95% CI) 30.8% (28.4-33.2) 72.5% (70.0-75.2) 43.1% (40.2-46.0) 
Positive Likelihood Ratio 1.37 2.25 1.47 
Negative Likelihood Ratio 0.17 0.53 0.37 
    Prevalence 36% 36%  
Positive predictive value; % (95% CI) 43.2% (40.7-45.8) 55.6% (52.6-58.5) 45.1% (42.2-48.0) 
Negative predictive value; % (95% CI) 91.5% (90.1-93.0) 77.2% (74.8-79.7) 82.8% (80.6-85.0) 
PAT: pulmonary acceleration time; TRG: tricuspid regurgitation gradient 
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Figure 3 Post-test probability relative to the presence of the studied population for a 
(A) positive test and (B) negative test. PAT = pulmonary artery systolic flow 
acceleration time.  
 
Evaluation of the model using right heart catheterisation 
The prevalence of mean pulmonary artery pressure ≥ 25 mmHg in this subset of 
patients was 75%. Based on the LHR-, our model predicts that a score < 3 should 
lower the post-test probability for pulmonary hypertension from 75% to 33% (Fig. 3) 
and corresponds to an expected negative predictive value of 67%. The results from the 
right heart catheterisation compared with the score-model are summarized in Table 6. 
Score < 3 decreased the pre-test probability from 75% to 26% as compared to 33% 
predicted by the model, corresponding with a measured negative predictive value of 
74%.  
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Table 6 Comparison of the score-model with the invasively determined diagnosis of 
pulmonary hypertension. Expected predictive values, determined based on the 
likelihood ratios are compared with the calculated values from the validation cohort. 
(n=number) 
 MeanPAP < 25 mmHg MeanPAP ≥ 25 mmHg total 
Score < 3 (n) 17 6 23 
Score ≥ 3 (n) 8 69 77 
 25 75 100 
     Expected predictive 
values based on the 
LHR+ and LHR- 
Measured predictive values 
from right heart 
catheterisation 
 
Prevalence 75% 75%  
Positive predictive value; % 
(95% CI) 
80% (78-83) 90 % (84-96)  
Negative predictive value; % 
(95% CI) 
67% (64-69) 74 % (65-83)  
 
Discussion 
First, this study shows that increasing TRG is characterized by a steadily increase in 
TR severity and RA dilatation. However, the RV dilates only significantly when TRG 
is markedly elevated. Secondly, the score-model based on right heart geometry and 
TR severity gives a good indication of the absence of pulmonary hypertension. When 
patients are screened for different clinical reasons by echocardiography, elevated PAP 
always needs to be excluded. RHC remains the gold standard to diagnose PH, but 
cannot be used as a screening tool. Therefore, PAP is estimated by TRG based on CW 
Doppler findings. When TRG cannot be obtained by echocardiography, alternatives to 
screen for elevated PAP are scarce. In daily practice the most utilised alternative to 
exclude the presence of elevated PAP is the measurement of PAT as determined by 
PW Doppler tracings at the right ventricular outflow tract.
10, 11
 However, this 
measurement is variable and dependent on heart rate.
11
  
PH is known to induce changes at the level of the right heart. Therefore, we wanted to 
investigate if the use of simple morphological criteria could exclude elevated PAP. It 
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is common practice that when the morphology of the right heart appears normal, 
elevated PAP is considered excluded, although this is not formally confirmed in the 
literature. Moreover, many physicians conclude that elevated PAP is excluded when 
the RV diameter is normal, but again, there are no data to support this. Therefore, we 
decided to select a large study sample of examinations from our department of 
echocardiography within a specific time period. This sample would provide us with 
enough morphologic information on the right heart, throughout different diseases. 
Because it was not possible to perform a RHC in all these patients, we compared the 
morphologic data with the TRG as a surrogate for PAP. For this purpose, the patient 
population was divided in 3 TRG categories. It is an on-going discussion which cut-
off values for TRG should be used in the screening for elevated PAP, therefore the 
cut-offs of TRG in our study were arbitrary but were based on a literature search and 
are currently used in our centre.
3, 17, 21, 22
 In patients with a TRG ≤ 30 mmHg, the 
diagnosis of PH is very unlikely. If the calculated TRG is between 30 and 40 mmHg 
and even more so if TRG is > 40 mmHg, a significant number of patients can be 
diagnosed with PH by RHC.
21, 22
  
In our study, the RV diameter was not significantly enlarged in those patients with a 
TRG between 30 and 40 mmHg when compared to those with a TRG ≤ 30 mmHg. As 
discussed earlier, in clinical practice, when RV dimensions are normal, the presence 
of elevated PAP is often ruled out. Based on these data, we have to conclude that the 
RV seems to dilate only in a later stage (if TRG > 40 mmHg) and, therefore, normal 
RV dimensions do not preclude the presence of increased PAP. RA dilatation and TR 
severity, however, show a steadily increase along the 3 categories. On the other hand, 
referring to table 3 and Figure 1 and 3, RA and RV dimensions might still be normal 
in the presence of clearly elevated PAP (group 3).  
Analysing these data, we decided that an integrative approach, combining several 
right heart parameters would yield a powerful, reliable and easy method to exclude 
the presence of elevated TRG. We decided not to evaluate the diameter of the inferior 
vena cava, as dilatation can occur in a range of pathologies as well as in sporty young 
adults without elevated PAP. Also, we did not focus on RV wall thickness as this is 
hard to measure in a standardized way and only significantly increases in patients 
with severe PH. Multivariate logistic regression showed in all 3 variables a strong and 
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significant relationship with TRG > 30 mmHg and a score-model was build. Figure 2 
and 3 show the performance of the score-model as well as a comparison with the 
currently applied cut-off values for PAT. A score < 3 reliably ruled out the presence 
of elevated pulmonary pressures as indicated by the negative LHR of 0.17. On the 
other hand, a positive test (i.e. a score ≥ 3) did not contribute importantly to the 
diagnosis of pulmonary hypertension (positive LHR = 1.37). Importantly, the 
predictive value of a test is highly influenced by the prevalence of the disease in the 
studied population. This is illustrated in Figure 3. This indicates that, based on this 
cut-off value, the presence of elevated PAP can be reliably excluded in low-risk 
populations if the test is negative. A positive test, however, did not add much 
information to the evaluation. Compared to PAT, the score-model excluded more 
reliably the presence of elevated PAP. Furthermore, in this sample, PAT was not 
helpful to diagnose elevated PAP as well, with a positive LHR comparable to a score 
≥ 3. 
Because controversy exists whether TRG is an accurate measurement of PAP, we 
validated the model in a subset of patients in whom invasive measurements were 
obtained and thus having a certain diagnosis of pulmonary hypertension.
22
 In this 
subset of patients, the prevalence of pulmonary hypertension was high and hence, 
negative predictive values would be unsatisfactory in clinical practice. It is obvious 
that this patient population would not qualify for a screening test, as the pre-test 
probability is very high. However, for the purpose of the study, we used this 
population to determine if our model reliably predicted the post-test probability of a 
positive and a negative test. We obtained similar results indicating that our model can 
be applied to exclude the presence of pulmonary hypertension. 
Combining several right heart parameters thus helps to exclude the presence of 
elevated PAP, as is indicated but not elaborated in the current guidelines on 
pulmonary hypertension.
3
 
 
Limitations 
Several limitations should be noted. First, although this study sample was large and 
spread in time, there might be always a selection bias. Second, the accuracy of the 
model could probably be improved when including more variables; however, this 
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adds to the complexity of the model and we believe that RA and RV dimensions, and 
TR severity are the easiest to obtain with high reproducibility. 
 
Conclusion 
This study showed that increasing TRG is characterized by a steadily increase in TR 
severity and RA dilatation. However, RV dilates only significantly when TRG is 
markedly elevated. An integrative approach to the patient with suspected elevated 
PAP is necessary, even more so if no good CW traces of the tricuspid valve can be 
obtained. The score-model based on geometry and TR severity could reliably exclude 
the presence of pulmonary hypertension in a low-risk population. 
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1.Increased pulmonary artery pressures during exercise are 
related to persistent tricuspid regurgitation after atrial septal 
defect closure 
 
Abstract 
Objective 
Although closure of an atrial septal defect type secundum often normalizes right heart 
dimensions and pressures, mild tricuspid insufficiency might persist. This study aimed 
at (1) identification of determinants, which could explain the persistence of tricuspid 
insufficiency after atrial septal defect closure and (2) evaluation of functional capacity 
of patients with persistent mild tricuspid insufficiency.  
Methods and results 
Twenty-five consecutive patients (age 42±17y) were included from the outpatient 
clinic of congenital heart disease at the University Hospitals of Leuven. All 
underwent transthoracic echocardiography, semi-supine bicycle stress 
echocardiography and cardio-pulmonary exercise testing. Six (24%) had mild 
tricuspid insufficiency (2/4) compared to 19 (76%) with no or minimal tricuspid 
insufficiency (≤1/4) as assessed by semi-quantitative colour Doppler 
echocardiography. Mann-Whitney U and Fishers Exact tests were performed where 
applicable. Patients with persistent mild tricuspid insufficiency were significantly 
older than those with no or minimal tricuspid insufficiency (p=0.042). At rest, no 
differences in right heart configuration, mean pulmonary artery pressure or right 
ventricular function were found. At peak exercise, mean pulmonary artery pressure 
was significantly higher in patients with mild persistent tricuspid insufficiency 
(p=0.026). Peak oxygen uptake was significantly lower in patients with mild 
persistent tricuspid insufficiency (p=0.019).  
Conclusions 
Mild tricuspid insufficiency after atrial septal defect repair occurs more frequently in 
older patients and in patients with higher mean pulmonary artery pressure at peak 
exercise. In patients with mild tricuspid insufficiency, functional capacity was more 
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reduced. Mild tricuspid insufficiency could be a marker of subclinical persistent 
pressure load on the right ventricle. 
 
Introduction 
Atrial septal defect type secundum is a common congenital heart defect with a 
prevalence of 1.43 in 1000 live births.
1
 Patients with an atrial septal defect present 
with a volume-overload of the right heart which leads to right ventricular and right 
atrial dilatation, decreased right ventricular function and finally right heart failure.
2, 3
 
Furthermore, pulmonary arterial pressure is frequently elevated.
4, 5
  
Tricuspid insufficiency is a common finding in patients with an atrial septal defect 
and is caused by a combination of elevated pulmonary artery pressure, right 
ventricular and tricuspid annulus dilatation, and an impaired right ventricular 
function.
6
 Moreover, increasing tricuspid insufficiency severity is associated with 
worse prognosis and decreased functional capacity.
7, 8
 Also after atrial septal defect 
closure, a persistent significant tricuspid insufficiency seems to be related with 
increased cardiovascular morbidity and mortality.
6
  
The reason why tricuspid insufficiency often persists after atrial septal defect closure, 
although pulmonary artery pressures at rest as well as right heart configuration 
normalizes, remains unknown.
9-14
 However, a recent study has shown that in patients 
with late atrial septal defect closure, although pulmonary artery pressure was normal 
at rest, pulmonary artery pressure increases more during exercise compared to patients 
who had an early intervention.
15
 We hypothesized that this abnormal increase in 
pulmonary artery pressure during exercise could maintain subtle morphological 
changes of the right heart and thus keeps tricuspid insufficiency. 
This study aimed at (1) the identification of determinants, which could explain the 
persistence of tricuspid insufficiency after atrial septal defect closure (including 
pulmonary artery pressure during exercise) and (2) the evaluation of functional 
capacity of patients with persistent mild tricuspid insufficiency after atrial septal 
defect closure.  
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Materials and Methods 
Patient selection and data collection 
Patients were retrieved from the outpatient clinic of congenital heart disease at the 
University Hospitals of Leuven between the 10
h
 of March and the 17
th
 of November 
2009. Patients had to have an atrial septal defect closed in the past and had to be older 
than 17 years. Further, patients with known coronary artery disease, significant 
valvular disease other than mild tricuspid or mitral regurgitation (>2/4), pulmonary 
disease, pulmonary embolism, concomitant congenital heart disease, a history of 
arrhythmias or current arrhythmias were excluded from the study. At the moment of 
inclusion, informed consent was obtained from all participants. The local ethics 
committee approved the data collection.  
Demographics 
Gender, age, and clinical characteristics were retrieved from the patients’ records. 
Mean blood pressure was calculated from the diastolic and systolic blood pressure 
values [(2 * diastolic blood pressure + systolic blood pressure) / 3]. 
Transthoracic echocardiography en bicycle stress echocardiography 
All patients underwent a standard transthoracic echocardiographic examination. All 
examinations were performed on a Vivid 7 or 9 ultrasound system (General Electric 
Vingmed Ultrasound, Horten, Norway) equipped with a 3 Mhz probe. Exercise 
echocardiography was performed on a semi-supine ergometer tilted laterally from 20° 
to 30° to the left (Easystress, Ecogito Medical sprl. Liège, Belgium). The protocol 
started at 25 watts with an increment of 25 watts every 2 minutes until the maximum 
tolerated load. Blood pressure and 12-lead ECG were recorded at rest and every 2 
minutes during exercise.  
A single observer performed the measurements. All measurements were made in 
triplicate. Analysis was done off-line using dedicated software (EchoPac BT08, 
General Electric Vingmed Ultrasound, Horten, Norway). 
In all patients, a complete resting echocardiographic study was performed in the 
supine position. All Doppler echocardiographic and Doppler tissue imaging 
recordings were obtained during normal respiration. At rest, valvular insufficiency of 
the atrioventricular valves was evaluated semi-quantitatively by colour Doppler flow 
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mapping with a jet-to-atrial-area ratio of <10% termed grade 1, 10-20% grade 2, 20-
40% grade 3 and > 40 % as grade 4. Care was taken in adjusting Nyquist limit and 
colour gain settings in every incidence to optimize the colour Doppler flow signal. 
From the apical window, the pulsed Doppler sample volume was placed at the mitral 
valve tips. Right ventricular diameter, as well as right atrial diameter was determined 
in the apical 4-chamber view. Measuring tricuspid annular plane systolic excursion on 
M-mode echocardiography assessed right ventricular function at rest.  
At rest as well as at every stage during exercise, right ventricular cardiac output was 
calculated from the flow velocity time integral in the right ventricular outflow tract 
obtained by pulsed wave Doppler echocardiography. When performing Doppler tissue 
imaging, filters were set to exclude high frequency signals and from the apical 4-
chamber view, a 5 mm sample volume was placed at the lateral corner of the mitral 
annulus. To evaluate diastolic function and elevation of left atrial pressure, e’ lower 
than 15 cm/sec and E/e’ higher than 8 was considered as impaired relaxation.16 
Tricuspid valve regurgitant gradient was calculated from tricuspid regurgitant 
velocities obtained by continuous Doppler echocardiography using the simplified 
Bernoulli equation (4 times velocity squared). Right atrial pressure was assumed 5 
mmHg as patients had no clinical symptoms of heart failure. Pulmonary artery 
systolic pressure was subsequently calculated as the sum of the tricuspid valve 
regurgitant gradient + 5 mmHg. Tricuspid valve regurgitant velocity was measured 
with contrast enhancement using agitated geloplasma, as previously validated at rest 
and during exercise.
17-19
  
Pulmonary vascular resistance (PVR) was calculated from the equation: (mean PAP – 
left atrial pressure) / cardiac output. Mean pulmonary artery pressure was calculated 
from pulmonary artery systolic pressure (0.61 times PASP + 2).
20
 Left atrial pressure 
was calculated from the equation: 1.91 + 1.24*(E/e’).21 
Cardio-pulmonary Exercise Testing: 
All participants underwent a symptom-limited, incremental cardio-pulmonary 
exercise test on a supine bicycle ergometer (Ergometrics, 800S, Ergometrics, Bitz, 
Germany). The initial workload of 20W was increased by 20W every minute until 
exhaustion. Twelve-lead ECG monitoring (Max Personal Exercise Testing, 
Marquette, WI), blood pressure monitoring and gas exchange measurements were 
CHAPTER 3 
1.INCREASED PULMONARY ARTERY PRESSURES DURING EXERCISE ARE RELATED TO 
PERSISTENT TRICUSPID REGURGITATION AFTER ATRIAL SEPTAL DEFECT CLOSURE 
 
103 
performed in all participants. Respiratory data were collected continuously by breath-
by-breath analysis (Oxygen AlphaR, Jaeger, Mijnhardt, Bunnik, The Netherlands). 
The Gas-exchange analyser was calibrated before each test. Oxygen and carbon 
dioxide concentration were continuously measured in the inspired and expired air to 
determine oxygen uptake (VO2) and carbon dioxide output (VCO2). Peak oxygen 
consumption (peakVO2) was defined as the highest 30s-average of oxygen uptake at 
the end of the test. Respiratory gas exchange ratio (RER) was calculated as carbon 
dioxide output divided by oxygen uptake (VCO2/VO2). 
Data analysis 
Patients were divided into two groups for comparison according to tricuspid 
insufficiency severity on resting echocardiography. One group consisted of patients 
with no or minimal tricuspid insufficiency, graded as ≤1/4 on semi-quantitative colour 
Doppler flow echocardiography. The second group consisted of patients with mild 
tricuspid insufficiency graded 2/4.  
Continuous data are presented as mean ± SD. Categorical data are presented as 
frequencies and percentages. Normality was assessed using the Shapiro-Wilk test of 
Normality. The criteria for normality were not met for mean pulmonary artery 
pressure at rest (p=0.035) and at peak exercise (p=0.016) as well as for tricuspid valve 
insufficiency severity (p<0.001). Mann-Whitney U non-parametric test or Fishers 
exact test were performed where appropriate. 
All tests were two-tailed. p<0.05 was considered significant. Statistical analysis was 
performed using SPSS
®
(version 19, SPSS, Chicago). 
 
Results 
Patient characteristics 
Twenty-seven patients with percutaneous closed atrial septal defect were retrieved for 
analysis. Two patients were excluded. In 1 patient, resting tricuspid regurgitant 
velocities could not be obtained, not in rest or at peak exercise. In another patient no 
tricuspid regurgitant velocities could be obtained at peak exercise. Data analysis was 
performed on the remaining 25 patients, mean age 42 ± 17 years. Demographic and 
clinical characteristics are listed in Table 1. There was a female predominance in our 
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study sample. Patients with persistent mild tricuspid insufficiency were significantly 
older than patients with no or minimal tricuspid insufficiency (p=0.042). There was 
no statistical difference between the two groups regarding the age at repair, although 
a trend can be assumed (p=0.065). Mean blood pressure, usage of calcium channel 
blockers and beta-blockade, body mass index and NT-pro BNP levels did not differ 
significantly between the 2 groups. (Table 1) 
Echocardiographic variables at rest and at peak exercise 
At rest, no significant differences were found for right ventricular diameter, right 
ventricular diastolic area, right atrial diameter, mean pulmonary artery pressure, right 
ventricular function as assessed by tricuspid annular plane systolic excursion or right 
ventricular cardiac output (Table 2). Further, there was no significant difference 
between the proportions of patients who presented with impaired relaxation of the left 
ventricle as assessed by e’ en E/e’ (Table 2). Calculated PVR did not differ 
significantly between groups. 
 
Table 1 Demographic and clinical characteristics. 
  Total TI ≤1/4 TI 2/4 P value 
Total patients N 25 19 6  
Gender (male) N (%) 6 (24) 6 (31.6) 0 (0) 0.278 
Age (y) Mean (±SD) 42 (17) 38 (15) 53 (18) 0.042* 
Age at repair (y) Mean (±SD) 34 (21) 30 (18) 47 (23) 0.065 
CCB N (%) 0 (0) 0 (0) 0 (0) -- 
Beta blocker N (%) 9 (36.0) 6 (31.6) 3 (50) 0.630 
NT pro-BNP (ng/l) Mean (±SD) 111 (80) 94 (64) 168 (97) 0.086 
BMI Mean (±SD) 26 (5) 25 (6) 27 (2) 0.127 
CCB: calcium channel blocker, BMI: body mass index; NT pro-BNP: NT pro natriuretic peptide 
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At peak exercise, mean pulmonary artery pressure was significantly higher in patients 
with mild TI compared to those with minimal TI (p=0.026). The evolution of mean 
pulmonary artery pressure during exercise is shown in Figure 1. The change in right 
ventricular cardiac output or in mean blood pressure did not differ significantly 
between the 2 groups at peak exercise (Table 2). E/e’ and e’ at peak exercise could be 
obtained in 18/25 patients. There was no significant difference in the prevalence of 
impaired relaxation between both patient groups (Table 2). 
Maximal exercise performance and severity of tricuspid insufficiency 
Peak oxygen uptake was significantly lower if mild persistent tricuspid insufficiency 
was present (p=0.019), however, no significant difference between the 2 groups was 
found when peak oxygen uptake was expressed as percentage of sedentary values. 
Furthermore, no significant differences concerning anaerobic threshold, respiratory 
gas exchange ratio or peak oxygen pulse were found (Table 3 and Figure 2). 
 
Figure 1 Evolution of mean PAP during exercise. Results are presented as means, 
error bars delineate standard deviation. (p<0.05 = significant) 
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Table 2 Echocardiographic parameters at rest and at peak exercise. 
  Total TI ≤1/4 TI 2/4 P value 
Values at rest      
MI  0/4 N (%) 15 (60%) 13 (68.4%) 2 (33.3%) 0.178 
  1/4  6 (24%) 3 (15.8 %) 3 (50%)  
  2/4  4 (16%) 3 (15.8 %) 1 (16.7%)  
Mean BP (mmHg) Mean (±SD) 88.4 (10.2) 87.1 (9.9) 92.7 (11) 0.203 
RV diameter (mm) Mean (±SD) 31.6 (6.8) 32.0 (7.7) 30.1 (2.8) 0.949 
RV area diast (cm
2
) Mean (±SD) 23.49 (5.5) 23.53 (6.14) 23.38 (3.47) 0.889 
RA diameter (mm) Mean (±SD) 45.3 (5.4) 45.1 (4.8) 45.9 (7.4) 1.000 
TAPSE (mm) Mean (±SD) 23.6 (5.0) 23.0 (5.3) 25.4 (3.7) 0.205 
RV CO (L/min) Mean (±SD) 4.2 (0.9) 4.2 (1.0) 4.1 (0.6) 0.656 
E’≤15 (cm/s) N (%) 13 (52) 8 (42) 5 (83.3) 0.605 
E/e’ ≥ 8 N (%) 2 (8) 2 (10.5) 0 (0) 0.456 
Mean PAP (mmHg) Mean (±SD) 18.95 (3.76) 18.46 (3.89) 20.51 (3.07) 0.127 
PVR (WU) Mean (±SD) 2.5 (1.1) 2.5 (1.3) 2.5 (1.3) 0.765 
Values at exercise      
Mean BP (mmHg) Mean (±SD) 104.0 (11.2) 104.3 (11.8) 102.8 (10.0) 0.545 
RV CO (l/min) Mean (±SD) 9.8 (2.8) 9.8 (3.2) 9.7 (1.5) 0.944 
E’≤15 (cm/s) N (%) 3 (16.7) 2 (11.1) 1 (5.6) 0.650 
E/e’ ≥ 8 N (%) 4 (22.2) 2 (11.1) 2 (11.1) 0.299 
Mean PAP (mmHg) Mean (±SD) 32.14 (6.39) 30.69 (6.08) 36.72 (5.46) 0.026* 
MI: mitral valve insufficiency; BP: blood pressure; RV: right ventricle; TAPSE: tricuspid annular 
plane systolic excursion; CO: cardiac output; mean PAP= mean pulmonary arterial pressure; PVR: 
pulmonary vascular resistance; WU: Wood Units. 
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Table 3 Exercise parameters.  
  Total TI ≤1/4 TI 2/4 P value 
Peak VO2 (ml/kg/min) Mean (±SD) 25.4 (8.7) 27.4 (8.7) 18.9 (4.6) 0.019* 
Peak VO2 % of predicted Mean (±SD) 90 (17) 90 (19) 90 (13) 0.774 
Peak Oxygen pulse (ml/beat) Mean (±SD) 11.6 (4.4) 12.2 (4.8) 9.7 (1.9) 0.408 
RER Mean (±SD) 1.14 (0.10) 1.15 (0.10) 1.11 (0.07) 0.390 
VE/VCO2 slope Mean (±SD) 27.1 (1.9) 26.7 (1.7) 28.6 (1.9) 0.026* 
Anaerobic threshold (Watt) Mean (±SD) 104 (65) 115 (71) 73 (27) 0.155 
Peak VO2: peak oxygen consumption; RER=respiratory gas exchange ratio 
 
Figure 2 Peak VO2 and percentage of predicted peak VO2. Results are presented as 
means, error bars delineate standard deviation.  
 
 
Discussion 
This study showed that patients with persistent mild tricuspid tricuspid valve 
insufficiency (2/4) after atrial septal defect closure are older, have a significantly 
higher mean pulmonary artery pressure at peak exercise, and tend to have their atrial 
septal defect closed at older age, when compared to patients with no or minimal 
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tricuspid insufficiency (≤ 1/4). Finally, patients with mild tricuspid insufficiency 
present with a lower maximal oxygen uptake. 
Tricuspid insufficiency is a common finding in patients with an atrial septal defect 
and originates from right ventricular dilatation, tricuspid annulus dilatation, increased 
pulmonary artery pressure as well as right ventricular dysfunction.
6, 22
 Persistent 
tricuspid insufficiency after atrial septal defect closure has been linked to an increased 
pulmonary artery pressure at rest.
13
 However, even though both right ventricle 
configuration and pulmonary artery pressure usually normalizes after atrial septal 
defect closure, persistent mild tricuspid insufficiency is often encountered.
9-14, 22, 23
 
This is also shown in our series.  
Persistent mild tricuspid valve insufficiency is age-related 
Patients who present with persistent mild tricuspid insufficiency after atrial septal 
defect closure are older than those with no or minimal tricuspid insufficiency. 
However, no significant relation between tricuspid insufficiency severity and late 
closure of the atrial septal defect was found, although a trend can be assumed. It can 
be hypothesized that the combination of age-related valve degeneration and a longer 
standing volume load by the presence of an atrial septal defect, interferes with the 
geometry of the tricuspid valve and, therefore, increases the age-related prevalence of 
tricuspid insufficiency. Moreover studies have indicated that if an atrial septal defect 
is closed after the age of 25 years, the mortality is slightly higher than in healthy 
controls with a 10 year survival of 90 % compared to 98 % respectively.
24
 This 
suggests that some processes in the right heart circulation are altered, including the 
development of tricuspid insufficiency, and lead to changes in outcome.   
Persistent mild tricuspid insufficiency is associated with higher mean pulmonary 
artery pressure at exercise 
We questioned why a different degree of tricuspid insufficiency was found in patients 
after atrial septal defect closure, although the morphological and functional 
characteristics of the right heart were similar between patients with mild and patients 
with minimal tricuspid insufficiency. However, at exercise there was a significant 
difference in mean pulmonary artery pressure between the patients that presented with 
persistent mild tricuspid insufficiency and those with no or minimal tricuspid 
insufficiency. It is known that in patients who underwent closure of the atrial septal 
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defect at older age, pulmonary artery pressure increases more during exercise 
compared to patients who underwent early closure.
15
 Additionally, we could now 
identify an association between persistent mild tricuspid insufficiency (2/4) and 
increased mean pulmonary artery pressure during exercise. This additional pressure-
load on the right ventricle during exercise might be a contributing factor to the 
persistence of tricuspid insufficiency after atrial septal defect closure maintaining 
subtle changes in right ventricular geometry, the valvular apparatus or the cardiac 
cytoskeleton. 
Reason for higher meanPAP at peak exercise 
The higher mean PAP at peak exercise could be explained by 2 mechanisms. First, 
long-standing volume-overload of the right ventricle as caused by an open atrial septal 
defect induces alterations in the histology of the pulmonary vasculature as well as 
pulmonary arterial vasoconstriction.
25-27
 Endothelial damage due to chronic 
pulmonary arterial congestion induces endothelial dysfunction, degradation of the 
extracellular matrix and inflammation of the pulmonary arterioles as well as the 
release of growth factors eventually leading to pulmonary hypertension.
28-30
 After 
atrial septal defect closure, these changes cause persistent elevated pulmonary artery 
pressure in some patients.
28, 31
 However, if these changes are minimal, pulmonary 
vascular resistance and consequently pulmonary artery pressure are normal at rest. 
When an exercise is initiated, the pulmonary vascular bed normally responds to this 
with lowering the pulmonary vascular resistance.
32
 If subclinical changes of the 
pulmonary vasculature have occurred, this decrease in pulmonary vascular resistance 
does not occur, leading to a larger increase in pulmonary artery pressure at peak 
exercise. On the other hand, age has been shown to be associated with higher 
pulmonary artery pressures at peak exercise.
33
 in the studied population; patients who 
presented with mild persistent TI were significantly older than those with TI ≤ 1/4. 
This fits with the higher meanPAP at peak exercise.  
Persistent mild tricuspid insufficiency is associated with a lower peak oxygen uptake 
Increasing severity of tricuspid insufficiency has an impact on the prognosis of 
patients.
7
 In patients with a closed atrial septal defect, persistent tricuspid 
insufficiency is associated with increased cardiovascular morbidity and mortality.
6, 13
 
In our series, patients with persistent mild tricuspid insufficiency had a significantly 
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lower peak oxygen uptake than patients with minimal or no tricuspid insufficiency, 
however, if peak oxygen uptake was expressed as a percentage of predicted peak 
oxygen uptake, no significant difference between groups was found. Other measures 
for exercise capacity or stroke volume were not significantly different either. Peak 
oxygen uptake is mainly determined by cardiac output (VO2=Cardiac Output * 
arteriovenous oxygen difference) and is age-dependent.
34
 The difference in peak 
oxygen uptake might therefore be solely attributed to the age difference between the 2 
groups. Nevertheless, lower pump efficiency caused by more severe tricuspid 
insufficiency, subclinical myocardial dysfunction as well as increased pulmonary 
artery pressure during exercise could lead to lower values for peak oxygen uptake. 
Possibly, in our series, the increase in mean pulmonary artery pressure at exercise 
causes only structural changes at the level of the right ventricle that lead to tricuspid 
insufficiency. The severity of tricuspid insufficiency however does not seem to 
influence exercise capacity. Most likely, tricuspid insufficiency in our studied 
population was not severe enough to see differences on cardio-pulmonary exercise 
testing. Unfortunately, the impact of more than mild tricuspid insufficiency could not 
be assessed from our dataset.   
Prognosis in patients after atrial septal defect closure 
Prognosis in patients who underwent atrial septal defect closure is good.
24
 Improving 
prognosis in patients who had late closure of an atrial septal defect remains difficult. 
A possible point of action might be the volume-overload of the right ventricle caused 
by persistent tricuspid insufficiency. Decreasing pulmonary artery pressure by 
targeted vasodilator therapy causes a reduction of tricuspid insufficiency severity.
35
 A 
possible therapeutic option in patients with mild persistent tricuspid insufficiency and 
increased pulmonary artery pressure during exercise could therefore be pulmonary 
specific vasodilator therapy. This could eventually lead to a decreased volume-
overload of the right ventricle, longer preservation of right ventricular function and 
improvement of functional capacity and prognosis. 
Study limitations 
This study has several limitations. Tricuspid insufficiency severity was graded semi-
quantitatively using colour Doppler flow echocardiography. During exercise, tricuspid 
insufficiency severity was not assessed. Patients with mild tricuspid insufficiency 
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were all female. However, although pulmonary artery systolic pressure at rest tends to 
be higher in females, studies have indicated that pulmonary artery systolic pressure at 
peak exercise is significantly higher in men than in women.
14, 36
 Next, tricuspid 
insufficiency 2/4 is currently not considered as pathological and most patients did not 
exhibit mean pulmonary artery pressure at peak exercise that are considered to be 
pathological.
37
 However, we did not want to identify exercise-induced pulmonary 
hypertension but wanted to assess differences in loading of the right ventricle as a 
cause of persistent mild tricuspid insufficiency. Further, analysis could be 
underpowered due to the small sample size. Last, these findings are based on 
descriptive statistics. A causative relation can thus only be hypothesized. 
Conclusion 
Persistent mild tricuspid insufficiency after atrial septal defect closure is common in 
clinical practice. A larger increase of pulmonary artery pressure during exercise could 
be the pathophysiological mechanism by which mild tricuspid insufficiency persists. 
However, further study is needed to confirm this hypothesis.  
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2. Functional and hemodynamic assessment of mild to 
moderate pulmonary valve stenosis at rest and during 
exercise.  
 
Abstract 
Objective 
In adult patients with mild to moderate pulmonary valve (PV) stenosis, exercise 
capacity and hemodynamics have not been extensively studied although regular 
exercise is recommended. Therefore, we aimed to assess exercise capacity, to study 
the increase in PV gradient during exercise, and to evaluate the impact of this 
increased pressure-load on the right ventricle.  
Methods 
Nineteen patients (8 female; 29±6.4 years) with isolated mild to moderate PV stenosis 
and no prior cardiac interventions were consecutively enrolled from the outpatient 
clinic of adult congenital heart disease. All patients underwent cardio-pulmonary 
exercise testing, transthoracic echocardiography and bicycle stress echocardiography. 
Results for exercise testing were compared to age and gender matched control 
patients.  
Results 
In the studied population, resting heart rate (89±11 vs. 75±14bpm; p=0.001), peak 
power (199±66 vs. 263±68Watt; p=0.006); peak VO2 (31.2±9.9 vs. 39±7.4ml/kg/min; 
p=0.011); Oxygen Uptake Efficiency Slope (2430±913 vs. 
3292±943(ml/min)/(l/min); p=0.007) and VE/VCO2 slope (26.8±5.2 vs. 22.6±4.3; 
p=0.01) differed significantly from controls. A linear increase of peak PV gradient 
with increasing flow was observed in the pooled dataset (Pearson’s R=0.947; 
p<0.0001) and slopes identical as for control patients were obtained for the oxygen 
pulse–workload relationship. Right heart morphology and function were preserved in 
the studied patients. 
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Conclusions 
Patients with mild to moderate PV stenosis have decreased exercise capacity. A linear 
increase in PV gradient with flow suggests a fixed valve area throughout the exercise. 
Although systolic RV pressure load increases during exercise, good ventricular 
performance was observed without signs of functional or morphological changes of 
the right heart. 
 
Introduction 
Pulmonary valve stenosis occurs in 1 per 2000 live births and accounts for 8% of all 
congenital heart defects. In 80-90 % of cases, the valve is dome-shaped with a pinhole 
orifice and no or incomplete separation of the leaflets. Rarely, the malformation 
consists of thickened valve leaflets with commissural fusion or pulmonary valve 
dysplasia.
1, 2, 3
 Evaluation of severity of stenosis is made by Doppler 
echocardiography with a transvalvular gradient <36 mmHg, between 36-64 mmHg 
and >64 mmHg considered as mild, moderate and severe pulmonary valve stenosis 
respectively.
4
 
In cases of severe outflow tract obstruction, infundibular hypertrophy and small 
subendocardial infarctions in the right ventricular free wall and papillary muscles can 
occur. Consequently, exercise capacity is reduced due to an inability to increase 
stroke volume with the increase in heart rate being the sole contributor to an increase 
in cardiac output.
5, 6
 Conversely, the natural evolution of mild pulmonary valve (PV) 
stenosis is considered to be benign without progression of the valve gradient after 
adolescence and no deaths are observed during an 8-year follow-up period.
3, 7
 Because 
of this, no restrictions in physical activity are imposed.
8, 9
  
However, the exercise capacity and hemodynamics of patients with mild to moderate 
PV stenosis have not been investigated thoroughly. Although the defect is simple, the 
increase in valvular gradient at peak exercise and its impact on exercise performance 
has hardly been investigated. Romeih et al. made a first attempt to investigate the 
mechanisms underlying possible impairment of the exercise capacity in patients with 
moderate PS. They demonstrated in a small group of asymptomatic patients with 
native moderate PS that the exercise capacity and cardiac reserve remained normal.
10
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However, their evaluation of cardiac function was based on pharmacological stress, 
rather than physical stress and the impact on pulmonary valve and right ventricular 
function was not documented.  
Therefore, we wanted to assess exercise capacity in patients with mild to moderate PV 
stenosis, to study the increase in pulmonary valve gradient with increasing cardiac 
output, and to evaluate the impact of the pressure-load at peak exercise on the right 
ventricle. 
 
Methods 
Patient selection and data collection 
From 18 October 2011 until 24 May 2013, consecutive patients were included from 
the outpatient clinic of congenital heart disease at the University Hospital of Leuven. 
Patients with isolated mild to moderate pulmonary valve stenosis, as evidenced by a 
PV Doppler gradient <64mmHg and no prior cardiac interventions were eligible for 
inclusion in the study. Exclusion criteria were age under 16 years and contra-
indication for exercise testing. Furthermore, patients with known coronary artery 
disease, significant valvular disease other than pulmonary regurgitation (>1/4), 
associated cardiac malformations and a history of arrhythmias or current arrhythmias 
were excluded from the study. Patients with Noonan’s syndrome or other 
chromosomal abnormalities were excluded. All patients had the classical form of 
pulmonary valve stenosis. All patients underwent symptom-limited cardio-pulmonary 
exercise testing and bicycle stress echocardiography. In all patients informed consent 
was obtained at inclusion. Approval for patient inclusion and data collection was 
obtained from the local ethics committee. 
Cardio-pulmonary exercise testing 
All participants underwent a symptom-limited, incremental cardio-pulmonary 
exercise test on a bicycle ergometer (Ergometrics, 800S, Ergometrics, Bitz, 
Germany). Workload was increased by 20 Watts every minute until exhaustion.  
Simultaneous gas exchange measurement, 12-lead ECG monitoring (Marquette Max 
Personal Exercise Testing, WI, USA) and blood pressure monitoring were performed. 
The oximeter was calibrated before each test. Respiratory data were collected by 
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breath-by-breath analysis (Oxygen Alpha®, Jaeger, Mijnhardt, Bunnik, The 
Netherlands) with continuous monitoring of oxygen and carbon dioxide 
concentrations in the inspired and expired air to determine oxygen uptake (VO2) and 
carbon dioxide output (VCO2). Peak oxygen consumption (peakVO2) was defined as 
the highest 30-s average of oxygen uptake at the end of the test. Respiratory gas 
exchange ratio was calculated as carbon dioxide output divided by oxygen uptake 
(VCO2/VO2). Anaerobic threshold was determined by the V-slope method. All slopes 
were calculated after exclusion of the first minute of exercise. The VE/VCO2 slope 
was calculated by plotting the VCO2 as a function of ventilation. The measurements 
after the respiratory compensation point were omitted. The oxygen uptake efficiency 
slope (OUES) was calculated by plotting the VO2 as a function of the log of 
ventilation. VO2 was plotted as a function of work rate resulting into the VO2/WR 
relationship. Oxygen pulse was calculated as the VO2 divided by heart rate.
11
 
Control population 
To compare the gas-exchange parameters of the patient population, a control 
population was selected from the database of cardio-pulmonary exercise testing at the 
university hospitals of Leuven by 1:1 age and gender matching. Matching was 
automated by using the “Fuzzy” extension command as available from the SPSS 
website (www.ibm.com). Parameters were set to obtain exact matches. 
Transthoracic echocardiography and bicycle stress echocardiography 
All patients underwent a standard transthoracic echocardiographic examination. All 
examinations were performed on a Vivid 9 ultrasound system (General Electric 
Vingmed Ultrasound, Horten, Norway) equipped with a 3 Mhz probe. Exercise 
echocardiography was performed on a semi-supine ergometer tilted laterally from 20° 
to 30° to the left (Easystress, Ecogito, Medical sprl, Liège, Belgium). The protocol 
started at 25 watts with an increment of 25 watts every 2 minutes until the maximum 
tolerated load.  
A single observer performed the measurements. All measurements were made in 
triplicate and averaged for analysis. Analysis was done off-line using dedicated 
software (EchoPac, Genereral Electric Vingmed Ultrasound, Horten, Norway).  
In all patients, a complete resting echocardiographic study was performed in the 
supine position. All Doppler echocardiographic and tissue Doppler imaging record-
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ings were obtained during normal respiration. At rest, valvular insufficiency of the 
atrioventricular valves was evaluated semi-quantitatively by colour Doppler flow 
mapping and valvular stenosis was evaluated by aligning the continuous wave 
Doppler beam with the studied valve. The highest velocities obtained were included 
for analysis and the pressure gradient was calculated from the simplified Bernoulli 
equation. From the apical window, the pulsed Doppler sample volume was placed at 
the tips of the mitral valve to evaluate the mitral valve inflow pattern. Also, right 
ventricular area was measured at end-diastole and end-systole from a RV focused 
apical 4-chamber view. Right atrium area was measured from the 4-chamber view at 
end-systole. Right ventricular function was evaluated by measuring the tricuspid 
annular plane systolic excursion (TAPSE) on M-mode echocardiography and 
fractional area change (FAC = (end-diastolic area – end-systolic area) / end-diastolic 
area) at rest from a RV focused apical 4-chamber view.  
At rest as well as at every stage during exercise, cardiac output and PV gradient were 
obtained. Cardiac output was calculated from the flow velocity time integral in the left 
ventricular outflow tract obtained by pulsed wave Doppler echocardiography. The left 
ventricular outflow tract diameter was measured at rest and assumed constant 
throughout exercise. PV velocities were measured by aligning the CW Doppler beam 
along the PV and the pressure gradient was subsequently calculated. TR severity was 
assessed by colour Doppler echocardiography and graded semi-quantitatively from 0-
4/4. 
Statistical Analysis 
Data of continuous variables are presented as means ± standard deviation and 
categorical variables as frequencies and percentages. 
Demographic and exercise parameters of the study and control population were 
evaluated using the independent student t-test and chi-square test where appropriate.  
Pearson’s correlation coefficient was calculated for resting pulmonary valve gradient 
and pulmonary valve gradient at peak exercise in each subject. Pearson’s correlation 
coefficient for cardiac output and PV gradient was calculated on the pooled 
measurements of all patients and every stage of exercise. Furthermore, the slope of 
the O2pulse–workload relationship of patients was compared to that of controls. To 
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allow for analysis of the pooled data and account for the inter-subject variability, 
Poon recalibration of the data was performed.
12
 
All tests were two-tailed. A P-value <0.05 was considered significant. Analyses were 
performed using SPSS
®
 (version 22 SPSS, Chicago, USA). 
 
Results 
Patient characteristics 
Nineteen patients with PV stenosis, 8 (42%) female, aged 29 ± 6.4 years, were 
included in the study. None of the patients had known chromosomal abnormalities 
and all were diagnosed with the classic form of PV stenosis. Demographic data can be 
found in Table 1.  
 
Table 1 Demographics of patients with pulmonary valve stenosis and healthy 
controls. Patients are compared using an independent student t-test or *chi
2
 test where 
applicable; p<0.05=significant.  
   Patients  Controls  
  N  N  P-value 
Gender N female (%) 19 8  (42) 19 8 (42) 1* 
Age (yrs.) Mean ± SD 19 29 ± 6.4 19 29 ± 6.4 1 
Height (cm.) Mean ± SD 19 174 ± 9 19 177 ± 12 0.33 
Weight (kg.) Mean ± SD 19 74.6 ± 15.6 19 74.6 ± 12.3 0.993 
BMI (kg/m
2
) Mean ± SD 19 24.6 ± 4.7 19 23.8 ± 3.5 0.538 
BSA (m
2
) Mean ± SD 19 1.9 ± 0.2 19 1.9 ± 0.2 0.704 
Heart rate (bpm) Mean ± SD 19 89 ± 11 19 75 ± 14 0.001 
Systolic BP (mmHg) Mean ± SD 19 122 ± 13 19 133 ± 18 0.049 
BMI= body mass index; BSA=body surface area; BP=blood pressure. 
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Cardio-pulmonary exercise test 
All patients performed a cardio-pulmonary exercise test at near maximal levels as 
evidenced by respiratory exchange ratio of 1.2 ± 0.08 in the patient population, 1.2 ± 
0.07 in the control population (p=0.067). 
In the studied patient population, heart rate increased from 89bpm ± 11 to 181bpm ± 
11. Resting heart rate was significantly higher in the patient population compared 
with age and gender matched controls (89 ± 11 vs. 75 ± 17 bpm; p=0.001). Heart rate 
reserve was significantly lower in the patient population ((92 ± 16 vs. 110 ± 21 bpm; 
p=0.007). (Figure 1) However, peak HR was not different compared to controls (181 
± 11 vs. 187 ± 17 bpm; p=0.5). 
Compared with controls, patients with PV stenosis presented with significantly lower 
exercise capacity as evidenced by a lower peak power (199 ± 66 vs. 263 ± 68 Watt; 
p=0.006); peak VO2 (31.2 ± 9.9 vs. 39 ± 7.4 ml/kg/min; p=0.011) and power at 
anaerobic threshold (83 ± 34 vs. 146 ± 41 Watt; p<0.0001). (Figure 1) 
Furthermore, patients had evidence of lower ventilatory efficiency as shown by a 
significantly lower OUES (2430 ± 913 vs. 3292 ± 943 (ml/min)/(l/min); p=0.007) and 
higher VE/VCO slope (26.8 ± 5.2 vs. 22.6 ± 4.3; p=0.01). (Figure 1) No significant 
difference in peak oxygen pulse (14.66 ± 4.3 vs. 15.98 ± 4.31; p=0.351) or in 
VO2/WR relationship (9.47 ± 1.18 vs. 9.73 ± 1.13; p=0.491) was observed. 
Lastly, the slope of the oxygen pulse as function of increasing workload didn’t differ 
between the patient population and the control population (y=0.039x+6.72 and 
0.040x+5.61 respectively; p=0.525). (Figure 2) 
Stress echocardiography 
Mean power at peak exercise for semi-supine bicycle stress echocardiography was 
146 Watt ± 47. The echocardiographic parameters at rest and during exercise of the 
PV stenosis patients can be found in Table 2. Left ventricular ejection fraction was 
68% ± 9%. None of the patients had signs of left ventricular diastolic dysfunction. 
Peak gradient across the pulmonary valve was 24 mmHg ± 12 at rest and increased to 
54 mmHg ± 22 at peak exercise. Cardiac output increased from 5.1 L/min ± 1.09 to 
12.4 L/min ± 3.2. Maximal gradient across the pulmonary valve correlated strongly 
with resting pulmonary gradient (Pearson’s R=0.905; p<0.0001). (Figure 3) 
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Evaluation of linearity of the pooled data showed a strong correlation between cardiac 
output and PV gradient (y=4.162x-2.463; Pearson’s R=0.947; p<0.0001). (Figure 4)  
PV gradient at rest and at peak exercise respectively didn’t correlate with peak cardiac 
output (R=-0.068; p=0.781 and R=0.212; p=0.480), peak stroke volume (R=-0.177; 
p=0.469 and R=0.051; p=0.835), TAPSE at rest (R=-0.086; p=0.727 and R=0.001; 
p=0.407) and RV fractional area change at rest (R=-0.282; p=0.257 and R=-0.208; 
p=0.407). Furthermore, no correlation was found for PV gradient at rest and at peak 
exercise for right atrial area (R=0.084; p=0.739 and R=0.336; p=0.173), RV diastolic 
area (R=0.253; p=0.331 and R=0.368; p=0.133) and RV systolic area (R=0.292; 
p=0.239 and R=0.362; p=0.140). No assessable increase in TR severity was seen 
throughout exercise. (Figure 5) 
Table 2 Echocardiography at rest and at peak exercise in the patient group.  
 Rest Peak exercise 
 Mean ± SD Mean ± SD 
Pulmonary valve gradient (mmHg) 24 ± 12 54 ± 22 
Stroke volume (ml) 69 ± 14 90 ± 19 
Cardiac output (L/min) 5.1 ± 1.09 12.4 ± 3.2 
Cardiac index (L/min/m
2
) 2.7 ± 0.6 6.5 ± 1.3 
LV ejection fraction (%) 68 ± 9  
Mitral inflow E velocity (cm/sec) 0.61 ± 0.14  
Mitral inflow A velocity (cm/sec) 0.53 ± 0.12  
Lateral mitral annulus E' velocity (cm/sec) 0.12 ± 0.02  
E/E' 4.12 ± 1.25  
RV fractional area change 0.40 ± 0.07  
TAPSE (cm) 2.3 ± 0.3  
RV area at diastole (cm
2
) 19.58 ± 4.76  
RV area at systole (cm
2
) 11.78 ± 3.70  
RA area at systole (cm
2
) 15.02 ± 3.49  
LV=left ventricle; RV=right ventricle; TAPSE=tricuspid annular plane systolic excursion. 
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Figure 1 Comparison of exercise parameters for patients with pulmonary valve 
stenosis and the age and gender matched control population. (A) Evaluation of heart 
rate at rest, peak exercise and the resultant heart rate reserve (HRR); (B) Peak oxygen 
uptake (VO2), peak power and power at anaerobic threshold (AT); and (C) 
Ventilatory efficiency by oxygen uptake efficiency slope (OUES) and 
ventilation/carbon dioxide output (VE/VCO2) slope. 
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Figure 2 Pooled analysis of all obtained measurements of oxygen pulse as a function 
of increasing workload. No difference in the slope of the oxygen pulse – workload 
relationship was found.  
 
Figure 3 Analysis of pulmonary valve gradient at rest and at peak exercise for all 
subjects. PV=pulmonary valve. 
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Figure 4 Pooled analysis of all obtained measurement of cardiac output and 
pulmonary valve gradient during exercise echocardiography.  
 
Figure 5 TR severity (X/4) at rest and at peak exercise as assessed by Colour Doppler 
Echocardiography. 
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Discussion 
This study showed that patients with mild to moderate PV stenosis present with 
decreased exercise capacity and ventilatory efficiency compared to age and gender 
matched controls. However, right ventricular performance and right heart morphology 
was preserved in the studied patients. Lastly, PV gradient increases linearly with 
increasing flow. 
In adult patients with severe PV stenosis, exercise capacity is limited.
5
 The 
hemodynamic response to exercise in patients with mild pulmonary valve stenosis is 
not well studied. Mild PV stenosis is considered benign and patients can participate in 
recreational or competitive sports. Adults with moderate pulmonary valve stenosis are 
subjected to closer follow-up, but when asymptomatic are not limited in moderate 
recreational sporting activity and should be encouraged to do so.
8, 9
  
In our study, only 4 patients had moderate pulmonary valve stenosis. Nevertheless, 
the studied population presented with a decreased exercise capacity. This in in 
contrast with Romeih et al. who documented a preserved exercise capacity in 11 
patients with moderate PS.
10
 Higher resting heart rate, lower heart rate reserve, peak 
oxygen levels and peak power all point towards a lower physical condition as 
compared with an age and gender matched control group. Additionally, ventilatory 
efficiency, i.e. OUES and VE/VCO2 slope, was equally impaired. These are known 
exercise parameters that are independent from the endpoint of a maximal exercise 
test, which have shown their value in different heart disease populations.
13, 14, 15
 
Furthermore, it has been shown that both exercise capacity and ventilatory efficiency 
improve after relieve of right ventricular pressure load in patients with pulmonary 
valve stenosis, even if only small improvements of valvular gradient are obtained 
post-intervention.
16, 17
 An increase in afterload reserve and the associated increase in 
stroke volume at peak exercise is the most likely underlying mechanism.
16 
Contradictory to these findings, no significant difference between patients and 
controls was observed for peak oxygen pulse or for the slope of the oxygen pulse – 
workload relationship. (Figure 2) Both TAPSE and RV fractional area change at rest 
were within the reference values. These data suggest that stroke volume is not 
influenced by the presence of mild to moderate PV stenosis. Because our patients 
were asymptomatic, differences in afterload reserve in our patients with mild to 
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moderate PV stenosis compared to controls might be less pronounced then in the 
patient population with more severe obstruction studied by others. Otherwise, in adult 
patients with only mild PV stenosis, diastolic dysfunction of the right ventricle may 
contribute to a decreased stroke volume.
6
 However, in this study severe diastolic 
dysfunction was not observed as evidenced by normal right atrial dimensions. 
Possibly, ventilation-perfusion mismatching due to preferential perfusion of certain 
regions of the lung might cause impaired ventilatory efficiency. Indeed, depending on 
the morphology of the valvular stenosis preferential flow to the left or right lung is 
noticed. Lastly, changes in respiratory function, oxygen delivery or oxygen extraction 
in the peripheral muscles could contribute as well.  
Furthermore, although pressure load of the right ventricle was significantly elevated at 
peak exercise, no changes in right heart morphology and onset of TR could be seen 
with increasing maximal pressure load. The pressure load on the right ventricle at 
peak exercise can be as high as 90 mmHg, well beyond what is considered to be 
physiological and could be associated with RV dysfunction or arrhythmic problems in 
the long-term. Patients included in the study were young and the consequences of life-
long pressure increase still have to be established. However, at present, our studied 
population with mild to moderate PV stenosis does not show morphometric changes 
in the right heart and no assessable increase in TR severity. (Figure 5) This is 
different to what we found in a cohort of patients with pulmonary hypertension where 
morphometric changes are strongly related with the pressure load on the right heart.
18
 
This might be because the absolute values of pressure-load in patients with pulmonary 
hypertension tend to be higher at rest and during exercise compared to our study 
sample and ventricular function is often impaired in PH patients. Furthermore, in PV 
stenosis, several factors are thought to contribute to better preservation of right 
ventricular morphology. The onset, hemodynamic profile and compensatory 
mechanisms in pulmonary hypertension are very different compared to patients with 
PV stenosis. In the studied patients, the pressure-load is already present to some 
extent at birth, it is a purely systolic pressure load and neurohormonal or gene and 
protein synthesis alterations are thought to play a role in the better preservation of 
right ventricular morphology and function.
19, 20, 21
 To what extent each contributes to 
this favourable remodelling of the right ventricle has still to be investigated.  
In summary, the studied patients presented with a decreased exercise capacity, but 
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were able to increase their stroke volume similarly to healthy controls. In these 
patients, the lower exercise capacity is therefore mainly attributable to a lower 
physical fitness, and probably not directly related to the higher right ventricular 
afterload. The preservation of right heart morphology and function is reassuring and 
confirms the current practice not withholding recreational exercise in these patients.
8, 9
 
Promotion of physical activity seems therefore safe and should be mandatory in 
routine follow-up. However, long-term effects of this lesion on right heart 
morphology and function remain uncertain. 
Finally, we showed a strong linear relation between PV gradient and cardiac output 
during exercise. Consequently, the resting PV gradient was predictive for the peak PV 
gradient and from the pulmonary resting gradient; the maximum pressure load at peak 
exercise can be calculated (y=1.669x+13.29). This linear relationship between 
pressure and flow indicates again a good ventricular performance. On the other hand 
this indicates a fairly fixed valve area in patients with the classical form of PV 
stenosis. The absence of a dynamic component also indicates the absence of 
infundibular hypertrophy as is seen in patients with severe PV stenosis. Our studied 
patients with mild to moderate pulmonary valve stenosis do not appear to present with 
such remodelling. This indicates that, if the PV echocardiographic gradient is only 
mild to moderately elevated, and if the gradient remains stable throughout follow-up, 
the pressure-load is well tolerated and early intervention is not indicated. 
 
Conclusion 
We showed that patients with mild to moderate PV stenosis do have impaired exercise 
capacity. In PV stenosis, the valve area is fixed throughout the exercise. At present, 
we don’t have a reason to exclude patients from recreational sports, as no signs of 
functional or morphological changes of the right heart were observed in the studied 
range of valve gradients. 
 
Limitations 
Our results are based on a fairly small study sample and the study has been done in a 
single centre. However, we were able to match the patient population with a well-
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established control population. This made useful comparative statistics possible. The 
number of patients is relatively low for calculating correlations.  However, the group 
of patients is quite homogenous with no outliers. Therefore, we believe that an 
absence of correlation can be interpreted, however, with careful consideration. Long-
term follow-up data are needed to confirm this. 
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3. Pilot trial: The impact of right ventricular contractile reserve 
on tricuspid regurgitation severity in patients with repaired 
tetralogy of Fallot.  
 
Abstract 
Objective 
The impact of right ventricular (RV) dysfunction in the pathogenesis of tricuspid 
regurgitation (TR) is incompletely understood. We aimed (1) to assess RV contractile 
reserve in patients with repaired tetralogy of Fallot and (2) its relation with TR 
severity in a pilot trial.  
Methods and results 
From March until June 2014, 5 patients [all male, median age 24 (range 20-32)] with 
repaired tetralogy of Fallot, were consecutively included from the outpatient clinic of 
congenital heart disease and were able to complete the study protocol. All patients had 
a pulmonary homograft at the level of the RV outflow tract. All patients underwent 
baseline echocardiography and symptom-limited bicycle stress echocardiography to 
evaluate the increase in pulmonary valve gradient with increasing flow. Next, low-
dose dobutamine stress cardiac magnetic resonance imaging (CMR) was performed to 
evaluate right ventricular contractile reserve. 
Patients performed submaximal on bicycle stress echocardiography with peak heart 
rate 140 bpm (range 120-142) and peak cardiac output 12 L/min (range 7.4-21). The 
median of the peak instantaneous pressure gradient across the pulmonary homograft 
at rest was 46 mmHg (range 12-55 mmHg) and increased to 68 mmHg (range 43-108 
mmHg) at peak exercise.  
On dobutamine-stress CMR, 4 patients showed a preserved contractile reserve. In 1 
patient, a bimodal response was observed with initial increase in RV stroke volume at 
10µg/kg/min but decreased stroke volume at 20µg/kg/min dobutamine infusion. 
Patients had no to only slight TR at baseline (median tricuspid regurgitant fraction 6% 
(range -3%–15%)). Only the patient with impaired RV contractile reserve showed an 
CHAPTER 3 
3. PILOT TRIAL: THE IMPACT OF RIGHT VENTRICULAR CONTRACTILE RESERVE ON TRICUSPID 
REGURGITATION SEVERITY IN PATIENTS WITH REPAIRED TETRALOGY OF FALLOT. 
 
132 
increase in regurgitant fraction from 6% to 41% and 34% at 10µg/kg/ml and 
20µg/kg/ml dobutamine infusion respectively. 
Conclusions 
We observed an increase in tricuspid regurgitant fraction in 1 patient presenting with 
impaired RV contractile reserve. Although we can’t make solid conclusions given the 
low patient number, these findings hint towards a possible contribution of right 
ventricular dysfunction in preservation of tricuspid valvular competence.  
 
Introduction 
In the general population, tricuspid regurgitation (TR) of any severity occurs in more 
than 80% of patients, whereas significant TR > 2/4 is observed in only 1%.
1
 On the 
other hand, TR is much more prevalent in many cardiac diseases and is associated 
with impaired prognosis.
2, 3
 Right ventricular (RV) dilatation, tricuspid annular 
dilatation and increased RV pressure are known determinants of TR.
4, 5, 6
 However, 
neither of these lead invariably to severe TR. Less than severe TR can be observed in 
patients with a dilated right ventricle or tricuspid annulus or in patients with 
pulmonary hypertension.
5, 7, 8
 RV function has sometimes been suggested as being a 
key factor in the pathogenesis of TR.
4, 9
 Unfortunately, it is often difficult to evaluate 
the influence of RV function as it occurs often in the presence of RV dilatation and/or 
in the pressure-loaded RV.  
Tetralogy of Fallot is the most common cyanotic congenital heart disease, consisting 
of a combination of 4 defects: (1) a non-restrictive ventricular septal defect, (2) an 
overriding aorta, (3) RV outflow tract obstruction and (4) RV hypertrophy. Patients 
present with cyanosis immediately after birth and complete surgical correction, 
sometimes as a staged approach to mature the pulmonary circulation, is performed at 
infancy. Although good long-term outcome is observed in these patients, development 
of RV outflow tract obstruction and RV failure can occur in follow-up. Furthermore, 
studies have shown that a subset of patients can present with impaired contractile 
reserve, as evaluated by low dose dobutamine-stress CMR.
10
 This offers the unique 
opportunity to study the evolution of TR severity in patients with preserved and 
decreased contractile reserve. 
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Therefore, we performed a pilot study to evaluate (1) right ventricular contractile 
reserve in patients with repaired tetralogy of Fallot and (2) to evaluate its impact on 
tricuspid regurgitant severity. 
 
Methods 
Patient selection 
From 14 March until 17 June 2014, patients were consecutively included from the 
outpatient clinic of congenital heart disease. Patients had repaired tetralogy of Fallot, 
with a pulmonary homograft in the position of the RV outflow tract. Patients had to be 
older than 18 years with no more than mild pulmonary and/or aortic valve 
regurgitation.  Other exclusion criteria were pregnancy, QRS duration ≥ 180 msec, a 
history of ventricular tachycardia or ventricular fibrillation, atrial fibrillation, 
claustrophobia and any contra-indication for CMR, dobutamine infusion or exercise 
testing. Patients with concomitant left-sided heart failure or chronic lung disease were 
excluded as well. Criteria for discontinuation of the study were significant discomfort 
of the patient, heart rate > 75% of predicted (220-age) or dysrhythmia. 
The ethics committee approved patient inclusion and data analysis. 
Baseline echocardiography and bicycle stress echocardiography 
Baseline transthoracic echocardiography and bicycle stress echocardiography were 
performed in all patients. All examinations were done on a Vivid 9 ultrasound system 
(General Electric Vingmed Ultrasound, Horten, Norway) with a 3 MHz probe. 
Symptom-limited bicycle stress echocardiography was performed in the semi-supine 
position, with the ergometer (Easystress, Ecogito, Medical sprl, Liège, Belgium) tilted 
laterally from 20°-30° to the left. An initial load of 25 Watts was increased with 25 
Watts every 2 minutes until the maximum tolerated load. 
RV morphologic and functional parameters were obtained at baseline from a RV 
focused apical four-chamber view, with measurement of the RV area at end-diastole 
and end-systole.  Fractional area change [FAC=(end-diastolic area – end-systolic 
area)/end-diastolic area] was calculated from these values. Furthermore, tricuspid 
annular plane systolic excursion (TAPSE) was evaluated on M-mode 
echocardiography. 
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Valvular stenosis at rest and during exercise was evaluated by aligning the continuous 
wave Doppler beam with the studied valve and the highest velocities obtained were 
used for analysis. From the obtained velocities, the peak instantaneous pressure 
gradient was calculated from the simplified Bernoulli equation. Cardiac output was 
calculated from the flow velocity time integral obtained from an apical 5 chamber 
view by placing the pulsed Doppler sample at the level of the left ventricular outflow 
tract. The cross-sectional area of the left ventricular outflow tract was derived from 
baseline measurement of its diameter from a parasternal long-axis view and was 
assumed constant throughout exercise. 
A single observer did data acquisition and analysis. Analysis was done offline using 
dedicated software (EchoPac, Genereral Electric Vingmed Ultrasound, Horten, 
Norway). All measurements were made in triplicate and averaged. 
Dobutamine-stress cardiac magnetic resonance imaging  
All patients were scanned using a 1.5 T MR scanner (Achieva, Philips Medical 
systems, Best, The Netherlands). Cardiac synchronisation was performed with vector 
electrocardiography. 
- Volumetry 
At baseline and during dobutamine infusion, a short axis and long-axis multi-slice 
volumetric dataset was obtained through a single breathold (9 slices) to cover the 
ventricles by a 2 dimensional balanced steady state free precession sequence. 
Volumetric analysis was repeated at every stage of dobutamine infusion, i.e. at 10 
µg/kg/min and at 20 µg/kg/min. 
Images were analysed on a software program developed in-house (Right-to–Right 
Volume Leuven, Leuven, Belgium.
11
 In short, end-diastolic and end-systolic frames 
of each short-axis slice were selected. Each short-axis image was manually traced and 
the points of transection with the long axis plane were indicated.  Trabeculations and 
papillary muscles were included into the volumes. The contours were used to 
calculate the volume by the summation of disks method. To take into account 
interventricular dyssynchrony in patients with repaired tetralogy of Fallot, maximal 
and minimal volumes were identified separately for the left and the right ventricle, to 
obtain maximal (and minimal) volumes for each cardiac phase in each ventricle.
12
  
CHAPTER 3 
3. PILOT TRIAL: THE IMPACT OF RIGHT VENTRICULAR CONTRACTILE RESERVE ON TRICUSPID 
REGURGITATION SEVERITY IN PATIENTS WITH REPAIRED TETRALOGY OF FALLOT. 
 
135 
Stroke volume was calculated by subtracting end-systolic volume from the end-
diastolic volume. Tricuspid valve regurgitant volume was obtained by subtracting left 
ventricular stroke volume from RV stroke volume. Tricuspid valve regurgitant 
fraction was calculated by dividing the regurgitant volume*100 by the RV stroke 
volume. 
- Flow quantification 
At baseline, pulmonary and aortic regurgitation were evaluated by 2D phase-contrast 
MRI during free breathing. Image planes were located at the level of the pulmonary 
and aortic valve respectively.  
Flow quantification was performed on dedicated software (QFlow, Philips Healthcare, 
Best, The Netherlands) in a semi-automated fashion. Contours were traced 
automatically by the software after selection of the target valve and were manually 
adjusted frame-by-frame to obtain the best fit.(Figure 1) From the obtained flow 
curves, regurgitant volume and regurgitant fraction were calculated. 
Representation of data 
Data are represented both graphically as in absolute numbers. Continuous data are 
represented by medians and minimal-maximal values, categorical data as frequency 
and percentage. Because of the pilot phase of the study and the small number of 
patients included, no comparisons between patient’s results were performed. 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
3. PILOT TRIAL: THE IMPACT OF RIGHT VENTRICULAR CONTRACTILE RESERVE ON TRICUSPID 
REGURGITATION SEVERITY IN PATIENTS WITH REPAIRED TETRALOGY OF FALLOT. 
 
136 
Figure 1 Flow quantification of the aortic and pulmonary valve. Flow was traced in a 
semi-automatic fashion with manual review and adjustment of each frame.  
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Results 
Patient inclusion 
A total of 6 patients were included for analysis. One patient didn’t tolerate the 
dobutamine infusion with significant patient discomfort and hyperventilation 
syndrome in the MR. This patient was excluded from the analysis. The remaining 5 
patients [all male, age 24 years (20-32)] underwent the entire protocol. Patient 
characteristics for each patient are listed in Table 1. 
Baseline and bicycle stress echocardiography 
Baseline echocardiographic parameters are listed in Table 1. The RV was dilated and 
low normal indexes of right ventricular function at rest were found.  
Patients performed submaximal on bicycle stress echocardiography with peak HR 140 
bpm (range 120-142) and peak cardiac output 12 L/min (range 7.4-21). The median of 
peak instantaneous pressure gradient across the pulmonary homograft increased from 
46 mmHg (range 12-55 mmHg) to 68 mmHg (range 43-108 mmHg) at peak exercise. 
(Table 2) 
Dobutamine-stress cardiac magnetic resonance imaging 
Results from volumetric measurements of the right ventricle can be found in Table 3 
and Figure 1. Volumetry of the left ventricle can be found in Figure 1. 
Aortic and pulmonary valve regurgitant volume and fraction can be found in Table 4. 
No more than mild regurgitation was observed at baseline. 
RV end-diastolic volumes increased in all patients from rest across the 2 stages of 
dobutamine infusion [from 194 ml at baseline (159-237) to 232 ml (165-255)]. RV 
end-systolic volumes decreased in all but 1 patient (patient 5) [from 97 ml (70-131) to 
88 ml (52-117)]. In patient 5, a bimodal response with an initial decrease in end-
systolic volume (from 126-117 ml), followed by an increase at 20 µg/kg/min infusion 
(from 117 ml to 123 ml) could be observed. RV stroke volume was decreased at 
20µg/kg/min in patient 5 whereas in the other 4 patients an increase of stroke volume 
could be seen. (Table 3 and Figure 1) 
When evaluating TV regurgitant volume and fraction, no increase in regurgitant 
volume and fraction could be seen in patients with preserved contractile reserve, 
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whereas in the 1 patient presenting with decreased contractile reserve, an increase of 
regurgitant volume and (fraction) could be seen from 4 ml (6%) at baseline to 28 ml 
(41%) and 23ml (34%) at 10µg/kg/ml and 20µg/kg/ml dobutamine infusion 
respectively. 
Table 1 Demography and baseline echocardiography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Patient characteristics for cardiac output and right ventricular outflow tract 
gradient as assessed by echocardiography at baseline and at peak exercise. (HR=heart 
rate; PIP=peak instantaneous pressure; RVOT=Right Ventricular Outflow Tract) 
   Baseline Peak exercise 
 Gender Age 
(years) 
HR 
(bpm) 
Cardiac 
Output 
(L/min) 
PIP RVOT 
gradient 
(mmHg) 
HR 
(bpm) 
Cardiac 
Output 
(L/min) 
PIP RVOT 
gradient 
(mmHg) 
pt1 M 21 60 3.2 12 120 7.4 43 
pt2 M 32 61 5.2 30 141 15 68 
pt3 M 24 71 6.7 46 142 12.2 57 
pt4 M 20 57 6.1 55 133 21 108 
pt5 M 24 77 6.4 55 140 11.4 92 
Gender n male (%)  5 (100%) 
Age Median (range) years 24 (20-32) 
BMI Median (range) kg/m2 22.4 (18.5-25.3) 
LVEF Median (range) % 53 (50-56) 
E' velocity Median (range) cm/sec 10 (8-12) 
E/e' Median (range)  7.6 (5.2-8.6) 
Eccentricity index Median (range)  1.2 (1.0-1.3) 
RVFAC Median (range) % 0.33 (0.27-0.45) 
TAPSE Median (range) mm 16 (15-18) 
RV diameter Median (range) mm 36 (33-44) 
RA long axis diameter Median (range) mm 50 (46-59) 
BMI=body mass index; LVEF=left ventricular ejection fraction; RV=right ventricle; 
FAC=fractional area change; RA=right atrium 
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Table 3 Volumetry obtained by CMR and calculation of regurgitant volume and 
regurgitant fraction.  
 Dobutamine 
(µg/kg/min) 
RV EDV 
(ml) 
RV ESV 
(ml) 
RV SV 
(ml) 
TV Reg 
Volume (ml) 
TV Reg 
fraction 
pt1 0 220 131 90 -3 -3% 
 10 232 122 110 -7 -8% 
 20 243 117 126 1 1% 
pt2 0 237 111 126 19 15% 
 10 248 104 144 1 1% 
 20 255 98 157 8 6% 
pt3 0 159 70 89 1 1% 
 10 174 66 108 -11 -12% 
 20 165 52 113 -4 -5% 
pt 4 0 176 83 93 10 11% 
 10 186 78 107 -8 -9% 
 20 202 69 133 5 5% 
pt 5 0 194 126 68 4 6% 
 10 233 117 115 28 41% 
 20 230 123 106 23 34% 
RV: right ventricle; EDV: end-diastolic volume; ESV: end-systolic volume; SV: stroke volume; TV: 
tricuspid valve 
Table 4 Pulmonary (PR) and aortic valve regurgitation (AR) at baseline obtained by 
flow velocity mapping. 
 AR (ml) AR fraction PR (ml) PR fraction 
pt 1 1 2% 0.3 0.4% 
pt 2 14 14% 14 10% 
pt 3 6 8% 2 2% 
pt 4 4 6% 17 17% 
pt 5 5 7% 8 8% 
CHAPTER 3 
3. PILOT TRIAL: THE IMPACT OF RIGHT VENTRICULAR CONTRACTILE RESERVE ON TRICUSPID 
REGURGITATION SEVERITY IN PATIENTS WITH REPAIRED TETRALOGY OF FALLOT. 
 
140 
Figure 2 Right ventricular (RV) volumes as obtained by cardiac magnetic resonance 
imaging. The regurgitant fraction was calculated from the difference between right 
ventricular stroke volume and left ventricular stroke volume derived from volumetric 
measurements. 
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Discussion 
In this pilot study, we showed that decreased RV contractile reserve in patients with 
repaired tetralogy of Fallot might contribute to an increase in tricuspid regurgitant 
flow and fraction. 
TR occurs from a variety of reasons and in various cardiac diseases. Right ventricular 
hypertension, is associated with increasing TR severity. Furthermore, increased RV 
pressure load leads to a more pronounced septal shift towards the left ventricle during 
systole. The septal chordal attachments of the tricuspid leaflets are of the utmost 
importance in preservation of the valvular competence and increased septal shift leads 
to increased leaflet tethering and tricuspid regurgitation.
13, 14
  
During exercise, increased flow causes an increase in pressure gradient across the RV 
outflow tract. However, we have already shown that an acute increase in pressure-
load during exercise doesn’t result in an increase in tricuspid regurgitant severity in 
patients with native pulmonary valve stenosis. (cfr. Chapter 3, paragraph 2) These 
patients were all able to increase their stroke volume normally, as evidenced by an 
oxygen-pulse/workload relationship not different from that of healthy controls. In 
patients with preserved RV function, tricuspid valve competence during exercise 
might be preserved through smaller end-systolic volumes resulting in better 
approximation of the papillary muscles and less leaflet tethering. Furthermore, end-
systolic volumes are decreased during exercise, and this is most likely associated with 
a decrease in annular circumference and hence valvular competence.
15, 16
 
Dobutamine infusion has a positive inotropic and chronotropic effect as a result of 
stimulation of the adrenoceptors. This results in an increase in stroke volume, heart 
rate and cardiac output. Administration of dobutamine has been used to evaluate 
contractile reserve of the left ventricle, especially in the setting of low-flow/low-
gradient aortic valve stenosis.
17, 18
 More recently, it was used to evaluate right 
ventricular contractile reserve in patients with repaired tetralogy of Fallot.
10
 In this 
study, we used both physical exercise and dobutamine stress to evaluate right 
ventricular hemodynamics. However, it should be noted that physical exercise and 
pharmacological stress have different hemodynamic effects. Contrary to physical 
exercise, dobutamine stress causes a decline in systemic arterial pressure and is not 
associated with increased venous return provided by the muscle pump. The lower left 
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ventricular afterload during stress results in an elevated transseptal pressure gradient 
during systole and can exaggerate the leftward septal shift in the setting of right 
ventricular outflow tract obstruction. This might lead to higher end-systolic volumes 
then would have been observed when left ventricular afterload was increased during 
exercise. Furthermore, the lower venous return during dobutamine stress might cause 
diminished right ventricular function due to leftward shift on the starling curve.  
This setting offers the possibility to evaluate the effect of impaired contractile reserve 
on TR severity without the added effect of augmented preload due to increased 
venous return during exercise.  
Our patients showed an increase in RV outflow tract gradient during bicycle stress 
echocardiography, although exercise was submaximal.  
To evaluate RV contractile reserve, we performed dobutamine-stress CMR. An 
increase in RV end-diastolic volumes and a decrease in end-systolic volume were 
seen in 4/5 patients. The increase in RV end-diastolic volume with increasing doses of 
dobutamine infusion was in contrast with Parish et al, who observed a decrease in 
both diastolic and systolic volumes.
10
 Some differences between the studied patients 
should be noted. Our study sample focussed on patients with a predominant RV 
pressure-load in contrast to the severe pulmonary regurgitation in the aforementioned 
study. Furthermore, interventricular dyssynchrony is often observed in patients with 
repaired tetralogy of Fallot and might be more pronounced during dobutamine 
stress.
12
 As we analysed RV and LV volumes separately, this resulted in maximal 
end-diastolic volumes. Mechanical dyssynchrony might cause increased maximal LV 
and RV diastolic volumes due to septal shift, occurring at different time-points.  
In 1 patient, impaired RV contractile reserve was identified. When evaluating 
tricuspid regurgitant fraction in this patient, we found an increase in regurgitant 
fraction, as evaluated by comparing left and right ventricular stroke volume. In the 4 
patients with preserved contractile reserve, this increase of regurgitation severity was 
not seen. This patient also presented with a high pulmonary homograft gradient at rest 
and at peak exercise. However, patient 4 had similar characteristics and didn’t present 
with a similar evolution in regurgitant fraction. 
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These findings indicate a possible relationship between right ventricular function and 
tricuspid regurgitant severity, although no conclusive statements can be made based 
on this small patient sample. 
  
Conclusion 
We observed an increase in tricuspid regurgitant fraction in 1 patient presenting with 
impaired right ventricular contractile reserve. Although we can’t make solid 
conclusions given the low patient number, these findings hint towards a possible 
contribution of right ventricular dysfunction in preservation of tricuspid valvular 
competence 
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Chapter 4  
Onset of tricuspid regurgitation determines prognosis 
in pre-capillary pulmonary hypertension
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Abstract 
Objective 
Patients with pulmonary hypertension (PH) often present with tricuspid valve 
regurgitation (TR). We aimed (1) to establish the impact of increasing TR severity in 
incident cases of patients with pre-capillary PH, (2) to evaluate the effect of new 
severe TR on outcome and (3) to evaluate the link between right ventricular function 
and TR in patients with pre-capillary PH. 
Methods and results 
Incident cases of patients with pre-capillary PH were included from the institutional 
database of PH between January 2000 and December 2012. In the diagnostic work-up, 
429 patients  (61% female; 60±10 years old) were diagnosed and had a transthoracic 
echocardiography within 3 months from the catheterisation. 193 (45%) of patients had 
Group 1, 28 (6.5%) Group 3, 188 (43.8%) Group 4 and 17 (4.0%) Group 5 PH 
according to the Dana Point classification. Follow-up was ended July 2013. 
Demographic, echocardiographic and invasive catheterisation data at inclusion were 
analysed. Primary endpoint was all-cause mortality. Median follow-up time was 10.7 
years. During follow-up, 159 patients died. Five-year survival of the entire cohort was 
66%.  
Multivariate cox regression, including baseline parameters age, gender, tricuspid 
annular plane systolic excursion (TAPSE) (18±5 mm), indexed right atrial long-axis 
diameter (30±5 mm), indexed right ventricular diameter (25±5 mm), pulmonary 
vascular resistance (9.7±5.2 Wood Units) and TR severity (2.5±0.9/4) revealed age 
[HR 1.029 (1.012-1.047); p=0.001] and TR [HR 1.579 (1.206-2.067); p=0.001) as 
independently associated with mortality. When development of severe TR>2/4 was 
modelled as a time dependent covariate, age [HR 1.031 (1.015-1.048); p=0.001], 
development of severe TR [HR 2.323 (1.398-3.862); p=0.001] and TAPSE at inclusion 
[HR 0.946 (0.903-0.990); p=0.017] emerged as predictors of outcome.   
From the 204 (48%) patients presenting with TR ≤ 2/4, 50 patients developed TR > 
2/4 during follow-up. From the consecutive echocardiographic measurements of 
tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary 
artery systolic pressure (PASP) before the onset of TR, a linear regression slope was 
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calculated for each individual patient. Decrease in TAPSE (1mm per year; HR 1.052 
(1.013-1.092); p=0.009) or TAPSE/PASP ratio (0.1 mm/mmHg per year; HR 1.168 
(1.075-1.268); p<0.001) was predictive for the onset of TR>2/4. 
Conclusions 
TR severity is independently related to worse outcome in patients with pre-capillary 
PH. Furthermore, survival is impaired if patients develop significant TR during 
follow-up. Severe TR is preceded by a progressive decline of right ventricular 
function.   
 
Introduction 
Pulmonary hypertension (PH) occurs in a variety of diseases and is associated with 
impaired prognosis.
1, 2 It is defined as a mean pulmonary artery pressure ≥ 25 mmHg 
on right heart catheterisation. Currently, patients with PH are classified according to 
the DANA point classification into 5 groups.
1
 The majority of patients have PH due to 
left-heart disease (Group 2), so-called post-capillary PH, characterized by high left 
atrial pressures > 15 mmHg. In these patients PH is either a marker of prognosis as 
well as an indication for surgical intervention for instance in mitral valve surgery. On 
the other hand, pre-capillary PH consists of patients with pulmonary arterial 
hypertension (Group 1), PH due to lung disease or hypoxia (Group 3), chronic 
thromboembolic PH (group 4) and PH due to unclear or multifactorial mechanisms 
(Group 5) and originates from within the pulmonary circulation, either because of 
thrombus formation or due to vascular remodelling.
3
 In these patients, even with 
modern targeted therapy, outcome is impaired also if they respond to therapy.
4 
Therefore, there is a continuing search for means to improve prognosis. 
Tricuspid regurgitation (TR) is often observed in patients with pre-capillary PH.
5
 It 
originates from increased pulmonary pressure, right ventricular dilatation and 
remodelling, and tricuspid annular dilation.
6
 In many diseases, the presence of TR is 
independently associated with worse prognosis.
7
 However, the impact of TR on 
outcome in patients with pre-capillary pulmonary hypertension is not fully 
understood. Even more so, TR is often encountered in the presence of right 
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ventricular dysfunction. Nonetheless, it is unclear whether TR is a symptom rather 
than a disease, eventually causing the right ventricle to fail. 
Determination of right ventricular function is difficult, especially in the pressure-
loaded ventricle. Indices of right ventricular function are load dependent. Therefore, 
interpretation of the results obtained should be performed in conjunction with the 
force developed, i.e. systolic pulmonary artery pressure. Guazzi et al. proposed an 
easy, non-invasive parameter to evaluate the length-force relationship of the right 
ventricular myocardium by dividing tricuspid annular plane systolic excursion 
(TAPSE) by Doppler derived pulmonary artery systolic pressure (PASP).
8
 
Therefore, we aimed (1) to establish the impact of increasing TR severity in incident 
cases of patients with pre-capillary PH, (2) to evaluate the effect of new severe TR on 
outcome and (3) to evaluate the link between right ventricular function and TR in 
patients with pre-capillary PH. 
 
Methods 
Patient selection and data collection 
From the specialised institutional database of PH, patients undergoing right heart 
catheterization as part of the diagnostic work-up for PH were included between 
January 2000 and December 2012. 
Incident cases of patients with pre-capillary PH, diagnosed as a mean PAP ≥ 25 
mmHg and pulmonary capillary wedge (PCW) < 15 mmHg were included. Diagnostic 
work-up was completed according to present guidelines and patients were classified 
into groups of PH according to the DANA point classification. 
Of 585 patients undergoing right heart catheterisation, 124 patients were diagnosed 
with PH due to left-sided heart disease (Dana point Group 2), 32 didn’t have a 
transthoracic echocardiogram within 3 months from the right heart catheterisation. 
This resulted in a total of 429 patients eligible for analysis. 
The ethics committee approved patient inclusion and data analysis. 
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Right heart catheterisation 
A Swan-Ganz catheter was inserted under local anaesthesia from the internal jugular 
or the femoral vein and placed at the level of the right heart. Invasive measurement of 
mean right atrial pressure; systolic, diastolic and mean pulmonary artery pressure and 
pulmonary capillary wedge pressure was obtained. Cardiac output was evaluated by 
the thermodilution method. Pulmonary vascular resistance in Wood Units was 
calculated as (meanPAP-PCW)/Cardiac output. The date of catheterisation was taken 
as the inclusion date. 
 
Figure 1 Inclusion algorithm. 
 
Transthoracic echocardiography at baseline and during follow-up 
Standard transthoracic echocardiography was performed in all subjects at baseline 
within a pre-specified timeframe of 3 months. Furthermore, echocardiographic 
measurements during follow-up were included as well. Development of severe TR 
was defined as TR>2/4 on 2 consecutive visits. Measurement of the right atrium was 
done from an apical 4-chamber view measuring the long axis at end-systole. The right 
ventricular diameter was measured from an apical 4-chamber view at the mid-
ventricular level at end-diastole. Right atrium and right ventricular diameter were 
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indexed for body surface area, calculated with the Mosteller formula. Tricuspid 
annular plane systolic excursion (TAPSE) was measured from an M-mode placed 
through the tricuspid annulus from an apical 4-chamber view. The tricuspid 
regurgitant gradient (TRG) was obtained by continuous wave Doppler examination of 
the tricuspid valve regurgitant jet during systole. Pulmonary artery systolic pressure 
(PASP) was calculated from the TRG by the simplified Bernoulli equation and an 
estimate of right atrial pressure was added. Right atrial pressure was estimated from 
the diameter and respiratory variation of the inferior vena cava (IVC). It was assumed 
5 mmHg if IVC diameter was < 2 cm and respiratory variation was > 50%, 10 mmHg 
if IVC<2 cm and respiratory variation < 50%, and 15 mmHg if IVC expiratory 
diameter was > 2 cm. From the obtained measurements, the ratio of TAPSE/PASP 
was calculated at each time point during follow-up.
9
 
 Other standard measurements were done according to the guidelines of 
echocardiography.
10
 
Statistical analysis: 
Continuous data and categorical data are represented by means and standard deviation 
or frequencies and percentages respectively.  
First, demographic data, invasive catheterisation and echocardiographic data at 
inclusion were analysed. Kaplan-Meier survival analysis was performed to evaluate 
all-cause mortality in the total cohort of patients. The primary endpoint for the 
survival analysis was all-cause mortality. 
Second, univariate and multivariate cox regression was performed to identify factors 
associated with outcome.  
Third, development of severe TR > 2/4 was modelled as a time-dependent covariate 
and multivariable cox regression with the same parameters was performed. 
Fourth, the evolution of TAPSE and TAPSE/PASP ratio was evaluated in patients 
presenting without severe TR (≤2/4) at inclusion. For each patient, linear regression of 
the studied parameter as a function of the time from inclusion until development of 
severe TR was performed. The unstandardized β-coefficient was used as the slope of 
TAPSE, TAPSE/PASP respectively to represent the evolution of right ventricular 
function before onset of severe TR. The number of observation for each patient was 
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used to perform a weighted analysis. Univariate cox regression with each slope 
weighted and normalized for the number of observations was used to evaluate the 
association of right ventricular deterioration with the occurrence of severe TR (>2/4). 
All tests were two-tailed. A P-value <0.05 was considered significant. Analyses were 
performed using SPSS
®
 (version 20) and SAS
®
. 
 
Results 
Patient inclusion: 
Data from eligible patients were available for 429 patients, 61% female, aged 60 yrs. 
± 15. Pulmonary arterial hypertension (Group 1) was diagnosed in 193 (45%) 
patients, PH due to lung disease (Group 3) in 28 (6.5%), chronic thromboembolic 
pulmonary hypertension (Group 4) in 188 (43.8%) and PH from unknown or 
multifactorial mechanism (Group 5) in 17 (4.0%) patients. [11] (Figure 2) From 429 
patients included, 225 had TR > 2/4 at inclusion. From the 204 patients presenting 
with TR ≤ 2/4, 50 patients developed TR > 2/4 during follow-up. 
During a median follow-up time of 10.7 years, 159 patients died. Five-year survival of 
the entire cohort was 66%.  
Baseline determinants of outcome: 
Univariate analysis showed age (HR 1.033 (1.02-1.046); p<0.0001); TR severity (HR 
1.765 (1.45-2.149); p<0.0001); RA index (HR 1.065 (1.036-1.094); p<0.0001); RV 
index (HR 1.042 (1.01-1.075); p=0.01); Right atrial pressure (HR 1.05 (1.021-1.08); 
p=0.001) and TAPSE (HR 0.938 (0.901-0.976); p=0.002) associated with all-cause 
mortality. On multivariate cox regression, only age (HR 1.56 (1.189-2.047); p=0.001) 
and TR severity (HR 1.031 (1.013-1.048); p=0.001) emerged as independent 
predictors of outcome.  
Evaluation of progression of TR on outcome 
Multivariate cox regression, showed that patients that developed TR > 2/4 during 
follow-up had a 2 fold increase in the hazard of dying (HR 2.296 (1.379-3.822); 
p=0.001). (Table 3) Furthermore, both older age (HR 1.032 (1.016-1.049); p=0.001) 
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and lower TAPSE at baseline (HR 0.949 (0.906-0.994); p:0.026) emerged as 
independent predictors of all-cause mortality.  
Evaluation of right ventricular function in the occurrence of severe TR in follow-up 
We could observe a strong relation between the evolution of TAPSE and TAPSE 
relative to PASP in the pathogenesis of severe TR. (Table 4) For each decrease of 
1mm/year in TAPSE, this is associated with a 5% increase in hazard to develop 
TR>2/4. Similarly, for decrease of 0.1 units (mm/mmHg) of the TAPSE/PASP ratio 
per year, this corresponds with a 17% increase in hazard of the occurrence of TR>2/4. 
The development of TR is represented graphically in Figure 3, for 2 groups split by 
the median of the slope of the TAPSE-time relationship and (B) for each quartile of 
the slope of the TAPSE/PASP-time relationship. 
 
Figure 2 Composition of the studied population (n=429). Categories are based on the 
current Dana point classification for pulmonary hypertension. 
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Table 1 Demography, data from right heart catheterisation and from transthoracic 
echocardiography at baseline. 
  N Total study sample 
Demography    
Age (years) mean±SD 429 60 ± 15 
Female gender n (%) 429 263 (61%) 
BSA (m
2
) mean±SD 383 1.9 ± 0.2 
Right heart catheterisation    
RAP (mmHg) mean±SD 422 8 ± 5 
sysPAP (mmHg) mean±SD 421 76 ± 20 
diasPAP (mmHg) mean±SD 421 29 ± 10 
meanPAP (mmHg) mean±SD 429 45 ± 12 
PCW (mmHg) mean±SD 426 9 ± 4 
PVR (Wood Units) mean±SD 423 10 ± 5 
Cardiac Output (L/min) mean±SD 423 4.2 ± 1.3 
Cardiac Index (L/min/kg mean±SD 413 2.3 ± 0.6 
Echocardiography    
LVEF (%) mean±SD 382 65 ± 9 
LVEDD (mm) mean±SD 380 41 ± 7 
RA diameter (mm) mean±SD 414 55 ± 8.5 
RA index (mm/m
2
) mean±SD 374 30 ± 5 
RV diameter (mm) mean±SD 416 46 ± 9 
RV index (mm/m
2
) mean±SD 376 25 ± 5 
TAPSE (mm) mean±SD 369 18 ± 5 
TAPSE/PASP (mm/mmHg) mean±SD 358 0.26±0.15 
TR           0/4 n (%)  4 (1%) 
          1/4 n (%)  56 (13%) 
          2/4 n (%)  136 (32%) 
          3/4 n (%)  161 (38%) 
          4/4 n (%)  64 (15%) 
TR regurgitant gradient (mmHg) mean±SD 416 69 ± 20 
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Table 2 Univariable and multivariable (n=327) cox regression for baseline 
demographic, echocardiographic and invasive parameters. 
  Univariable  Multivariable 
 N HR (95% CI) P-value N HR (95% CI) P-value 
Age (years) 429 1.033 (1.02-1.046) p<0.0001* 327 1.031 (1.013-1.048) 0.001* 
TR (x/4) 421 1.765 (1.45-2.149) p<0.0001*  1.56 (1.189-2.047) 0.001* 
PVR (Wood Units) 423 1.014 (0.982-1.046) 0.399  0.992 (0.945-1.041) 0.74 
RAP (mmHg) 422 1.05 (1.021-1.08) 0.001*  1.02 (0.981-1.06) 0.314 
RV index (mm/m2) 376 1.042 (1.01-1.075) 0.01*  0.998 (0.947-1.051) 0.931 
RA index (mm/m2) 374 1.065 (1.036-1.094) <0.0001*  1023 (0.969-1.079) 0.415 
TAPSE (baseline) (mm) 369 0.938 (0.901-0.976) 0.002*  0.964 (0.917-1.014) 0.158 
Gender 429 1.089 (0.772-1.538) 0.627  1.247 (0.818-1.899) 0.305 
MeanPAP (mmHg) 429 1.006 (0.992-1.019) 0.42    
LVEF (%) 382 0.991 (0.973-1.01) 0.366    
TR=tricuspid regurgitation; TAPSE=tricuspid annular plane systolic excursion; RA=right atrium; RV=right 
ventricle; RAP=right atrial pressure; PVR=pulmonary vascular resistance; meanPAP=mean pulmonary artery 
pressure. *P<0.05=significant. 
Table 3 Multivariable cox regression with evolution towards severe TR as time-
dependent covariate. Progression of TR was defined as TR>2/4 on 2 consecutive 
outpatient or hospital visits. 
 N HR (95% CI) P-value 
Progression of TR 327 2.296 (1.379-3.822) 0.001* 
Age (years)  1.032 (1.016-1.049) <0.0001* 
Gender  1.272 (0.868-1.865) 0.217 
TAPSE (baseline) (mm)  0.949 (0.906-0.994) 0.026* 
RA index (mm/m
2
)  1.021 (0.973-1.072) 0.396 
RV index (mm/m
2
)  0.996 (0.948-1.045) 0.865 
RAP (mmHg)  1.018 (0.983-1.055) 0.326 
PVR (Wood units)  0.976 (0.932-1.023) 0.312 
TAPSE=tricuspid annular plane systolic excursion; RA=right atrium; RV=right ventricle; RAP=right 
atrial pressure; PVR=pulmonary vascular resistance. *P<0.05=significant. 
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Table 4 Cox regression with onset of TR as outcome, implementing evolution of 
TAPSE (1 mm per year) or TAPSE relative to PASP (0.1 mm/mmHg per year) as 
covariate. 
 N HR (95% CI) P-value 
Slope of TAPSE 197 1.052 (1.013-1.092) 0.0092* 
Slope of TAPSE/PASP 196 1.168 (1.075-1.268) 0.0002* 
TAPSE=tricuspid annular plane systolic excursion; PASP=pulmonary artery systolic pressure. 
P<0.05=significant. 
 
Figure 3 Cumulative incidence ratio for the development of TR > 2/4 for (A) the 
slope of the TAPSE-time relationship split by median slope (=0) and (B) the slope of 
the TAPSE/PASP-time relationship for each quartile (Quartile 1 < -0.009361; 
Quartile 2&3 = -0.009361-0.012763; Quartile 4 > 0.012763).  
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Discussion 
This study shows that TR severity at baseline has an impact on prognosis in patients 
with pre-capillary PH. Moreover, the development of severe TR impairs prognosis. 
Furthermore, in patients with pre-capillary pulmonary hypertension, a decrease in RV 
function over time is associated with TR progression. 
The effect of TR on prognosis has long been debated. Although TR is known to 
impact prognosis, it is still unclear if TR is the cause, or merely an indicator of worse 
survival.
7
 When performing cross-sectional studies, an inverse relation between right 
ventricular function and TR severity can be seen.
12
 However, based on these results it 
is difficult to determine a causative relation. Our study shows that TR at inclusion is 
an independent predictor of outcome in patients with pre-capillary PH. Furthermore; 
the development of TR is associated with worse outcome independently of baseline 
parameters. This suggests a causative relationship, with the added volume-load on the 
already pressure-loaded ventricle leading to accelerated right ventricular dysfunction. 
Although TR is reasonably well tolerated for a long period in the normal RV, 
eventually ventricular failure ensues and heart symptoms of heart failure develop.
13 
The volume-load associated with TR increases stroke work of the RV. However, the 
RV, with its thin walled and compliant ventricle, seems to be well adjusted to support 
this volume load for a long time.
14, 15
 On the other hand, a pressure-load is associated 
with early remodelling of the right ventricle, with a thicker and less compliant 
ventricular wall and a more spherical geometry.
14
 Moreover, the stroke work further 
increases when a combination of pressure- and volume load is present. 
Studies in patients with congenitally corrected transposition of the great arteries have 
shown rapid deterioration of the right ventricular function at the moment TR 
develops.
16, 17 
In these patients, RV dysfunction is seldom encountered without severe 
TR.  Furthermore, in these patients maintenance of tricuspid valvular competence is 
associated with better prognosis and if TR occurs, surgery before RV ejection fraction 
is <44% seems to stop the onset of RV dysfunction.  
If this is also applicable to patients with pre-capillary PH is not clear. If so, RV 
function should be preserved at the time of development of TR. In contrast with this, 
we found that deterioration of RV function is predictive for the development of severe 
TR.  Especially the TAPSE/PASP ratio, a representation of the length/force 
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relationship of the right ventricle is a strong predictor of severe TR. [9] In the 
assessment of right ventricular function in pre-capillary PH, obtained values are often 
difficult to interpret. Indeed, many parameters of right ventricular function are load-
dependent, especially if pulmonary vascular resistance is raised and right ventricular 
afterload is consequently increased.
18
 The use of TAPSE relative to PASP provides an 
index of the right ventricular force-length relationship as it relates the longitudinal 
shortening of the muscle fibers to the force developed.
8
 
Interpreting these results, it seems TR is a symptom of progressive right ventricular 
deterioration. However, the development of severe TR is a strong predictor of 
outcome in this patient population. It seems that progressive RV dysfunction 
eventually leads towards more severe TR and this added volume-load causes a vicious 
circle of added volume-load, further deterioration of RV function and eventually 
death. To stop rapid deterioration of right ventricular function, it is tempting to 
suggest surgical correction of TR. However, in the setting of pre-capillary PH, 
progressive right ventricular dysfunction due to persistent pressure-load will probably 
ensue after surgery. Indeed, we showed that the presence of PH is associated with 
worse survival when isolated tricuspid valve surgery is performed.
19
 Conversely, in 
the setting of functional TR, secondary to left-sided heart disease, studies show 
favourable remodelling and clinical benefit of tricuspid annuloplasty in combination 
with mitral valve surgery. In these patients, correction of the left-sided valvular 
disease lowers pulmonary arterial pressures. In these patients, there seems to be an 
additional benefit of removal of the volume-load associated with TR to preserve right 
ventricular function for a longer time. (Chapter 5, section 2) 
The development of severe TR indicates therefore worse prognosis and should trigger 
close follow-up and/or might be an indication for dose adjustment of targeted therapy. 
Even more so, TAPSE and TAPSE/PASP relationship should be monitored during 
follow-up, with a decrease indicative for disease progression. 
However, prospective studies are needed to prove the additional benefit of early dose 
adjustment of specific vasodilator therapy in the case of progression TR and decline 
in TAPSE or TAPSE/PASP ratio. 
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Conclusion 
Tricuspid regurgitation and the development of severe TR during follow-up are 
associated with increased mortality. Right ventricular function deterioration is 
predictive for the development of TR. If TR severity increases and if indices of right 
ventricular function deteriorate over time, the treatment of the patient should be re-
evaluated.  
 
Limitations 
Our results are based on a retrospective analysis of patients followed in a single 
institution. The patients in this study cohort were classified according to the Dana 
point classification of 2008, in use at the time of study design and conduct.
11
 
However, a new classification, Nice 2013, has been recently introduced.
20
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1. Outcome and determinants of prognosis in patients 
undergoing isolated tricuspid valve surgery: retrospective 
single centre analysis. 
 
Abstract 
Aims 
Although tricuspid valve (TV) surgery has become more popular, isolated TV surgery 
is infrequently performed. The aims of this study were (1) to evaluate the 
postoperative and long-term mortality of patients undergoing isolated TV surgery, (2) 
to compare the outcomes of patients undergoing their first TV surgery or TV 
reoperation, and (3) to assess the additive value of echocardiographic and invasive 
hemodynamic evaluations for predicting postoperative outcome.  
Methods  
We followed a contemporary cohort of patients undergoing isolated TV surgery from 
January 1, 1995, through December 31, 2011. Preoperative demographic, 
echocardiographic, hemodynamic, and operative data were included. Outcome was 
all-cause mortality.  
Results 
Ninety-two patients (38% male; mean age: 56±14 years) were included. Kaplan-
Meier survival analyses showed that 30-day, 3-month, 5-year, and 10-year mortality 
were 7.9%, 15.2%, 25.7%, and 53.7%, respectively. No difference in outcome was 
found between patients undergoing first TV surgery (n=61) and TV reoperation 
(n=31) (p=0.669). Univariable Cox analysis identified age (p<0.0001), extracardiac 
vascular disease (p=0.001), glomerular filtration rate (p=0.022), NYHA classification 
(p=0.010), and mean pulmonary artery pressure (p=0.005) as predictors of mortality. 
Multivariable analysis identified significant associations with outcome, only for age 
(p=0.010) and NYHA functional class (p=0.044). In younger patients (<59 years), 
mean pulmonary artery pressure was associated with the worse outcome (p=0.024).
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Conclusions 
Isolated TV surgery is still associated with important postoperative and long-term 
mortality, both for first TV surgery and TV reoperation. Pre-operative NYHA 
functional class and, in younger patients, pulmonary hypertension appear to determine 
prognosis. 
 
Introduction 
In recent years, interventions involving the tricuspid valve (TV) have become 
increasingly popular. European Society of Cardiology guidelines have recently been 
updated and now advocate a more liberal approach towards TV surgery, especially in 
combination with operations on left-sided valves.
1
 On the other hand, AHA/ACC 
guidelines are largely silent on tricuspid valve surgery.
2
 However, a registry 
describing hospital admissions for TV surgery in the United States showed that the 
number of tricuspid procedures more than doubled from 1999 to 2008.
3
  
TV disease affects morbidity and mortality as well as functional capacity in different 
types of heart disease.
4-10
 The great majority of TV interventions is performed due to 
tricuspid regurgitation, most often secondary to left-sided valvular disease. Although 
a low threshold to perform TV surgery in conjunction with mitral valve surgery is 
currently advocated, isolated TV surgery is still infrequently performed.
3
 ESC 
guidelines advise isolated TV intervention if patients are symptomatic and tricuspid 
regurgitation is severe. TV surgery can be considered if tricuspid regurgitation is 
severe and signs of right ventricular dilatation or dysfunction are present.
1
 However, 
if tricuspid regurgitation is severe and surgery is postponed, right ventricular failure 
can develop, increasing morbidity and mortality dramatically.
11, 12
  
Determining when to perform isolated TV surgery remains difficult. Registries and 
small studies have shown that isolated TV surgery is still associated with significant 
perioperative morbidity and mortality, especially when compared to left-sided valve 
surgery.
13-17
 However, studies on the postoperative and long-term outcomes of 
isolated TV surgery are scarce and often include patient cohorts operated decades ago, 
making application to present-day patient care difficult.  
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Therefore, the aims of the present study were (1) to evaluate the postoperative and 
long-term mortality of patients undergoing isolated TV surgery, (2) to compare the 
outcomes of patients undergoing first TV surgery or TV reoperation, and (3) to assess 
the additive value of pre-operative echocardiographic and invasive hemodynamic 
evaluations for predicting outcome after surgery. 
 
Methods 
Population and Data Collection 
We followed a contemporary cohort of consecutive patients undergoing isolated TV 
surgery at the University Hospitals Leuven in Leuven, Belgium between January 1, 
1995, and December 31, 2011. Data were collected at the time of surgery and stored 
in the database of cardiac surgery. A search from the database of cardiac surgery was 
performed and data were exported for analysis after review of each patient file for 
completeness of the data studied. Follow-up of patients for all-cause mortality ended 
January 1, 2012. Echocardiography and invasive hemodynamic assessment via 
cardiac catheterization were performed within 2 months before surgery. Patients had 
to be older than 18 years of age at the time of surgery to be included in our study. All 
patients underwent isolated TV surgery (first TV surgery or TV reoperation), during 
which the TV was repaired or replaced with a biological or mechanical prosthesis.  
The local ethics committee approved the selection process and the review of the data. 
Variables 
Preoperative demographic, echocardiographic and hemodynamic data as well as 
operative data were included in the analysis. Thirty-day, 3-month postoperative, and 
long-term follow-up of all-cause mortality were considered as outcomes. 
Preoperative demographic variables included age; gender; body mass index; cardiac 
risk profile (including currently smoking, presence of diabetes mellitus, high blood 
pressure, hypercholesterolemia, family history of coronary artery disease); 
extracardiac vascular disease (carotid endarterectomy, carotid disease defined as total 
occlusion or >50% stenosis of the carotid arteries, clinical claudication, amputation 
due to peripheral vascular disease); previous cardiac surgery; recent myocardial 
infarction (<90 days preoperatively); angina; chronic lung disease; renal function 
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(glomerular filtration rate as calculated using Cockcroft-Gault formula); cardiac 
rhythm (sinus rhythm, atrial fibrillation, or pacemaker dependent); New York Heart 
Association (NYHA) functional class; cause of valvular disease (primary TV disease 
defined as disease of the TV leaflets and secondary annular dilatation defined as 
dilatation of the tricuspid annulus causing tricuspid regurgitation (TR) but with intact 
leaflets); urgency grade of TV surgery; and type of TV surgery (annuloplasty, valve 
replacement with a bioprosthetic or mechanical valve). The use of loop diuretics, 
potassium sparing diuretics, ACE-inhibitor or angiotensin receptor blocker and beta-
blockade was included. The EuroScore II was calculated for each patient.
18
 
Echocardiographic variables included the grade of TR as assessed by colour Doppler 
imaging, right ventricular (RV) end-diastolic diameter, right atrial (RA) end-systolic 
diameter, right ventricular function assessed by eyeballing, tricuspid regurgitant 
gradient, calculated from the CW Doppler velocity of the tricuspid regurgitant jet and 
left ventricular ejection fraction. The RV diameter was measured at end-diastole at the 
mid-ventricular level in the apical 4-chamber view.  The RA long-axis dimensions 
were measured at end-systole in the apical 4-chamber view.  
19, 20
 Right ventricular 
function was graded by eyeballing and was graded as normal, mild, moderate or 
severe impairment. Furthermore, digitally available echocardiographic images were 
reanalysed for tricuspid annular plane systolic excursion (TAPSE). 
Hemodynamic variables included right atrial pressure; systolic and diastolic right 
ventricular pressure; and systolic, diastolic, and mean pulmonary artery pressure 
(PAP), determined invasively by right heart catheterization. Postoperative, in-hospital 
(<3 months) complications were reoperation due to bleeding; cardiac tamponed; valve 
dysfunction or postoperative myocardial infarction; infection (sternal infection, 
sepsis); cerebrovascular accident or transient ischemic stroke; pulmonary events 
(pulmonary embolism or pneumonia) and the need for artificial ventilation; renal 
failure and the need for renal dialysis; postoperative heart block; postoperative 
arrhythmias; and pleural effusion. 
Statistical Analysis 
Data are presented as means ± standard deviations or as numbers and proportions 
where appropriate. Firstly, the Kaplan-Meier method was used to estimate survival 
probabilities in the total population. Secondly, the patient population was divided into 
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two groups based on prior TV surgery: one group consisted of patients undergoing 
their first TV surgery; another group consisted of patients undergoing TV reoperation. 
Baseline characteristics of both groups were compared by using unpaired t-test, 
Pearson’s chi-square, or Fishers’ exact test where appropriate. Multivariable analysis 
was performed to evaluate the effect of TV reoperation on post-operative survival. 
Thirdly, on the total population, we performed univariable and multivariable analyses 
using the Cox proportional hazards model to identify predictors of outcome in the 
total population. Kaplan Meier and log rank analysis was performed for comparison 
of survival in patients presenting in NYHA 1-2 compared to NYHA 3-4. Because 
PAP is age-dependent, we split the study-population according to median age and we 
checked for interactions between age and mean PAP.
21
 P<0.1 was considered 
significant for interactions. Cox proportional hazards were recalculated for mean PAP 
in both age groups. Pulmonary hypertension (PH) was defined as a mean PAP ≥ 25 
mmHg on right heart catheterization.  Kaplan Meier analysis was performed for both 
age groups, followed by a log-rank test after stratification into “no PH” and “PH”. 
Data were analysed using SPSS
®
 (version 20, SPSS, Chicago). All tests were two-
tailed, and p<0.05 was considered significant. 
 
Results 
Population Characteristics, Postoperative Events, and Outcome Mortality 
We included 92 patients (38% male; mean age: 56 ± 14 years) in the analysis. 
Demographic data and indication for TV operation are summarized in Tables 1 and 2, 
respectively. All but one of the patients underwent sternotomy as opposed to lateral 
thoracotomy. Detailed information regarding postoperative (in hospital and <3 
months) complications is listed in Table 3. The 30-day in-hospital mortality for the 
total population was 7.9%, 3-month mortality was 15.2%, 5-year mortality was 
25.7%, and 10-year mortality was 53.7% (Figure 1).  
Comparison of First Intervention and TV Reoperation 
Sixty-one patients (66%) underwent their first TV intervention, while 31 patients 
(34%) underwent TV reoperation. Of the 61 patients undergoing their first 
intervention on the TV, 26 (42.6%) already underwent prior cardiovascular surgery by 
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median sternotomy. Baseline characteristics and comparison between the two groups 
are listed in Tables 1 and 2. The Euro Score II was significantly higher in patients 
who underwent reoperation on the TV. Patients who underwent first TV intervention 
had significantly more TR and had more dilated right ventricles. Significantly more 
TV reoperation patients experienced postoperative high-grade atrioventricular block 
and needed implantation of a definitive pacemaker (Table 3). On multivariable 
analysis, including TV reoperation, previous cardiac surgery by median sternotomy, 
age and the EuroScore II, no significant association of TV reoperation on outcome 
was observed (HR 1.273 (0.420-3.860); p=0.669).  
 
Figure 1 Kaplan-Meier curve showing the overall survival in the total population. 
The 30-day in-hospital mortality for the total population was 7.9%, 3-month in-
hospital mortality was 15.2%, 5-year mortality was 25.7%, and 10-year mortality was 
53.7%. 
 
 
  
Table 1 Demographic, Echocardiographic and Hemodynamic Parameters in the Total Population and Comparison between First TV 
surgery and TV Reoperation. 
  Total First TV surgery TV reoperation P-value 
Demographics                 
   N   N  N     
Age (years) (mean ± SD) 92 56 ± 14 61 58 ± 13 31 53 ± 16 0.128
*
 
Gender n male (%) 92 35 (38%) 61 23 (37.7%) 31 12 (38.7%) 0.925
†
 
BMI (kg/m
2
) (mean ± SD) 91 24.6 ± 4.5 60 24.9 ± 4.6 31 23.9 ± 4.3 0.326
*
 
Number of risk factors: 0 n (%) 88 38 (43.2%) 57 21 (36.8%) 31 17 (54.8%) 0.586
‡
 
 1    30 (34.1%)  21 (36.8%)   9 (29%)   
 2    13 (14.8%)  9 (15.8%)   4 (12.9%)   
 3    5 (5.7%)  4 (7%)   1 (3.2%)   
 4    2 (2.3%)  2 (3.5%)   0 (0%)   
 5    0 (0%)  0 (0%)   0 (0%)   
Extracardiac vascular disease n (%) 92 5 (5.4%) 61 3 (4.9%) 31 2 (6.5%) 1
‡
 
Previous cardiac surgery n (%) 92 57   (62%) 61 26 (42.6%) 31 31 (100%) <0.0001
†
 
Recent MI (<90 days)  92 3 (3.3%) 61 3 (4.9%) 31 0 (0%) 0.548
‡
 
Angina pectoris  92 8 (8.7%) 61 5 (8.2%) 31 3 (9.7%) 1
‡
 
Chronic lung disease n (%) 91 9 (9.8%) 60 7 (11.7%) 31 2 (6.5%) 0.713
‡
 
  
Table 1 continued
 
Renal function: GFR>85 ml*min
-1
 
                          GFR 50-85 ml*min
-1
 
                          GFR<50 ml* min
-1
 
n (%) 92 31 (33.7%) 
34 (37.0%) 
27 (29.3%) 
61 22 (36.1%) 
20 (32.8%) 
19 (31.1%) 
31 9 (29.0%) 
14 (45.2%) 
8 (25.8%) 
‡
 
Cardiac rhythm:       sinus  92 40 (43.5%) 61 31 (50.8%) 31 9 (29%) 0.061
†
 
AF    31 (33.7%)  20 (32.8%)   11 (35.5%)   
pacemaker    21 (22.8%)  10 (16.4%)   11 (35.5%)   
         
Table 1 continued         
NYHA  1 n (%) 90 1 (1.1%) 59 0 (0%) 31 1 (3.2%) 0.078
‡
 
 2    24 (26.7%)  20 (33.9%)   4 (12.9%)   
 3    48 (53.3%)  29 (49.2%)   19 (61.3%)   
 4    17 (18.9%)  10 (16.9%)   7 (22.6%)   
EuroScoreII %±SD 92 5.2±4.1 61 4.5±3.8 31 6.5±4.4 0.021* 
Preoperative heart failure treatment         
Loop diuretics  88 53 (60.2%) 58 34 (58.6%) 30 19 (63.3%) 0.819
†
 
Potassium sparing diuretics  88 43 (48.9%) 58 27 (46.6%) 30 16 (53.3%) 0.373
†
 
ACE-I or ARB  88 31 (35.2%) 58 22 (37.9%) 30 9 (30.0%) 0.491
†
 
Beta-blockade  88 37 (42.0%) 58 26 (44.8%) 30 11 (36.7%) 0.502
†
 
  
Table 1 continued         
Hemodynamics (mmHg)            
RAP (mmHg) mean ± SD 65 14.2 ± 6.0 41 13.9 ± 6.6 24 14.9 ± 5.1 0.515
*
 
RVPsys (mmHg) mean ± SD 65 38.5 ± 13.3 41 38.4 ± 11.6 24 38.8 ± 16.0 0.923
*
 
RVPdiast (mmHg) mean ± SD 64 10.4 ± 5.7 40 10.7 ± 5.6 24 9.9 ± 6.1 0.582
*
 
PAPsyst (mmHg) mean ± SD 69 37.7 ± 13.9 46 37.6 ± 12.4 23 37.9 ± 16.8 0.947
*
 
PAPdiast (mmHg) mean ± SD 69 16.5 ± 6.4 46 16.5 ± 6.0 23 16.4 ± 7.2 0.947
*
 
PAPmean (mmHg) mean ± SD 63 24.2 ± 9.2 40 23.8 ± 8.5 23 24.8 ± 10.6 0.667
*
 
PH vs. no PH (mean PAP ≥ 25 mmHg) n (%) 63 32 (50.8%) 40 19 (47.5%) 23 13 (56.5%) 0.490† 
 
Echocardiography 
        
TR 
0/4 
1/4 
2/4 
3/4 
4/4 
 
n (%) 
 
90 
 
1 (1.1%) 
9 (10.0%) 
11 (12.2%) 
25 (27.8%) 
44 (48.9%) 
 
60 
 
0 (0%) 
2 (3.3%) 
4 (6.7%) 
18 (30%) 
36 (60%) 
 
30 
 
1 (3.3%) 
7 (23.3%) 
7 (23.3%) 
7 (23.3%) 
8 (26.7%) 
 
<0.0001
†
 
Table 1 continued         
Right atrium major axis  90 63 ± 13 60 63 ± 13 30 65 ± 13 0.453* 
Right ventricular diameter  71 44 ± 12 45 46 ± 12 26 42 ± 12 0.258* 
  
Table 1 continued         
TAPSE  33 16 ± 6 20 18 ± 5 13 13 ± 6 0.008* 
RV function 
normal 
lightly impaired 
moderately impaired 
severely impaired 
 
n (%) 
 
89 
 
54 (60.7%) 
15 (16.9%) 
17 (19.1%) 
3 (3.4%) 
 
59 
 
35 (59.3%) 
10 (16.9%) 
12 (20.3%) 
2 (3.4%) 
 
30 
 
19 (63.3%) 
5 (16.7%) 
5 (16.7%) 
1 (3.3%) 
 
0.976
†
 
Tricuspid regurgitant gradient mean±SD 68 30.2±13.3 45 31.6±13.6 23 27.6±12.7 0.255* 
LV Ejection Fraction mean±SD 86 57.8±5.9 57 58.4±5.2 29 56.8±6.9 0.264* 
Mortality                 
30-day n 92 7 (7.9 %)      
3-month n 92 13 (15.2 %)      
5-year  n 92 20 (25.7 %)      
AF, Atrial fibrillation; BMI, Body mass index; MI, myocardial infarction; NYHA, New York Heart Association functional class; PAP, pulmonary artery 
pressure; PH, pulmonary hypertension; RAP, right atrial pressure; RVP, right ventricular pressure; SD, standard deviation; TV, tricuspid valve. 
*T-test. †Pearson’s Chi-Square test. ‡Fishers’ Exact test. 
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Table 2 Indications for Valve Surgery, Degree of Emergency, and Type of TV 
Surgery in the Total Population and in the Two Surgical Groups. 
  Total 
N (%) 
First TV surgery 
N (%) 
TV reoperation 
N (%) 
Total 92 (100%) 61 (100%) 31 (100%) 
Primary TV disease: 
- Carcinoid tumour 
 
2 (2.2%) 
 
2 (3.3%) 
0 (0%) 
- Ebstein’s anomaly 6 (6.5%) 6 (9.8%) 0 (0%) 
- TV endocarditis 8 (8.7%) 6 (9.8%) 2 (6.5%) 
- Rheumatic valve disease 12 (13.0%) 9 (14.8%) 3 (9.7%) 
Secondary TV disease:    
- Secondary annular dilatation 38 (41.3%) 33 (54.1%) 5 (16.1%) 
Traumatic TR 5 (5.4%) 5 (8.2%) 0 (0%) 
Prosthetic valve dysfunction 21 (22.8%) 0 (0%) 21 (67.7%) 
Elective 37 (40.2%) 22 (36.1%) 15 (48.4%) 
Low emergency  47 (51.1%) 32 (52.5%) 15 (48.4%) 
High emergency  3 (3.3%) 2 (3.3%) 1 (3.2%) 
Salvage 1 (1.1%) 1 (1.6%) 0 (0%) 
Annuloplasty (DE Vega) 8 (8.7%) 8 (13.1%) 0 (0.0%) 
Annuloplasty + ring 25 (27.2%) 22 (36.1%) 3 (9.7%) 
Valve replacement 
Bioprosthesis 
Mechanical valve 
59 (64.1%) 
33 (35.9%) 
26 (28.3%) 
31 (50.8%) 
24 (39.3%) 
7 (11.5%) 
28 (90.3%) 
9 (29%) 
19 (61.3%) 
N, Number; TR, tricuspid regurgitation; TV, tricuspid valve. 
 
Identification of Predictors of Outcome after TV Surgery 
For the entire cohort, univariable Cox proportional hazards analysis revealed that age 
(p<0.0001), extracardiac vascular disease (p=0.001), renal function (p=0.022), NYHA 
functional class 1-2 compared to NYHA 3-4 (p=0.010), and use of loop diuretics 
(p=0.017) or potassium-sparing diuretics (p=0.002) were significantly associated with 
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outcome. Whether valve repair or valve replacement was performed did not influence 
outcome (HR=0.722 (0.346-1.510); p=0.387). Similarly, whether valve replacement 
was performed with a bioprosthesis compared to a mechanical valve did not influence 
outcome (HR=0.691 (0.301-1.587); p=0.384). Hemodynamic parameters associated 
with outcome were right atrial pressure (p=0.004); right ventricular systolic and 
diastolic pressure (p=0.038 and p=0.043 respectively); and systolic, diastolic, and 
mean PAP (p=0.003; p=0.015; p=0.005, respectively). (Table 4) The only 
echocardiographic parameter that was associated with outcome was the tricuspid 
regurgitant gradient (p=0.027). Multivariable Cox proportional hazards analysis 
identified age (HR=1.089 (1.054-1.165); p=0.015) and NYHA functional class 1-2 vs. 
3-4 (HR 6.671 (1.154-38.551); p=0.034) as factors significantly associated with 
outcome. (Table 5) 
When patients presented in NYHA functional class 3 or 4, survival was significantly 
worse compared to patients presenting in NYHA functional class 1 or 2. Thirty-day, 
90-day and 5 year survival was 100%, 100%, 94.7% respectively for NYHA class I 
and II whereas survival was 88.8%, 79.1% and 66.9% respectively for NYHA class 
III and IV (log-rank test, p=0.005). (Figure 2) 
There was a significant interaction between mean PAP and the age-categories (HR 
0.921 (0.839-1.011); p= 0.084). Only for the younger age group (<59 years of age), 
mean PAP was associated with the worse outcome  (HR 1.090 (1.012-1.175); 
p=0.024). In the younger age group, thirty-day, 3 month, 5 year survival was 100%, 
100%, 100% respectively for mean PAP < 25 mmHg whereas survival was 100%, 
90%, 80% respectively for mean PAP ≥ 25 mmHg (log-rank test, p=0.008). PH didn’t 
influence the survival of patients in the older age group (log-rank test, p=0.485) 
(Figure 3). 
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Table 3 Postoperative Complications in the population and in the two surgical Groups 
Postoperative complication Total 
N=92 
First TV surgery 
N=61 
TV reoperation 
N=31 
P-value 
Reoperation     
Tamponade 6 (6.5%)
‡
 4 (7%)
§
 2 (6.7%)
||
 1
*
 
Bleeding 12 (13%) 8 (13.1%) 4 (12.9%) 1
*
 
Valve dysfunction 10 (10.9%) 7 (11.5%) 3 (9.7%) 1
*
 
Postoperative MI 1 (1.1%) 0 (0%) 1 (3.2%) 0.337
*
 
Infection (sternal/sepsis) 7 (7.6%) 5 (8.2%) 2 (6.5%) 1
*
 
CVA/TIA 3 (3.3%) 1 (1.6%) 2 (6.5%) 0.262
*
 
Pulmonary event 15 (16.3%) 10 (16.4%) 5 (16.1%) 0.974
†
 
 + mechanical ventilation 14 (15.2%) 10 (16.4%) 4 (12.9%) 0.766
*
 
Renal failure 12 (13.0%) 9 (14.8%) 3 (9.7%) 0.745
*
 
 + dialysis 11 (12.0%) 9 (14.8%) 2 (6.5%) 0.323
*
 
Postoperative high grade AV block 14 (15.2%) 5 (8.2%) 9 (29.0%) 0.013
*
 
Postoperative definitive pacemaker 11 (12%) 4 (6.6%) 4 (6.6%) 0.039
*
 
Arrhythmia (atrial and ventricular) 22 (25.3%)
‡
 14 (23%)
§
 8 (26.7%)
||
 0.830
†
 
Pleural effusion 9 (10.3%)
‡
 6 (10.5%)
§
 3 (10.0%)
||
 1
*
 
AV, atrioventricular; CVA, cerebrovascular accident; MI, myocardial infarction; TIA, transient ischemic 
attack; TV, tricuspid valve. *Fishers’ Exact test. †Pearson’s Chi Square test. ‡Statistics were calculated on 
n=87. §Statistics were calculated on n=57. ||Statistics were calculated on n=30. 
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Figure 2 Kaplan-Meier curve showing survival stratified by NYHA functional class. 
Survival in patients presenting in NYHA functional class 3 or 4 was significantly 
worse compared to patients presenting in NYHA functional class 1 or 2. Thirty-day, 
90-day and 5 year survival was 100%, 100%, 94.7% respectively for NYHA class I 
and II whereas survival was 88.8%, 79.1% and 66.9% respectively for NYHA class 
III and IV (log-rank test, p=0.005). NYHA: New York Heart Association. 
 
 
  
Table 4 Univariable Cox regression for all-cause mortality. Evaluation of demographic, echocardiographic and hemodynamic 
parameters. 
 N P-value HR (95% CI)  N P-value HR (95% CI) 
Demographics    Medical treatment    
Age (years) 92 < 0.0001* 1.071 (1.035-1.108) Loop diuretics 88 0.017* 2.980 (1.212-7.327) 
Gender 92 0.079 0.492 (0.223-1.086) Potassium sparing 
diuretics 
88 0.002* 3.868 (1.665-8.985) 
BMI (kg/m
2
) 91 0.344 0.959 (0.880-1.046) ACE-I or ARB 88 0.767 1.118 (0.535-2.338) 
Cardiac risk profile 88 0.510 1.098 (0.831-1.450) Beta-blockade 88 0.954 1.021 (0.498-2.095) 
Extracardiac vascular disease 92 0.001* 4.961 (1.865-13.200) Echocardiography    
Previous cardiac surgery 92 0.803 1.099 (0.524-2.304) TR (0-4/4) 90 0.510 0.904 (0.669-1.221) 
Recent MI (<90 days) 83 0.420 1.815 (0.426-7.735) RV diameter 71 0.825 0.996 (0.961-1.033) 
Angina pectoris 89 0.479 0.649 (0.196-2.152) RV function (normal-
severe impairment) 
89 0.975 0.994 (0.688-1.436) 
Chronic lung disease 91 0.064 2.309 (0.951-5.605) RA major 90 0.723 1.055 (0.977-1.034) 
Renal failure 92 0.022* 1.725 (1.081-2.751) Tricuspid regurgitant 
gradient 
68 0.027* 1.031 (1.004-1.060) 
Cardiac rhythm 92 0.543 1.138 (0.751-1.722) LV Ejection Fraction 86 0.597 0.987 (0.941-1.035) 
NYHA 1-2 vs. NYHA 3-4 90 0.010* 4.733 (1.444-15.508) Hemodynamics    
First TV surgery vs. TV 
reoperation  
92 0.341 0.704 (0.341-1.452) RAP (mmHg) 65 0.004* 1.122 (1.037-1.213) 
Type of TV surgery 92 0.779 1.071 (0.666-1.722) RVPsyst (mmHg) 65 0.038* 1.030 (1.002-1.059) 
  
Table 4 continued        
annuloplasty versus 
replacement 
33 0.387 0.722 (0.346-1.510) RVPdiast (mmHg) 64 0.043* 1.081 (1.002-1.167) 
Bioprosthesis versus 
mechanical valve 
59 0.384 0.691 (0.301-1.587) PAPsyst (mmHg) 69 0.003* 1.038 (1.013-1.063) 
Urgency grade 88 0.713 0.882 (0.452-1.723) PAPdiast (mmHg) 69 0.015* 1.076 (1.015-1.141) 
EuroScoreII 92 0.002* 1.119 (1.041-1.204) PAPmean (mmHg) 63 0.005* 1.061 (1.018-1.106) 
BMI, Body mass index; MI, myocardial infarction; NYHA, New York Heart Association functional class; PAP, pulmonary artery pressure; RAP, right atrial 
pressure; RVP, right ventricular pressure; TV, tricuspid valve. * P<0.05; 
† 
P for interaction <0.10. 
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Table 5 Multivariable Cox Regression for all-cause mortality. 
 N P-value HR (95% CI) 
Age 60 0.015* 1.089 (1.054-1.165) 
NYHA 1-2 vs. 3-4  0.034* 6.671 (1.154-38.551) 
Extracardiac vascular disease  0.095 5.696 (0.739-43.909) 
Renal failure  0.227 1.699 (0.719-4.011) 
First TV surgery vs. TV reoperation  0.500 1.389 (0.535-3.609) 
EuroscoreII  0.177 0.903 (0.779-1.047) 
PAPmean  0.984 0.999 (0.945-1.057) 
Loop diuretics  0.191 2.619 (0.619-11.094) 
NYHA: New York Heart Association functional class; TV: tricuspid valve; PAP: pulmonary artery pressure. 
*P<0.05. 
 
 
  
Figure 3 Kaplan-Meier curve showing survival in the younger (<59 years of age) and older groups, stratified by mean PAP (≥ 25 
mmHg). In the younger age group, thirty-day, 3 month, 5 year survival was 100%, 100%, 100% respectively for mean PAP < 25 mmHg 
whereas survival was 100%, 90%, 80% respectively for mean PAP ≥ 25 mmHg (log-rank test, p=0.008). PAP: pulmonary artery pressure 
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Discussion 
This study showed that isolated TV surgery in present-day practice is still associated 
with significant postoperative and long-term mortality. In this study sample, no 
difference between first TV surgery and reoperation of the TV was observed. Age and 
NYHA functional class appear to influence outcome while PH is only associated with 
the worse outcome in younger patients (<59 years of age). 
Short-term and long-term mortality in the studied cohort of patients is high. The 
postoperative mortality of 7.9% is comparable to that reported in contemporary 
series.
3, 17
 However, different studies report varying mortality rates depending on the 
studied population. It should be noted that the indication for surgery and whether 
combined surgery is performed greatly influences outcome.
16, 22, 23
 Carcinoid disease 
is associated with a postoperative mortality of 60%.
24
 For comparison, TV repair for 
primary structural TV disease has a postoperative mortality of only 4%.
15
 Together, 
this suggests that TV dysfunction results from a diverse pathology that originates 
because of several diseases with different hemodynamic and functional properties.
25
 
However, in our series we could not identify indication of surgery as a predictor of 
outcome, probably because of the diversity of our dataset. Unfortunately, we were not 
able to compare the outcomes of our surgical group with a matched control group in 
whom severe TR was treated medically. We believe that this aspect should be studied 
prospectively in the future.  
NYHA functional class is a known predictor of mortality in TV surgery, as confirmed 
by our dataset.
13, 26, 27
 We report excellent survival in patients who present in NYHA 
functional class 1 and 2 pre-operatively. Postponing surgery until symptoms occur is 
associated with the worse outcome.
11, 12, 28
 On the other hand, when patients are 
asymptomatic, surgery can be performed at a low operative risk.
11
 Furthermore, age 
itself seems to be a very important and statistically independent predictor of outcome 
in patients undergoing TV surgery.
29, 30
 Therefore, our data support the approach of 
intervening at a younger age, when symptoms of TV disease are absent or minimal. 
Although current guidelines do not advise routine intervention for asymptomatic 
isolated moderate to severe TV pathology, long-standing volume overload of the right 
ventricle is associated with increased stroke work, structural changes of the right 
ventricle and valvular apparatus, and eventually the development of right ventricular 
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failure.
31-34
 These morphological and functional changes might explain the low 
success rate of surgery when performed at later stages of the disease, when changes 
are irreversible. RV function has been identified as a predictor of outcome.
12, 35
 
Unfortunately, our pre-operative echocardiographic data failed to show an association 
between RV function and outcome. Reason for this could be that 2D 
echocardiographic evaluation of the RV is difficult and often inaccurate compared to 
other imaging techniques such as magnetic resonance. Also, RV end-diastolic 
pressure as determined by right heart catheterization were associated with outcome 
and could be a better marker of RV dysfunction. On the other hand, significant 
remodelling of the right heart after TV surgery can occur. It has been shown that RV 
geometry and RV ejection fraction improve after surgery.
36
 The evolution of RV 
geometry and function after surgery might therefore be more important than the pre-
operative evaluation. In these series remodelling of the right ventricle after surgery 
could not be evaluated because of the lack of echocardiographic follow-up data within 
a narrow time frame. 
We also studied whether invasive pulmonary hemodynamic data such as PAP affect 
outcome. Controversy exists on the use of invasive hemodynamic assessment during 
the preoperative evaluation of valvular heart disease.
1
 Indeed, an invasive approach is 
currently not recommended in guidelines, although a pressure-load on the right 
ventricle is associated with worse outcome in different heart disease. Mean PAP is the 
most reproducible measurement in invasive assessment of pulmonary hemodynamics 
as it is less dependent on adrenergic state and volume-overload. When included in the 
univariable regression analysis on the entire dataset (i.e., no age stratification), 
increasing mean PAP was related to worse outcome; however, multivariable analysis 
revealed that age and NYHA functional class were more important.
29, 30
 PAP tends to 
increase with age and in our dataset a significant interaction between age and PAP 
was noted.
21
 Indeed, in the younger population PH seems to influence prognosis while 
no significant association of PH with outcome was observed in the older age group. 
We hypothesize that the persisting pressure-load on the right ventricle in patients with 
PH in time impairs right ventricular function. Furthermore, it is possible that once PH 
occurs, the optimal window for performing TV surgery has closed.  
It is generally accepted that patients who undergo a second cardiovascular 
intervention by median sternotomy have a higher operative risk. Redo surgery is a risk 
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factor in many established risk scores.
18
 In this study sample, TV reoperation did not 
have a higher mortality when compared to first TV operation. However, 43% of the 
patients with a first tricuspid valve intervention already underwent previous 
sternotomy and thus presented with an operative risk, similar to the patients who 
underwent TV reoperation. This might explain the similar outcome in both groups. 
Moreover, because of the observational nature of the study, a selection bias could 
have occurred as reoperation is generally reserved to the patients that are considered 
to have the better prognosis. Nevertheless, both study groups were equally matched in 
baseline characteristics, except for the EuroScore II, which was even higher in the TV 
reoperation group. Our data suggest that the general preoperative state of a patient 
might be more important than technical difficulties related to the surgery itself. 
 
Limitations 
We present observational data from a single institution.  At inclusion, no 
randomization was performed and patients were referred for cardiac surgery after 
multidisciplinary consultation based on current guidelines and best medical practice. 
Therefore these results should be interpreted with caution, as a potential selection bias 
is not excluded. Furthermore, because isolated TV surgery is rarely performed, the 
studied number of patients is relatively low. Nevertheless, to our knowledge, we 
present the largest patient population undergoing isolated tricuspid valve surgery. A 
multicentre registry could possibly overcome these shortcomings especially when all 
institutions follow the same registry protocol. 
 
Conclusions 
Isolated TV surgery is still associated with important postoperative and long-term 
mortality, both for first TV surgery and TV reoperation. Pre-operative NYHA 
functional class and, in younger patients, pulmonary hypertension appear to determine 
prognosis. 
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2. Additional tricuspid annuloplasty in mitral valve surgery 
results in better clinical outcome: a propensity matched 
analysis.   
 
Abstract 
Objective 
The clinical benefit of tricuspid annuloplasty (TA) in patients undergoing mitral valve 
surgery (MVS) is still debated. We evaluated the immediate surgical success of MVS 
with or without TA, post-operative outcome and the medium-term additional effect of 
TA. 
Methods 
Patients undergoing MVS with or without TA between 09-2003 and 12-2009 were 
included and were followed until 09-2013 to achieve a median follow-up time of 5 
years (IQ3.7-6.9). The endpoint of mortality due to cardiac causes and the combined 
end-point of cardiac mortality and hospitalisation for heart failure were evaluated. A 
propensity score was constructed for the chosen surgical strategy and included in the 
cox regression model to evaluate the clinical benefit of TA at the time of MVS. 
Results 
From 150 patients (84 female; age 67±12 years), 82 presented with tricuspid 
regurgitation (TR)<2/4 and underwent isolated MVS. Of 68 patients presenting with 
TR≥2/4, 31 underwent isolated MVS whereas 37 underwent additional TA.  
In the patients with preoperative TR>2, TR was significantly reduced at 6-month 
follow-up when additional TA was done [mean TR reduction 1.13(SE0.20); 
p<0.0001]. 
Patients with preoperative TR≥2/4 had worse survival (log-rank p=0.009), compared 
to patients with TR<2, and in these patients, propensity score-adjusted event-free 
survival for the combined end-point was significantly better when concomitant TA 
was performed [Cox Regression HR 2.855(1.082-7.532); p=0.035]. 
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Conclusion 
Additional TA at the time of MVS is an effective surgical measure to reduce 
functional TR severity. Propensity-matched analysis shows a clinical benefit of this 
approach over isolated MVS in patients with preoperative TR≥2/4. 
 
Introduction 
Functional tricuspid regurgitation (TR) often accompanies mitral regurgitation (MR).
1
 
Although TR may be only mild at the time of surgery, TR severity progresses after 
isolated mitral valve surgery in ca. 30% of patients and can occur years after the 
initial left-sided surgery.
2-4
 The complex pathophysiology of functional TR makes the 
natural history unpredictable.
1, 5, 6
 Increasing TR severity is known to be associated 
with worse prognosis.
2, 7
 Furthermore, reoperation for isolated TR is associated with a 
high perioperative, short- and long-term mortality whereas performing tricuspid 
annuloplasty at the time of mitral valve surgery (MVS) adds little time to the 
procedure.
8, 9
 Therefore, a more liberal approach in performing tricuspid valve repair 
at the time of MV surgery is now advocated by both the ESC and the AHA/ACC 
guidelines on valvular heart disease.
10, 11
 
Although such an approach results in favourable remodelling of the right ventricle and 
lesser recurrence of TR, data on clinical outcome are scarce. 
4, 12, 13
 Improved mid-
term survival of concomitant tricuspid annuloplasty (TA) has been reported in 
patients with functional MR due to, mainly ischemic, cardiomyopathy.
14
 However, the 
gross majority of MVS is performed for chronic degenerative valvular disease.
15
 
Comparison of the outcome in patients undergoing MV surgery with or without TA is 
notoriously difficult because the former often present in a worse clinical state with 
more severe TR, higher NYHA functional class and decreased right ventricular 
function.
4
 Cross-sectional studies therefore failed to show improved outcome for 
patients undergoing simultaneous TA and MVS in the past. 
16, 17
  
The aim of our study was to assess the immediate surgical success of MVS with or 
without TA, to examine post-operative outcome and to evaluate the clinical benefit of 
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TA in the setting of MVS corrected for pre-operative parameters using a propensity 
score analysis. 
Methods 
Patient selection and data collection 
From the institutional database of Cardiac Surgery at the University Hospitals 
Leuven, patients undergoing MVS were retrospectively included from September 
2003 until December 2009 and followed until September 2013. All patients had their 
follow-up at the University Hospitals Leuven, a tertiary care center. Patients with 
primary tricuspid valve pathology, redo surgery or severe cardiac and non-cardiac 
disease other than valvular heart disease at the moment of inclusion were excluded.  
Patients underwent either isolated MVS or MVS in combination with TA. Patients 
were divided into 3 groups: (1) patients with TR<2/4 undergoing isolated mitral valve 
surgery (Group TR-/MVS); (2) patients with TR≥2/4 undergoing isolated mitral valve 
surgery (Group TR+/MVS) and (3) patients with TR≥2/4 undergoing mitral valve 
surgery in combination with tricuspid annuloplasty (Group TR+/MVS+TA). 
The mitral valve was repaired whenever feasible, otherwise, mitral valve replacement 
was performed. The decision to perform concomitant TA was taken after multi-
disciplinary discussion by the institutions heart team. Demographic and clinical data 
as well as echocardiographic data were included. Post-operative data including 
echocardiography immediately post-operative and at 6-month follow-up were 
reviewed.  Outcome for every patient was evaluated. The local ethics committee 
approved patient inclusion and analysis.  
Endpoints 
Cardiac mortality and the combined endpoint of cardiac mortality and hospitalisation 
for heart failure were evaluated for each group. Heart failure was defined as 
presentation in NYHA functional class III and higher, signs of sodium and water 
retention and echocardiographic evidence of fluid overload or elevated NT-proBNP.  
Statistical analysis 
Continuous data and categorical data are represented by means and standard deviation 
or frequencies and percentages, respectively.  
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First, pre-operative demographic data and echocardiographic data were analysed and 
compared between groups by unpaired t-test or Fisher’s exact test where applicable.  
Next, immediate surgical success was evaluated by comparison of pre-operative 
echocardiographic data with echocardiography directly post-operative and at 6 
months post-operatively by paired t-test with Bonferoni-correction for multiple 
testing.  
Third, the occurrence of cardiac mortality and the combined endpoint of cardiac 
mortality and hospitalisation for heart failure were evaluated for each group by 
Kaplan-Meier survival analysis.  
Last, a non-parsimonious propensity score was constructed by multivariate binary 
logistic regression and the probability was calculated for each patient with TR ≥ 2/4 to 
be allocated by the heart team to concomitant tricuspid annuloplasty (Group 
TR+/MVS vs. Group TR+/MVS+TA). Based on current guidelines and practice in our 
hospital, age, preoperative NYHA functional class, TR severity, tricuspid annular 
diameter and preoperative tricuspid annular plane systolic excursion (TAPSE) were 
included in the model [C-statistic 0.861 (95%CI=0.767-0.956); Hosmer Lemeshow 
p=0.279]. 
Multivariate Cox regression was performed with the propensity score and the surgical 
approach as variables and propensity score-adjusted survival curves were plotted 
subsequently.  
All tests were two-tailed. A P-value <0.05 was considered significant. Analyses were 
performed using SPSS
®
 (version 22 SPSS, Chicago, USA). 
 
Results 
Patient inclusion 
From September 2003 until December 2009, 882 patients underwent MVS at the 
University Hospitals Leuven. Of these, 625 were referred from and later followed 
outside the hospital. From the remaining 257 patients, 17 were lost to follow-up. 
Another 90 patients were excluded for various reasons as is summarized in Figure 1. 
CHAPTER 5 
2. ADDITIONAL TRICUSPID ANNULOPLASTY IN MITRAL VALVE SURGERY RESULTS IN BETTER 
CLINICAL OUTCOME: A PROPENSITY MATCHED ANALYSIS 
 
193 
 
The study cohort comprised the remaining 150 patients. Follow-up was 100% 
complete. Median follow-up time was 5 years (IQ range 3.7-6.9). 
Patient characteristics 
Demographic, echocardiographic and post-operative data are listed in Table 1. 
Eighty-two patients had pre-operative TR<2/4 (group TR-/MVS). From the 68 
patients with TR ≥ 2/4, 37 underwent concomitant tricuspid valve repair (group 
TR+/MVS+TA), and 31 patients underwent isolated mitral valve surgery (group 
TR+/MVS). Patients in group TR+/MVS+TA had significantly more TR and 
significantly lower TAPSE than patients in group TR+/MVS.  The indication for 
surgery can be found in Figure 2. 
In 82 (55%) patients, mitral valve repair was feasible. The other 68 (45%) patients 
underwent mitral valve replacement, in 37 (54%) cases with a mechanical prosthetic 
valve. The distribution of the surgical strategy was not significantly different across 
groups (Fisher’s Exact p=0.518). 
Of 37 patients undergoing additional tricuspid annuloplasty, 21 (56%) underwent De 
Vega annuloplasty and 16 (44%) underwent ring annuloplasty.  
Figure 1 Flow chart to identify patients eligible for analysis 
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Figure 2 Indication for surgery expressed as percentage of total within each group. 
 
 
Immediate surgical success after mitral and tricuspid valve surgery 
Significant reduction of MR was observed in all patients early post-operatively and at 
6 months follow-up. Results are summarized in Table 2. In patients presenting 
without significant TR (Group TR-/MVS), TR post-operatively was slightly but 
significantly increased (p<0.001 immediately post-operatively and p=0.018 at 6 
months), albeit still in what is considered to be the physiological range. In Group 
TR+/MVS, small but significant decrease of TR could be seen directly post-
operatively. This decrease did not persist 6 months post-operatively. Patients 
undergoing simultaneous tricuspid and mitral valve surgery presented with a large and 
significant decrease of TR post-operatively. This improvement persisted at 6 months 
follow-up.  
NYHA functional class was significantly better compared to pre-operatively in all 
patients, alive at 6 months follow-up. 
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Table 1 Demographic, pre-operative echocardiographic parameters and post-
operative variables in Group TR-/MVS; Group TR+/MVS and Group TR+/MVS+TA.  
 
 
    TR-/MVS TR+/MVS TR+/MVS+TA p 2 vs. 3 
Demographics  n  n  n   
Gender n female (%) 82 42 (51%) 31 17 (55%) 37 27 (73%) 
§
0.135 
Age (years) mean (±SD) 82 64 (±12) 31 72 (±8) 37 70 (±11) 0.383 
BMI (kg/m
2
) mean (±SD) 82 26.8 (±5.4) 31 26.1 (±3.8) 37 24.7 (±4.2) 0.146 
Creatinine (mg/dL) mean (±SD) 81 1.22 (±1.15) 31 1.22 (±0.42) 37 1.18 (±0.32) 0.634 
NYHA functional class mean (±SD) 82 2.2 (±0.9) 31 2.5 (±0.8) 37 2.6 (±0.7) 0.741 
Atrial fibrillation n (%) 82 30 (36.6%) 31 18 (58.1%) 37 25 (67.6%) 
§
0.004* 
Pacemaker n (%) 82 3 (3.7%) 31 1 (3.2%) 37 1 (2.7%) 
§
1 
Echocardiography         
Mitral Regurgitation (x/4) mean (±SD) 81 3.1 (±0.6) 31 3.2 (±0.7) 37 3.1 (±0.6) 0.622 
Tricuspid Regurgitation (x/4) mean (±SD) 82 1.06 (±0.47) 31 2.3 (±0.4) 37 2.6 (±0.8) 0.018* 
RV-RA gradient (mmHg) mean (±SD) 81 29 (±9) 31 43 (±13) 37 37 (±14) 0.179 
LVEDD (mm) mean (±SD) 73 52 (±10) 31 51 (±12) 37 51 (±9.6) 0.996 
LVEF (%) mean (±SD) 79 60 (±13) 31 62 (±12) 37 59 (±12) 0.385 
RV diameter (mm) mean (±SD) 68 29 (±5) 31 31 (±7) 37 33 (±6) 0.412 
RV annular diameter (mm) mean (±SD) 62 30 (±5) 31 32 (±7) 37 34 (±6) 0.412 
TAPSE (mm) mean (±SD) 54 22 (±5) 31 23 (±4) 37 18 (±4) <0.0001* 
Post-operative         
30-day all-cause mortality n (%) 82 2 (2.4%) 31 3 (9.7%) 37 0 (0%) 
§
0.090 
3-month all-cause mortality n (%) 82 3 (3.7%) 31 4 (12.9%) 37 2 (5.4%) 
§
0.400 
Duration ITE stay (days) mean (±SD) 82 5 (±8) 28 6 (±12) 36 6 (±9) 0.829 
Duration hospitalisation(days) mean (±SD) 80 18 (±18) 28 19 (±17) 35 26 (±39) 0.399 
New onset atrial fibrillation n (%) 52 18 (34.6%) 13 4 (30.8%) 12 4 (33.3%) 
§
1 
New permanent pacemaker n (%) 79 12 (15.2%) 30 3 (10%) 36 10 (27.8%) 
§
0.153
 
BMI= body mass index; RV=right ventricle; LVEDD=left ventricular end-diastolic diameter; LVEF=left ventricular 
ejection fraction; TAPSE=tricuspid annular plane systolic excursion. *p<0.05=significant. 
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Table 2 Procedural success of surgery across groups. Mitral regurgitation was 
reduced in all study groups. TR was only significantly decreased at 6 months in 
patients undergoing tricuspid annuloplasty. TR+ indicates TR≥2/4 preoperatively. 
MVS indicates isolated mitral valve surgery. MVS+TA indicates additional tricuspid 
annuloplasty. Note: 8 patients didn’t have echocardiography at 6 months follow-up. 
  TR-/MVS TR+/MVS TR+/MVS+TA 
 N Mean t-test N Mean t-test N Mean t-test 
MR          
Preop 82 3.11 (±0.63)  31 3.21 (±0.67)  37 3.14 (±0.57)  
Postop 80 0.44 (±0.71) <0.0001* 29 0.48 (±0.74) <0.0001* 36 0.68 (±0.81) <0.0001* 
6months 78 0.71 (±0.87) <0.0001* 24 0.71 (±0.91) <0.0001* 34 0.88 (±0.78) <0.0001* 
TR          
Preop 82 1.06 (±0.47)  31 2.27 (±0.44)  37 2.65 (±0.80)  
Postop 80 1.44 (±0.84) 0.0001* 29 1.78 (±0.86) 0.0388* 36 1.15 (±0.74) <0.0001* 
6months 78 1.30 (±0.85) 0.0185* 24 1.90 (±0.92) 0.2204 34 1.46 (±0.91) <0.0001* 
NYHA          
Preop 82 2.2 (±0.9)  31 2.5 (±0.8)  37 2.6 (0.7)  
6months 78 1.5 (±0.7) <0.0001* 26 1.7 (±0.9) <0.0001* 35 1.6 (±0.7) <0.0001* 
 
Short- and medium-term clinical outcome after mitral and tricuspid valve surgery 
Early post-operative all-cause mortality at 30 days and 3 months was 3.3% and 6% 
respectively.(Table 1) Event-rate for the combined endpoint of cardiac mortality and 
hospitalisation for heart failure, for cardiac mortality and for hospitalisation for heart 
failure can be found in Table 3. 
Event free survival was significantly better in patients presenting without significant 
preoperative TR (<2/4), compared to patients with preoperative TR > 2 (30-day 
cardiac mortality=2.4% vs 4.4%; 1-year=3.7% vs 10.6%; 5-year=7% vs 22.3%; Log 
Rank p=0.009). In unadjusted analysis, there was no difference in cardiac mortality 
between patients with TR≥2/4 undergoing isolated mitral valve surgery (Group 
TR+/MVS) and patients undergoing additional tricuspid annuloplasty (Group 
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TR+/MVS+TA) (30-day cardiac mortality=9.7% vs 0%; 1-year=16.1% vs 5.6%; 5-
year=24.6% vs 20.3%; Log Rank p=0.414). (Figure 3), whereas a trend towards 
better outcome for the combined endpoint of cardiac mortality and hospitalisation for 
heart failure in the TR+/MVS+TA group could be seen (30 day event-rate=9.7% vs 
0%; 1-year=29% vs 5.6; 5-year=57.2 vs 39.4%; Log Rank p=0.077).  
When incorporating the propensity score into a multivariable Cox regression model, 
no significant benefit in cardiac mortality of additional TA in patients with 
preoperative TR≥2/4 could be observed [HR 2.9 (0.8-10.7); p=0.108], whereas 
propensity score-adjusted event-free survival for the combined endpoint of cardiac 
death and hospitalisation for heart failure was significantly better for patients with 
preoperative TR >2 undergoing additional TA [HR 2.9 (1.1-7.5); p=0.034]. (Figure 
4) 
 
Table 3 Medium-term event-rate for each group studied. The combined endpoint was 
composed of cardiac death and hospitalisation for heart failure. 
 TR-/MVS TR+/MVS TR+/MVS+TA 
Combined endpoint 
30 days 3 (4%) 3 (10%) 0 (0%) 
1 year 10 (12%) 9 (29%) 2 (6%) 
5 years 17 (22%) 16 (57%) 13 (39%) 
Cardiac-related death 
30 days 2 (2%) 3 (10%) 0 (0%) 
1 year 3 (4%) 5 (16%) 2 (6%) 
5 years 5 (7%) 7 (25%) 7 (20%) 
Hospitalization for heart failure  
30 days 1 (1%) 0 (0%) 0 (0%) 
1 year 7 (9%) 4 (13%) 0 (0%) 
5 years 12 (15%) 9 (33%) 6 (19%) 
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Figure 3  
Unadjusted event-free survival for (A) Cardiac mortality and (B) Cardiac mortality 
and hospitalisation for heart failure.  
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Figure 4 Propensity matched adjusted event-free survival for (A) cardiac mortality 
and (B) Cardiac mortality and hospitalisation for heart failure in patients with 
significant preoperative functional tricuspid regurgitation (TR ≥2/4).  
 
 
Discussion 
This study shows that additional tricuspid annuloplasty at the time of MVS 
significantly reduces TR severity postoperatively. Patients with TR ≥ 2/4 who 
undergo simultaneous MVS and TA have an improved event-free survival for the 
combined endpoint of cardiac mortality and hospitalisation for heart failure.  
The value of tricuspid annuloplasty with MVS is still debated. However, both the 
European and American guidelines on valvular heart disease have implemented 
indications for concomitant tricuspid annuloplasty at the time of MVS in their 
recommendations.
10, 11
 TR severity, tricuspid annular diameter and right ventricular 
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function are all important factors in the decision process whether the tricuspid valve 
has to be repaired at the time of MVS. Some authors even advocate tricuspid 
annuloplasty in the absence of preoperative TR to prevent progression of TR in the 
long term.
18, 19
 
Increased pulmonary arterial pressure, right ventricular and TV annular dimensions 
contribute independently to functional TR.
1, 20-23
 Although surgery of the MV can 
reduce the increased pulmonary arterial pressure caused by chronic MR, the structural 
alterations at the level of the right ventricle often persist after isolated MVS.
24, 25
 Also, 
in degenerative MR, disease of the fibrous skeleton could be progressive and 
causative for the further deterioration of the valvular function, especially of the 
“untreated” tricuspid valve.23 Because of this, it is clear that TR doesn’t resolve after 
isolated MVS and even progresses after successful left-side valve surgery.
2
 
Progression or persistence of TR in the setting of MVS occurs frequently and is 
associated with worse prognosis.
2-4
 If we aim to reduce TR and prevent the 
development of TR, TA should be considered at the time of MVS. The durability of 
TA in the setting of mitral valve disease has been shown in other published series.
26
 
Our data show successful reduction of MR severity and NYHA functional class in all 
surgical-treated patients. However, when preoperative TR was present, there was no 
significant reduction of TR at 6 months follow-up when the tricuspid valve was left 
untreated. On the other hand, persistent reduction of TR at 6 months was noted in the 
patient group undergoing tricuspid annuloplasty.  
Although TA successfully reduces TR, the net clinical benefit of performing 
simultaneous tricuspid valve surgery is unclear.
26
 In patients with functional MR, 
mainly due to ischemic cardiomyopathy, 5-year mortality was lower in patients 
undergoing TA at the time of mitral valve repair.
14
 These data were adjusted for left 
ventricular parameters, as possible confounders of outcome. Opposed to this, several 
studies failed to show that tricuspid annuloplasty is beneficial in patients with other 
causes of MR.
16, 17
 As the majority of MR occurs due to reasons other than ischemic 
cardiomyopathy, the true benefit of TA remains to be proven.  
In addition, a registry including post-operative results in 17 centers showed a higher 
mortality and an increased operative time in patients undergoing additional TA.
27
 
Furthermore, we observed a higher but not significant incidence of permanent 
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pacemaker implantation in the TR+/MVS+TA group compared to the TR+/MVS 
group (27.8% vs 10%; p=0.153). On the other hand, additional TA was not associated 
with higher post-operative mortality in our study sample and no increased mortality 
was reported in studies from centers where a liberal approach towards tricuspid 
annular repair is practiced.
4, 8, 9
 
A comparison of both surgical approaches is hampered by the heterogeneity of 
patients. The decision to operate on the tricuspid valve concomitantly with the mitral 
valve is taken by multi-disciplinary consultation by the institution’s heart team. This 
often results in proposing the combined approach in “sicker” patients with already 
decreased right ventricular function, more dilated tricuspid valve annulus, more 
severe TR and in higher NYHA functional class. These are all known determinants of 
worse post-operative outcome. 
4, 8, 9
 To adjust for possible confounders, we calculated 
the probability for allocation to one of the surgical approaches for each patient. After 
adjustment, an improved event-free survival for the combined end-point of cardiac 
mortality and hospitalisation for heart failure could be shown in patients undergoing 
MVS with TA (Group TR+/MVS+TA).(Figure 4) The better event-free survival for 
patients undergoing simultaneous TA is mainly due to a lower number of 
hospitalisations for heart failure.(Table 3) The volume-load associated with TR 
increases stroke work of the right ventricle and impairs ventricular interdependence.
28, 
29
 In the post-operative setting, persistent or increased TR is one of the causes of 
right-sided heart failure.
29
 Theoretically, TA should better preserve right ventricular 
function post-operatively and in the long-term. However, the relation between right 
heart failure en TR severity is still incompletely understood. Some suggest that TR is 
caused by right ventricular failure rather than vice-versa.
30
 Indeed, we observed 
higher TR severity and lower right ventricular function in patients undergoing 
additional TA. This would mean that repairing tricuspid competence does not restore 
ventricular function. However, others have shown favourable remodelling of the right 
ventricle after TA, especially in patients with severe TR preoperatively.
12, 13
 We now 
add to this evidence with an improved event-free survival, probably due to better 
preservation of right ventricular function when the tricuspid valve is concomitantly 
repaired.  
Lastly, 32% of patients undergoing concomitant TA had a tricuspid annulus diameter 
>40 mm or >21 mm/m
2
 as assessed by echocardiography. The better survival 
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observed in this patient population therefore is an indication for an even more liberal 
approach towards TA. It seems to us, that current cut-off values for tricuspid annular 
dimensions are quite conservative and it seems obligatory to integrate several 
parameters in the decision process in this difficult patient population. The exact 
indication for performing simultaneous TA remains difficult to determine, exactly 
because of this multi-causality.  
 
Conclusion 
These data provide evidence on the clinical benefit to perform TA in conjunction with 
MVS. The heart team should be alerted for TR progression during follow-up and if 
any doubt about the necessity, performing tricuspid annuloplasty seems to be the 
wiser decision. As TA will be performed more readily, more insights in which 
patients the tricuspid valve can be left alone will probably emerge. 
 
Limitations 
Our results are based on a retrospective analysis of patients followed in a single 
institution. However, this resulted in accurate data of the studied patients and 
propensity matching tried to eliminate surgical selection bias.  
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General discussion 
1. Summary of Key results 
1.1 Tricuspid regurgitation: different determinants and complex interactions 
Secondary or functional TR is associated with different types of heart disease. We 
evaluated the pathophysiology of TR as described in literature and added new 
determinants from analyses we have done. A summarizing diagram of the 
pathogenesis of TR is depicted in Figure 1. Each type of cardiac pathology presents 
with specific disease characteristics in which TR originates from a complex interplay 
of determinants, all of them to a different extent contributing to the pathophysiology. 
 
Figure 1 Determinants of secondary TR as reported in literature (black) and 
investigated in the current thesis project (red). 
 
1.1.1 Valvular interdependence 
Mitral valve regurgitation is known to cause functional TR. This is thought to be a 
consequence of elevated left atrial pressure, leading to venous pulmonary 
hypertension. However, we found a strong and independent correlation of the degree 
of mitral valve regurgitation with TR, without increased pulmonary artery pressures. 
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A possible explanation for this newly found correlation might be the close relation of 
the MV annulus and the TV annulus, connected to each other by the fibrous trigonum, 
part of the valvular cytoskeleton. From a mechanical point of view, mitral valve 
annular dilatation might lead towards disturbances in tricuspid annular geometry, 
causing secondary TR.  
1.1.2 Right ventricular dilatation itself is important in the pathogenesis 
of TR in the pressure-loaded ventricle.  
Increased pressure-load is thought to be the main cause of TR in patients with 
pulmonary hypertension. However, chronic RV pressure-load causes changes in the 
morphology and function of the right ventricle. When looking in detail to patients 
with pre-capillary pulmonary hypertension, we found that the degree of right 
ventricular remodelling, defined as right ventricular dilatation, is also an independent 
determinant of TR. This emphasizes the importance of right ventricular dilatation in 
the pathogenesis of secondary TR.  
1.1.3 Increased dynamic pulmonary vascular resistance is associated 
with persistent TR.  
After closure of an atrial septal defect (ASD) type 2, significant right ventricular 
remodelling occurs. However, right ventricular remodelling does not lead invariably 
to the resolution of pre-existing TR. We evaluated the increase in pulmonary artery 
pressure during exercise and found that patients with mild persistent TR after ASD 
closure present with more increased pulmonary pressures at peak exercise. As a 
consequence, patients after ASD closure often present with a smaller decrease of PVR 
during exercise than healthy controls. We hypothesize that persistent pressure load 
during exercise maintains TR persistence. 
1.1.4 Right ventricular function is important to preserve tricuspid valve 
competence 
We evaluated the impact of RV function on TR in patients with a pressure-loaded RV 
during exercise. 
First, although the pressure gradient across a congenital pulmonary valve stenosis 
during exercise increased linearly with cardiac output, we couldn’t observe an 
increase in TR severity as assessed by colour Doppler echocardiography.  In these 
patients, RV dimensions and RV function at rest were normal and the cardiac 
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response to exercise didn’t differ from healthy controls. The good response of the 
myocardium to exercise might explain the lack of increase in TR although RV 
pressure load was importantly elevated. We concluded that, if the RV is still healthy, 
no TR occurs in mild to moderate congenital pulmonary valve stenosis. 
In addition, we designed a pilot trial to evaluate the impact of decreased contractile 
reserve on TR severity in patients with repaired tetralogy of Fallot with a pulmonary 
homograft. During low-dose dobutamine stress MRI, 1/5 patients presented with 
impaired contractile reserve, as evidenced by a decrease in stroke volume. As 
hypothesized, we found an increase in tricuspid regurgitant fraction during stress, 
whereas in patients with a preserved contractile reserve, this phenomenon could not 
be observed. However, the low number of patients studied does not allow making any 
firm conclusions.  
 
1.2 Development of TR and right ventricular dysfunction in pre-capillary PH 
We analysed incident patients with pre-capillary PH for the impact of TR on outcome. 
TR at baseline was associated with worse prognosis. Moreover, the development of 
severe TR during follow-up was associated with a 2-fold increased risk of death. This 
indicates the importance of development of TR in the follow-up of patients with pre-
capillary PH. In addition, by evaluating consecutive measurements of right ventricular 
function, we were able to identify right ventricular deterioration predictive for the 
development of TR during follow-up. Hence, right ventricular function is already 
deteriorating at the time severe TR develops. The added volume-load at the time of 
TR progression probably causes a vicious circle, with further deterioration of RV 
function and eventually death. These findings confirm the importance of right 
ventricular deterioration prior to development of severe TR.  
 
1.3 Exclusion of pulmonary hypertension: a predictive model, with integration of 
right heart morphology and TR severity. 
In an attempt to simplify exclusion of pulmonary hypertension, we evaluated whether 
a score of simple echocardiographic parameters (right atrial dilatation, right 
ventricular dilatation and TR severity) would be able to offer an alternative for 
measurements of tricuspid regurgitant velocities or pulmonary artery acceleration 
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time. Furthermore, we validated this score with right heart catheterization in a 
subgroup of patients. 
We found that our newly developed model could reliably exclude patients with 
pulmonary hypertension in a low risk population. Patients who present with a score 
<3 wouldn’t need additional investigation to exclude pulmonary hypertension. On the 
other hand, if the score is ≥3, invasive pressure measurements are advocated. We 
believe that this scoring model would be a fast and easy way to screen low risk 
populations for pulmonary hypertension. 
 
1.4 Isolated tricuspid valve surgery: when is it time to intervene? 
Short and long-term results of isolated TV surgery were evaluated in our centre. In the 
studied patient cohort, post-operative and long-term mortality was high and 
comparable to other reported contemporary series. We found that patients presenting 
in NYHA functional class II or I had excellent post-operative and long-term outcome. 
On top of this, the presence of pulmonary hypertension before surgery was associated 
with worse outcome. We hypothesize that isolated TV surgery has the best outcome 
when symptoms are limited and pulmonary hypertension is lacking. 
Table 1 Pre-operative parameters associated with worse outcome after surgery for 
tricuspid valve regurgitation as reported in literature. Predictors found in our study 
cohort are indicated in red. 
Demography Functional Morphology Invasive Biochemistry 
- Age - NYHA  - RV dilatation - Mean PAP - Hgb  
- Male gender - Diuretic treatment 
- RV function 
(RIMP) 
- RV ESA (≥20cm2)  - Renal failure 
  - TV tethering area  - Liver cirrhosis 
  - RA dilatation  - Albumin 
RV=right ventricle; RIMP=right index of myocardial performance; ESA=end-systolic area; TV=tricuspid 
valve; RA=right atrium; Hgb=hemoglobin. 
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1.5 Concomitant tricuspid valve annuloplasty at the time of mitral valve surgery: 
an opportunity to improve patient outcome? 
Controversy exists whether the tricuspid valve should be repaired at the time of left-
sided valvular disease. Although current guidelines advocate a more liberal approach 
towards concomitant tricuspid valve annuloplasty at the time of valvular surgery, the 
clinical benefit of this intervention has not been proven.  
A major confounder in patients undergoing tricuspid valve repair at the time of mitral 
valve surgery is the inherent selection bias. The decision to perform additional 
tricuspid valve surgery is made by multidisciplinary consultation, which often leads 
towards performing surgery in patients with higher TR severity, higher NYHA 
functional class, more dilated right ventricles, and more signs of impaired right 
ventricular function.  
By implementing a propensity score, we eliminated this selection bias in our studied 
cohort of patients. We found that patients undergoing concomitant tricuspid 
annuloplasty at the time of mitral valve surgery had better event-free survival for the 
combined end-point of cardiac mortality and hospitalisation for heart failure.  
 
2. Clinical applicability and future perspectives 
The integration of the different etiological determinants seems to be key in the 
evaluation of TR. The morphometric changes of the right ventricle influence the 
occurrence TR.  In patients with pre-capillary PH, negative right ventricular 
remodelling, dilatation and decreased RV function are important predictors of the 
occurrence of TR. Building on these morphometric changes observed, an exclusion 
score for elevated pulmonary pressures was developed.  
The implementation of such a scoring could be used as part of large-scale population-
based screening. The function of the tricuspid valve contributes importantly to the 
scoring process. 
In pre-capillary PH, the pressure-load on the RV is often high and leads to important 
RV dilatation and a more spherical RV. Separation of the papillary muscles is further 
accentuated by systolic bowing of the interventricular septum towards the left 
ventricle with increased tension on the septal TV chordal insertions. This leads to 
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important leaflet tethering and consequently, TR. Lastly, as RV dysfunction develops, 
a further increase in TR occurs. Right ventricular function seems to be a key factor 
in the pathogenesis of TR. When the ventricle is healthy, it is able to withstand the 
increased pressure-load during exercise, whereas RV dysfunction during exercise 
could cause increased TR. Likewise, in patients with pre-capillary PH, development 
of severe TR was preceded by progressive right ventricular dysfunction. 
Therefore, RV function and RV function relative to pulmonary artery pressure should 
be systematically evaluated during the follow-up of patients with pre-capillary PH. In 
summary, TR is predominantly determined by morphometric and functional changes 
of the right ventricle due to the increased pressure-load.  
Although the determinants of TR in left-sided heart disease are largely similar, the 
pathway of TR occurrence may be different. Elevated pulmonary artery pressures 
secondary to left heart disease lead to changes in RV morphology and function. 
However, left-sided heart disease is also associated with LV dilatation and 
dysfunction. Because of ventricular interdependence, the left ventricle has also an 
effect on both morphology and function of the RV. The resulting TR then accelerates 
the underlying disease process. Furthermore, we showed that the function of both 
atrioventricular valves are closely linked to each other. This may be an additional 
pathway in the pathogenesis of TR, especially in left-sided valvular disease.  Many 
studies have indicated that tricuspid valve disease can occur late after mitral valve 
surgery. The concept of valvular interdependence emphasizes both atrioventricular 
valves should be evaluated simultaneously. This concept might also be important in 
the planning of mitral valve surgery. The effect of annuloplasty and the degree of 
annular reduction in mitral valve surgery might have important consequences with 
regards to occurrence of late TR. We believe that further study should investigate the 
mechanical relationship of the mitral and tricuspid annulus. 
An impaired dynamic PVR response to exercise after surgical correction of an 
ASD2 late in life is associated with persistent mild TR. More elevated pulmonary 
artery pressures during daily activities can lead to subtle morphological changes of 
the TV apparatus. Future follow-up should evaluate if these changes lead to 
progression of TR severity in long-term follow-up or to worse prognosis compared to 
patients who had their ASD closed early in life.  Future follow-up of these patients 
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might indicate if TR is progressive compared to patients who had their ASD closed 
early in life.  
The development of severe TR impacts survival in patients with pre-capillary PH.  
Acute TR in patients after tricuspid valvectomy because of tricuspid valve 
endocarditis showed that the sudden volume-load on the right heart is tolerated for 
some time. In contrast, patients with TR due to progressive remodelling of the right 
heart represent a population with advanced myocardial disease. An added volume-
load by TR on an already damaged/remodelled ventricle will therefore accelerate RV 
dysfunction in the presence of increased pressure-load. 
Because of the irreversibility of elevated RV pressure-load in patients with pre-
capillary PH, surgery of the TV is not indicated. Concordant with this, we found that 
in isolated tricuspid valve surgery, PH was associated with worse prognosis. 
Careful evaluation of potential reversibility of PH pre-operatively is therefore 
important, as irreversible PH leads to unsatisfactory surgical results. Furthermore, 
severe symptoms of heart failure also lead to high mortality post-operatively. Earlier 
referral for isolated tricuspid valve surgery is therefore indicated. To evaluate this, a 
multi-disciplinary consultation by a “heart valve team” is important. In addition, in 
surgery for mitral valve regurgitation, concomitant tricuspid annuloplasty leads to 
improved outcome. An evaluation of all patient parameters remains of the utmost 
importance and if any doubt about whether tricuspid annuloplasty should be 
performed, a low threshold towards concomitant repair seems to be appropriate and 
safe.  
In pre-capillary PH, preservation of right ventricular form and function, by targeting 
the underlying disease, is important in preserving tricuspid valve function and 
improving outcome.  When RV function deteriorates, the patient is at risk of 
developing severe TR, which is associated with worse outcome. Progressive lowering 
of indices of RV function and the development of severe TR could be indications for 
dose adjustment of targeted therapy. In this, the evaluation of RV fibrosis due to the 
chronic hemodynamic load might also play a role.  
Likewise, in functional TR secondary to left-sided heart disease, prevention of 
negative remodelling, preservation of right ventricular function and geometry, and 
preservation of the low-pressure/low impedance pulmonary arterial system should be 
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attempted in clinical follow-up. Earlier surgery, before negative remodelling has 
occurred might be indicated and is already suggested in current guidelines. 
Hemodynamic consequences of the increased volume-load, increased left atrial 
volume and occurrence of pulmonary hypertension, are increasingly recognized 
indications for surgery. Such approach might prevent TR occurrence in long-term 
follow-up. Still, the risks of surgery should be carefully weighted with regards to the 
benefits.  
It might be interesting to perform exercise tests in patients undergoing mitral valve 
surgery with or without tricuspid annuloplasty. Persistence, early or late progression 
of TR might all be linked with impaired contractile reserve pre-operatively.  
Prospective studies should evaluate the impact earlier referral and careful pre-
operative assessment of pulmonary hypertension on outcome.  Future study should 
further try to identify those patients that truly benefit from tricuspid annuloplasty. 
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Thesis abstract 
Tricuspid regurgitation (TR) is frequently encountered in the routine cardiology 
practice. Although mild TR is not considered pathological, increasing TR severity is 
independently associated with impaired prognosis. Furthermore, post-operative results 
for TR are unsatisfactory. 
We have shown in different studies, both descriptive and experimental, that TR 
originates due to right ventricular (RV) dilatation, tricuspid annular dilatation and RV 
pressure load, sometimes in the setting of increased dynamic pulmonary vascular 
resistance. RV remodelling seems to play an important role in this. Also, the close 
anatomical relationship between the tricuspid and mitral valve annulus might 
contribute to the development of TR. Furthermore, especially in the pressure-loaded 
right ventricle, ventricular function seems to play a key role and development of TR 
has an important impact on prognosis.  
To improve outcome in patients undergoing tricuspid valve surgery, we identified pre-
operative functional state as an important predictor. Also, when the patient presents 
with increase pulmonary artery pressures, outcome is impaired. Currently, it seems 
that patients are operated too late, when significant impairment and end-organ damage 
already occurred. Patients with pulmonary hypertension should be evaluated carefully 
on the reversibility of the elevated pulmonary pressures. Therefore, we advise earlier 
referral for tricuspid valve surgery.  
Similarly, we evaluated the added effect of tricuspid valve annuloplasty at the time of 
left-sided valve surgery and showed improved clinical outcome in patients undergoing 
concomitant tricuspid valve annuloplasty. 
Experimental validation of the effect of right ventricular function on the pathogenesis 
of tricuspid regurgitation has been initiated and the effect of different types of mitral 
valve surgery on the tricuspid valve is under investigation. 
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Summary 
The heart consists of a “low-pressure” (right-sided) chamber, pumping deoxygenated 
(“blue”) blood towards the lungs and a “high-pressure” (left-sided) chamber, 
providing oxygenated (“red”) blood to the muscles and organs of the body. In contrast 
to the valves at the left side of the heart, the tricuspid valve, located at the right side, 
is less well studied. Hence, it is often referred to as “the forgotten valve”. Tricuspid 
valve regurgitation can be best described as a “leaky” valve, which causes part of the 
blood to be pumped backwards rather than forwards. Recent study has revealed that 
patients presenting with tricuspid valve regurgitation have a worse prognosis. 
Surprisingly, mortality after tricuspid valve surgery is high, although tricuspid valve 
repair is technically relatively easy. 
In this thesis project, we focussed on the elements that cause tricuspid regurgitation. 
Furthermore, we evaluated which factors are associated with worse prognosis after 
surgery and when surgery of the tricuspid valve is indicated. 
Although tricuspid valve regurgitation can occur because of a single disturbance of 
the morphology or function of the heart, we showed that it originates most often by a 
combination of factors. If the primary cause of tricuspid regurgitation is not well 
addressed, this can cause adaptations of both the structure and function of the heart, 
further aggravating the severity of tricuspid valve regurgitation. This way a vicious 
circle is started, which eventually leads to signs of breathlessness and decreased 
exercise capacity.  
During exercise, the heart increases its blood flow to provide the necessary oxygen to 
the muscles. In this situation, the heart is acutely stressed, with increasing pressures in 
the heart. We showed that, if the heart muscle functions normal, no increase in 
tricuspid valve regurgitation occurs despite this increased load. However, if the heart 
muscle is not able to respond to exercise appropriately, an increase in tricuspid valve 
regurgitation is seen. This was also confirmed in patients with chronically increased 
pressures at the level of the right heart. In these patients, we found that a progressive 
deterioration of the function of the heart muscle eventually leads to tricuspid valve 
regurgitation.  
With this in mind, the question is raised if we can improve prognosis of patients with 
tricuspid valve regurgitation. We found that if patients undergo surgery early, the 
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outcome is excellent, whereas in patients that have already severe symptoms of 
breathlessness and decreased exercise capacity, we might be too late. On the other 
hand, if we can intervene in the disease process early, the vicious circle can be 
broken. Therefore, we evaluated whether patients undergoing surgery of the left-sided 
valves would have benefit of simultaneous intervention on the tricuspid valve, 
although only mild disease might be visible. In these patients, we found indeed 
improved outcome if the tricuspid valve was addressed as well. 
Taken together, our findings show that tricuspid regurgitation is a disease that can 
occur in a number of clinical scenario’s, each with their own combination of risk 
factors for disease progression. Close evaluation of the patient is of the utmost 
importance to evaluate whether surgery is indicated or not. If so, one should not 
hesitate to perform early surgery. 
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Samenvatting 
Het hart bestaat uit 2 hartkamers. De rechtszijdige hartkamer werkt aan lagedruk en 
pompt het zuurstofarme (“blauwe”) bloed naar de longen. De linkszijdige hartkamer 
werkt onder hoge druk en ontvangt het zuurstofrijke (“rode”) bloed van de longen en 
pompt deze  naar de spieren en organen van het lichaam. Voor de goede werking van 
het hart zijn er verschillende kleppen in het hart aanwezig, die ervoor zorgen dat het 
bloed in de juiste richting gepompt wordt. In tegenstelling met het kleppensysteem 
aan de linkerkant van het hart, werd er naar de “tricuspidalisklep”, die zich aan 
rechterkant van het hart bevindt, weinig onderzoek gedaan. Er wordt daardoor vaak 
naar de tricuspidalisklep gerefereerd als “the forgotten valve”.  
Indien de tricuspidalisklep onvoldoende afsluit, wordt een deel van het bloed de 
verkeerde richting uitgestuurd. Dit fenomeen wordt “tricuspidalisklep insufficiëntie” 
genoemd. Recente studies hebben aangetoond dat patiënten die zich presenteren met 
tricuspidalisklep insufficiëntie een slechtere prognose hebben. Daarnaast merken we 
in de klinische praktijk dat patiënten die geopereerd worden voor tricuspidalisklep 
insufficiëntie, soms blijvend klachten hebben van kortademigheid. Dit is enigszins 
verrassend, aangezien tricuspidalisklep herstel technisch relatief gemakkelijk is. 
In dit onderzoeksproject, hebben we de verschillende elementen die tricuspidalisklep 
insufficiëntie veroorzaken in detail onderzocht. Daarnaast zijn we nagegaan welke 
factoren de slechte uitkomst van chirurgisch ingrijpen verklaren om zo te kunnen 
identificeren wanneer chirurgie aangewezen is. 
Alhoewel tricuspidalisklep insufficiëntie kan ontstaan door een geïsoleerde 
verandering van de morfologie of functie van het hart, konden wij aantonen dat het 
voornamelijk de combinatie van factoren is die uiteindelijk de ernst van de ziekte 
verklaart. Als de primaire oorzaak van tricuspidalisklep insufficiëntie niet goed 
behandeld wordt, geeft deze aanleiding tot veranderingen ter hoogte van zowel de 
structuur, als de functie van het hart. Deze veranderingen kunnen dan op hun beurt 
aanleiding geven tot tricuspidalisklep insufficiëntie en zo ontstaat er een vicieuze 
cirkel, die uiteindelijk leidt tot de symptomen van kortademigheid en verminderde 
inspanningscapaciteit.
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Als we een inspanning leveren, dient het hart de hoeveelheid bloed die het rondpompt 
op te drijven, om er zo voor te zorgen dat er voldoende zuurstof naar de spieren gaat. 
In deze situatie wordt het hart acuut belast, en verhoogt de druk in de hartkamers. In 
theorie zou dit aanleiding kunnen geven tot een toenemend lek op de kleppen. We 
konden echter aantonen dat, indien de hartspier normaal functioneert, geen toename 
van het lek op de kleppen optreedt. Daartegenover staat echter dat er een toename van 
de ernst van de tricuspidalisklep insufficiëntie wordt gezien indien de hartspier 
(beperkte) schade vertoont, en zo onvoldoende kan reageren op de verhoogde eisen 
die een inspanning vraagt. Dit werd eveneens bevestigd in een patiëntengroep die een 
chronisch verhoogde druk ter hoogte van de hartkamers hebben. In deze patiënten 
konden we een progressieve achteruitgang van de hartspierfunctie vaststellen die 
uiteindelijk leidde tot ernstige tricuspidalisklep insufficiëntie. 
De vraag kan dan ook gesteld worden of we de prognose van patiënten met 
tricuspidalisklep insufficiëntie kunnen verbeteren. In de bestudeerde patiënten konden 
we echter vaststellen dat patiënten die vroeg in het ziekteproces chirurgie 
ondergingen, een uitstekende prognose hadden. Daartegenover staat dat we 
vermoedelijk te laat zijn om chirurgie voor te stellen bij patiënten die reeds 
uitgesproken klachten van kortademigheid of een verminderde inspanningscapaciteit 
hebben. Indien we echter vroeger kunnen tussenkomen in het ziekteproces, kan de 
vicieuze cirkel gebroken worden. Aanvullend evalueerden we patiënten die chirurgie 
ondergingen van een linkszijdige klep. We keken na of het tegelijk uitvoeren van een 
herstel van de tricuspidalisklep bij deze patiënten een voordeel zou bieden, ook al was 
er enkel milde ziekte aanwezig op het moment van chirurgie. In deze patiënten 
vonden we inderdaad betere uitkomst als de tricuspidalisklep tegelijkertijd aangepakt 
werd. 
Samenvattend kunnen we besluiten dat tricuspidalisklep insufficiëntie een ziekte is 
die kan ontstaan in verschillende klinische situaties, die elk hun eigen combinatie van 
risicofactoren hebben voor ziekteprogressie. Om de indicatie voor chirurgie duidelijk 
te maken is het belangrijk om de reden van de tricuspidalisklep insufficiëntie te 
identificeren. Indien chirurgie aangewezen is, is een snelle interventie aangewezen. 
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